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CHAPtER 1
General introducti on
Adapted from: 
Chapter 16: Autoimmune encephalitis. A. van Sonderen and M.J. Titulaer.
Published in: Deisenhammer F, Sellebjerg F, Teunissen CE, Tumani H. Cerebrospinal Fluid 
in Clinical Neurology. Springer, pp 247-276. 
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History and classification of antibodies in neurology
The discovery of antibodies in tumor patients was a major step in the field of antibody-
associated neurological syndromes. The Dutch Professor B. Brouwer (1881-1949) 
reported cerebellar degeneration in a patient with a pelvic tumor in 1919. He was the 
first to link neurological diseases to remote tumors, considering a toxic effect.1 The 
association of limbic encephalitis and tumors was reported half a century later. One 
of the first patients was a 60-years old bus driver, referred to the hospital in 1960 
with complaints of weakness and weight loss. In the following weeks, he had seizures, 
confusion and complete loss of memory for the previous eight weeks. At that time, 
extensive investigation consisting of blood examination, cerebrospinal fluid (CSF) 
analysis and electroencephalogram (EEG) did not show a cause for his illness.  In the 
following two years, disease worsened and he suddenly died in 1961. Post-mortem 
examination revealed a bronchial carcinoma. Death was attributed to an “unidentified 
cerebral illness”, but this case, together with a few similar cases, raised the question 
whether there might be an association between inflammatory brain disease and tumors: 
“THERE are several kinds of neurological disorder which may develop in patients with 
carcinoma, even though no manifest spread of tumour cells to the nervous system has occurred.
(…) Both the degenerative and the inflammatory changes have generally been considered to 
occur only at levels caudal to the basal ganglia. In recent years, however, evidence has been 
accumulating that the cerebral hemispheres may be affected rather than the hind-brain.(…) 
The damage moreover has been severe at times and there has then been a noticeable tendency 
for the patients to develop memory disturbances or to be demented. The first question to arise 
therefore is whether the assertion of a connexion between carcinoma and “limbic encephalitis” 
is now justified.”
Corsellis. Brain, 19682
Although the opportunities for ancillary testing have greatly expanded, our findings 
are not much different than fifty years ago: severely affected patients, with minimal or 
aspecific abnormalities at extensive examinations. Fortunately, we are now able to make 
a diagnosis in the majority of these patients, based on antibody-detection. Prognosis and 
treatment options have improved, but are mainly dependent on the antibodies’ target: 
intracellular vs extracellular antigens. 
 The ‘classical paraneoplastic antibodies’ are directed to intracellular proteins, 
such as Hu, Ri and Yo. Due to its intracellular target, these antibodies are probably 
not directly pathogenic. Antibodies are thought to occur as an epiphenomenon of a 
hypothesized T-cell mediated inflammation. This inflammation results in mostly 
irreversible neuronal damage, and therefore the effect of immunotherapy is limited.3,4 
There is a strong antibody-dependent tumor association. For example, 85% of the anti-
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Hu patients have a small cell lung cancer, while patients with anti-DNER should be 
analyzed for Hodgkin lymphoma. Because of the remarkable tumor association, these 
diseases as often referred to as ‘paraneoplastic antibodies’, but the term ‘onconeural 
antibodies’ is preferred.
 In the year 2007, the discovery of N-methyl-d-aspartate receptor (NMDAR) 
antibodies was a major breakthrough recognizing cell surface proteins as antigens in 
encephalitis.5 Several other cell surface or synaptic antigens and their clinical syndrome 
have been reported more recently, including the alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) in 2009 and leucine-rich glioma-inactivated 
protein1 (LGI1) and contactin-associated protein-like 2 (Caspr2) in 2010.6-8 In contrast 
to the classical syndromes, these antibodies are thought to be directly pathogenic and 
patients tend to have a more favorable response to immunotherapy. Only a minority 
of these patients have an associated tumor, although the incidence of cancer differs per 
antigen: 30-40% of the anti-NMDAR encephalitis patients have a tumor, while tumors 
occur in only 11% of the patients with antibodies to LGI1.6,8,9 
 This chapter gives an overview of the syndromes associated with antibodies 
directed to extracellular antigens. Antibodies related to the presynaptic voltage-gated 
potassium channel (VGKC) complex are discussed first, including LGI1 and Caspr2. 
Subsequently, the postsynaptic glutamate receptors AMPA and NMDA are discussed. 
Extensive descriptions of antibodies to glycine, dipeptyl-peptidase-like protein-6 
(DPP6) and γ-aminobutyric acid (GABA) receptor type B and type A are beyond the 
scope of this thesis, but a short summary is added to this chapter. 
The presynaptic voltage-gated potassium channel (VGKC) complex 
Introduction
Antibodies to the VGKC were initially detected in patients with acquired neuromyotonia, 
a peripheral nerve disorder characterized by muscle cramps, impaired relaxation and 
stiffness.10 A pathogenic role of VGKC antibodies was subsequently suspected in 
Morvan’s syndrome, showing neuromyotonia accompanied by autonomic and cognitive 
symptoms and insomnia,11 and in patients with limbic encephalitis.12 Antibodies were 
eventually thought to be directed to subunits of the VGKC receptor.13 However, the exact 
role of VGKC-antibodies remained controversial as no laboratory succeeded in showing 
staining with serum in VGKC-transfected cells. In the year 2010, this reconsideration 
led two laboratories to identify simultaneously that these antibodies are not directed to 
the subunits of the VGKC itself, but to VGKC-associated proteins: LGI1 and Caspr2.6,8 
The VGKC-test is a commercially available 125-I-α-dendrotoxin radioimmunoassay 
(RIA). Values and cut off values vary among laboratories; usually titer > 100 pM or > 
400 pM are interpreted as positive. The test is only applicable on serum and is not able 
to discriminate sera with antibodies to LGI1, Caspr2 or neither of them. This relevant 
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distinction can be made with immunocytochemistry or immunohistochemistry, using 
serum or CSF. 
Leucine-rich glioma-inactivated 1 (LGI1)
The LGI1 protein is secreted into the synaptic cleft, where it binds a disintegrin and 
metalloprotease domain-containing protein 23 (ADAM23) to postsynaptic ADAM22, 
thereby influencing synaptic transmission to the AMPAR.3,14 This transsynaptic fine tuning 
is thought to have an anti-epileptic effect.14 Patients with antibodies to LGI1 show the 
typical features of limbic encephalitis: seizures, memory deficit, confusion and behavioral 
problems. Typical for anti-LGI1 encephalitis are faciobrachial dystonic seizures (FBDS). 
These are brief involuntary unilateral movements involving the arm, usually ipsilateral face 
and less commonly the trunk or a leg. FBDS occur very frequent, up to 100 times per day, 
but are seen in only half of the patients.15,16 No trials analyzed the effect of immunotherapy 
in anti-LGI1 encephalitis, but treatment response is series is mostly favorable.17,18 Until 
recently, extensive analysis of long-term outcome was lacking. 
 We analyzed a cohort of 38 Dutch anti-LGI1 patients to clarify the clinical 
syndrome in more detail, giving clues for clinical recognition of this relatively ‘new’ 
disease. Long-term outcome was analyzed, including neuropsychological assessment 
and relapse rates. (Chapter 2) 
 In the clinical setting, we noticed a common HLA-DRB1*07 (DR7) allele in 
our anti-LGI1 patients. For systematic analysis, we performed HLA-phenotyping in 
a larger group of anti-LGI1 patients. The aim was to analyze the association between 
HLA-type and predisposition for anti-LGI1 encephalitis in non-tumor patients. 
(Chapter 3)
Contactin-associated protein-like 2 (Caspr2)
Caspr2 is a membrane protein in myelinated axons in both the central and peripheral 
nervous system, essential to stabilize the VGKC’s at the juxtaparanodes.6,19 Disruption 
of the Caspr2 protein is thought to diminish repolarization, causing hyperexcitability. 
Mutation in the Caspr2 coding gene, CNTNAP2, causes childhood onset refractory 
epilepsy with mental retardation.3 Only a few dozen patients with Caspr2 antibodies 
had been published before we started our analysis. The majority of these patients 
were male, and most patients presented with limbic encephalitis, neuromyotonia or 
a combination of central and peripheral nerve system symptoms known as Morvan’s 
syndrome. Again, treatment trials are lacking, but patient series report a good response 
to immunotherapy.6,19 
 To gain more insight in the disease, we analyzed the largest cohort of 38 anti-
Caspr2 patients. We studied the overlap in earlier described syndromes, defined the 
core symptoms and analyzed treatment responses. IgG subclasses were tested in serum.
(Chapter 4)
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VGKC-positivity in the absence of antibodies to LGI1 and Caspr2
A significant part of the VGKC-positive patients do not have LGI1 or Caspr2 antibodies. 
Unfortunately, many studies (including over 800 patients) do not distinguish this third 
group in there analysis, complicating the extraction of group-specific data.20-25 VGKC-
positive patients lacking antibodies to LGI1 and Caspr2 can present with the typical 
clinical syndromes of limbic encephalitis or neuromyotonia.10,26,27 But in recent years, 
the clinical spectrum has expanded: pain syndromes, psychogenic non-epileptic seizures, 
REM sleep behavior disorder, multiple system atrophy, peripheral neuropathy, vasculitis, 
seizures and many other clinical syndromes were reported.21,23,28-30 In addition, VGKC-
positivity was reported in patients with pathology-proven Creutzfeldt Jakob Disease.31 
 The clinical heterogeneity raised the question whether VGKC-positivity in 
the absence of LGI1 and Caspr2 antibodies is clinically relevant in all. Several studies 
addressed this issue by comparing patients with high and low VGKC-titers, and 
concluded that higher titers are associated with autoimmune disease. However, patients 
with LGI1 and Caspr2 antibodies (known to have high titers) were not excluded. Others 
conclude that the clinical relevance of VGKC-positivity is supported by the favorable 
response to immunotherapy. For example, symptoms improved after immunotherapy 
in 8/10 patients with pain syndromes and in 3/4 patients with seizures.24,32 These results 
seem promising. However, conclusions regarding clinical relevance of VGKC-positivity 
require a comparison with VGKC-negative patients. Therefore, we compared 25 VGKC-
positive patients without LGI1 and Caspr2 antibodies to 50 VGKC-negative patients, 
matched by age, gender and clinical syndrome. We compared criteria for autoimmune 
inflammation, treatment responses and VGKC titers between the two groups. We aimed 
to analyze whether VGKC-positivity in the absence of antibodies to LGI1 and Caspr2 
is clinically relevant. (Chapter 5)
 A review of the etiology, pathogenesis and clinical syndromes caused by 
antibodies to LGI1 and Caspr2, as well as the complex issue of VGKC-patients lacking 
both antibodies, is given in Chapter 6. 
The postsynaptic glutamate receptors
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
In 2009, 43 patients with limbic encephalitis of unknown origin were investigated in 
order to identify the antigen. Among these, antibodies of ten patients showed a similar 
pattern of reactivity to neuropil of rat brain and cerebellum. Further tests showed that 
the AMPAR was the target antigen in these patients.7 The AMPAR is an ionotropic 
glutamate receptor concentrated at synapses, mediating most of the fast excitatory 
neurotransmission in the brain.33 Antibody reaction leads to a decrease in the number 
of receptors at synapses and a decrease of receptors along dendrites due to increased 
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internalization of AMPARs. Removal of antibodies from neuronal cultures has shown 
to restore receptor number and localization of AMPAR clusters.7
 Two series described just over a dozen patients altogether.7,34 Most patients 
were women > 50 years of age. Patient usually presented with limbic encephalitis with 
memory disorder, confusion and often psychiatric symptoms. Seizures were less common 
compared to other antibodies. 
 We further characterized this clinical syndrome in 22 newly identified patients 
with anti-AMPAR-encephalitis. Co-occurrence of other antibodies, response to 
immunotherapy and clinical outcome were analyzed. (Chapter 7)
N-methyl-d-aspartate receptor (NMDAR)
In 2005, four young women were described with acute psychiatric symptoms, memory 
deficit, seizures, decreased level of consciousness and central hypoventilation. All four 
had ovarian teratoma. CSF showed a common pattern of reactivity to the cytoplasmic 
membrane of hippocampal neurons.35 In 2007, this had led to the identification of the 
NMDAR as the target antigen.5 
 Binding of antibodies to the NMDAR results in prolongation of the opening time 
of the receptor.36 This hyperfunction might induce excessive calcium influx, resulting in 
damage to the receptor, although the exact mechanism is yet undetermined. In neuronal 
cultures, patients’ antibodies are shown to induce capping and internalization of the 
NMDAR, resulting in a (reversible) decrease of the amount of NMDAR clusters.37-39 
Injection of patient CSF in mice was shown to decrease hippocampal NMDARs, causing 
reversible memory and behavioral deficits in the animal.40 Unprovoked NMDAR-
encephalitis in animals occurs as well: the popular polar bear Knut drowned during a 
seizure in the Berlin Zoo in 2011. Post-mortem, he appeared to have high concentrates 
of NMDAR-antibodies in his CSF.41 
 In humans, NMDAR-antibodies are the most common cause of antibody-
mediated encephalitis. The largest cohort describes 577 patients, of which 80% are 
female. The vast majority of the patients is between 18 and 45 years. In this observational 
study, 38% of the patients had a tumor, of which 94% were ovarian teratoma. 
 Half of the patients have prodromal symptoms suggesting a nonspecific viral 
infection.9 In the following days to weeks patients, develop psychiatric symptoms, short 
term memory deficit, confusion, insomnia and language deterioration.42,43 Abnormal 
movements, such as orofacial dyskinesias and chorea, are common. Subsequently, 
level of consciousness decreases and autonomic instability and hypoventilation may 
occur, requiring admission to the intensive care unit in the majority. Recovery from 
anti-NMDAR-encephalitis occurs in the reverse order of symptom presentation.9 
Trials concerning treatment of anti-NMDAR encephalitis have not been performed, 
but large series show a convincing effect. Treatment usually consists of a combination 
of methylprednisolone and intravenous immunoglobulins, and tumor removal if 
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applicable. Over half of the patients respond within four weeks.9 If first line therapy fails, 
second line therapy with rituximab and cyclophosphamide can be initiated. However, 
in extreme cases, response is lacking after adequate first and second line treatment. We 
report a severe case of anti-NMDAR encephalitis, and discuss treatment considerations 
after first and second line failure. This is the first report of intrathecal administration of 
rituximab. (Chapter 8)
 EEG usually shows diffuse background slowing. One fourth of the patients 
have electrographic seizures.9 A unique EEG pattern has characterized in anti-NMDAR 
encephalitis, consisting of rhythmic delta activity with superimposed bursts of beta 
activity.44,45 This pattern of ‘extreme delta brushes’ was named after the delta brush EEG 
pattern known in premature infants. Besides the presence of extreme delta brushes in 
the minority of the patients, data regarding EEG in anti-NMDAR encephalitis was 
limited. We analyzed first EEG and follow up registrations in 53 adult and pediatric 
patients. Initial EEG and follow up registrations were re-evaluated. Besides describing 
the  most relevant EEG patterns, the study focuses on the predictive value of first EEG 
recordings. (Chapter 9)
Metabotropic glutamate receptors: mGluR5 and mGluR1
The NMDA receptor and AMPA receptor are ionotropic glutamate receptors. In 
contrast, there are several metabotropic subtypes of glutamate receptors (mGluR). These 
receptors indirectly activate ion channels. A few patients with antibodies directed to the 
mGluR5 or mGluR1 subtype have been reported.3,46 
 Antibodies to mGluR5 cause the ‘Ophelia syndrome’, named after the character 
in Shakespeare’s Hamlet. The syndrome was first described in 1982 by Dr Ian Carr. 
He wrote a moving personal paper about the subacute loss of memory and psychosis 
in his fifteen years old daughter Jane, who subsequently appeared to have Hodgkin 
lymphoma.47 More recently three patients with a comparable clinical picture in Hodgkin 
lymphoma were reported. In these patients mGluR5 was detected as the target antigen 
of the antibodies.46,48,49 All patients had a favorable outcome, similar to Carr’s daughter. 
 Antibodies to mGluR1 are described in five patients with subacute cerebellar 
ataxia.49 46,50,51 The pathogenic role of mGluR1 antibodies has been demonstrated by the 
induction of cerebellar symptoms in mice after passive transfer of patient’s antibodies.49 
Neurological outcome in the five reported patients is variable, despite immunotherapy.
Beyond the scope of this thesis
The major progressions made in the field of antibody-mediated neurologic disease has 
led to the discovery of a number of other extracellular antigens. A short description of 
the four most prominent follows here, but an extensive description is beyond the scope 
of this thesis. 
General introduction
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 Antibodies to the glycine receptor (GlyR) are detected in patients with 
progressive encephalomyelitis with rigidity and myoclonus (PERM) or stiff person 
syndrome (SPS). GlyRs are chloride channels on the cell surface membrane, facilitating 
inhibitory neurotransmission in the brain and spinal cord. Receptor dysfunction leads 
to abnormal discharges of motor neurons and widespread muscular rigidity.52,53 Case 
reports describe beneficial effect of immunotherapy, but patients tend to relapse. 
 Antibodies to the dipeptyl-peptidase-like protein-6 (DPP6, or DPPX) were 
identified in four patients with rapidly progressive encephalopathy in the year 2012. 
Interestingly, three of these patients had severe prodromal diarrhea.54 In 2014, DPP6 
antibodies were detected in three patients with PERM.55 DPP6 is a cell surface subunit 
of the Kv4.2 potassium channel, most prominent in hippocampal neurons. DPP6 is 
present in the myenteric plexus as well, explaining diarrhea in a part of the patients.3,54 
 The γ-aminobutyric acid-B (GABAB) receptor was identified as target antigen 
in limbic encephalitis in 2010. GABAB receptors have an inhibitory function both 
presynaptic and postsynaptic. Seizures, often refractory, are prominent in anti-GABAB 
patients. The majority of the patients have memory deficit and confusion as well, 
meeting the criteria for limbic encephalitis.56-58 Over half of the patients have a tumor, 
mainly small cell lung cancer (SCLC).56 The majority of the patients respond well to 
immunotherapy.
 In 2014, two patients with encephalitis and refractory seizures showed an 
immunohistochemistry pattern similar to GABAB receptor antibodies, but specific 
testing for GABAB was negative. In these two patients, and in four others, antibodies to 
the GABAA receptor were detected.59 Patients had a rapidly progressive encephalopathy 
resulting in refractory seizure, mostly status epilepticus. 
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Hypothesis
The chapters refer to the studies answering these hypotheses:
•	 Anti-LGI1 encephalitis is greatly underdiagnosed. More insight in the clinical 
features will be the key to improve recognition. (Chapter 2)
•	 Long-term outcome in anti-LGI1 encephalitis is mostly favorable, but residual 
cognitive deficits are common. (Chapter 2)
•	 Anti-LGI1 encephalitis is associated with a HLA-subtype, supporting the 
autoimmune hypothesis. (Chapter 3) 
•	 Anti-LGI1 encephalitis and anti-Caspr2 encephalitis can mimic dementia. 
(Chapters 2 and 4)
•	 Anti-Caspr2 encephalitis can present with various syndromes, but there is substantial 
overlap in the main symptoms. (Chapter  4)
•	 In many patients, VGKC-positivity in the absence of antibodies to LGI1 or Caspr2 
is not clinically relevant. (Chapter  5)
•	 AMPAR-antibodies are associated with a treatment-responsive limbic encephalitis, 
often with psychiatric symptoms. (Chapter 7)
•	 Tumor incidence is high in anti-AMPAR-encephalitis. (Chapter 7)
•	 Response to therapy and clinical recovery in anti-NMDAR encephalitis can be 
delayed. (Chapter 8)
•	 EEG is predictive for clinical outcome in anti-NMDAR encephalitis. 
(Chapter  9)
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Abstract
Objectives 
This nationwide study gives a detailed description of the clinical features and long-term 
outcome of anti-LGI1 encephalitis. 
Methods 
We collected patients prospectively from October 2013, and retrospectively from 
samples sent to our laboratory from January 2007. LGI1-antibodies were confirmed with 
both cell-based assay and immunohistochemistry. Clinical information was obtained in 
interviews with patients and their relatives and from medical records. Initial MRI and 
follow-up MRI were revised blindly. Neuropsychological assessment was performed in 
those patients with follow-up over two years. 
Results 
Annual incidence in the Netherlands was 0.83/million. 34/38 patients had a limbic 
encephalitis. Subtle focal seizures (66%, autonomic and/or dyscognitive) and 
faciobrachial dystonic seizures (FBDS, 47%) mostly occurred before onset of memory 
disturbance. Later in disease course, 63% had tonic-clonic seizures. Initial MRI showed 
hippocampal T2 hyperintensity in 74% of the patients. These lesions evolved regularly 
into mesotemporal sclerosis (44%). Substantial response to immunotherapy was seen 
in 80%, with early response of seizures and slow recovery of cognition. At follow-up 
≥2 years, most surviving patients reported mild residual cognitive deficit with spatial 
disorientation. 86% had persistent amnesia for the disease period. Relapses were 
common (35%) and presented up to eight years after initial disease. 2-years case fatality 
rate was 19%. 
Conclusions 
Anti-LGI1 encephalitis is a homogenous clinical syndrome, showing early FBDS and 
other focal seizures with subtle clinical manifestations, followed by memory disturbances. 
Better recognition will lead to earlier diagnosis, essential for prompt start of treatment. 
Long-term outcome of surviving patients is mostly favorable, but relapses are common. 
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Introduction
Antibodies directed to leucine-rich glioma-inactivated 1 (LGI1) were discovered in 
2010.1,2 Before, patients were thought to have antibodies against voltage-gated potassium 
channels (VGKC), to which the LGI1-protein is functionally related. Most anti-LGI1 
patients present with limbic encephalitis (LE). LE is clinically characterized by a subacute 
disturbance of memory and behavior, often accompanied by seizures. Patients tend to 
improve on immune therapy, but long-term outcome is characterized poorly. 
 LGI1 is mainly expressed in the hippocampus and the temporal cortex, 
where it is secreted into the synaptic space. It is part of an inhibitory pathway linking 
the presynaptic VGKC and the postsynaptic α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic-acid-receptor (AMPAR).3,4 Genetic disruption of the LGI1-protein 
causes autosomal dominant lateral temporal epilepsy.5,6 Seizures are common in patients 
with LGI1-antibody-mediated disease as well. Faciobrachial dystonic seizures (FBDS) 
are very specific for anti-LGI1 encephalitis, although only present in a minority of the 
patients.7  FBDS are involuntary contractions of 1-2 seconds, affecting the unilateral 
arm (or leg) and face, occurring up to 100 times a day, but often unrecognized by 
patients and physicians. 
 Approximately 250 anti-LGI1-patients have been reported, mostly described 
as “VGKC-encephalitis”. Due to better recognition, incidence is expected to increase 
dramatically, but data regarding incidence are scarce. This nationwide study provides 
the opportunity to report incidence rates. We describe the disease course in detail, and 
provide clues to improve clinical recognition and avoid laboratory pitfalls. We report 
long-term outcome, including neuropsychological assessment and relapse rates. 
Methods
Patients accrual and laboratory testing
Samples had been sent for antibody testing to the laboratory of Medical Immunology 
of the Erasmus University Medical Center, Rotterdam. This national referral center is 
the only laboratory performing LGI1-antibody analysis in the Netherlands. Patients 
with confirmed LGI1-antibodies were included irrespective of age or clinical syndrome. 
Patients diagnosed between 2007 and October 2013 were included retrospectively and 
invited for neuropsychological assessment to analyze long-term cognitive outcome. 
Patients diagnosed between October 2013 and October 2015 were assessed prospectively. 
 LGI1-antibodies were detected with both cell-based assay and 
immunohistochemistry in serum (and CSF if available) as previously reported.9   
Incidence rate was based on the number of patients diagnosed in the Netherlands in the 
last twelve months (October 2014-September 2015), and compared to the three-year 
period before this study started (Oct 2010-Sept 2013). 
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Clinical information
Clinical information was obtained in an interview with patient and relatives (if possible) 
during visit to our clinic (n=21) or by telephone (n=17), and from medical records and 
telephone interviews with the treating physicians. 
 Seizures were classified by an experienced epileptologist (RT), based on 
interviews, files and EEG reports. FBDS were defined as frequent seizures (> 8/day) 
with a dystonic posture of the arm, often accompanied by facial contraction, lasting 
less than 30 seconds.10 Current sleep complaints were assessed with Epworth Sleepiness 
Scale (ESS) for daytime sleepiness and Pittsburgh Sleep Quality Index (PSQI) for 
sleep quality and disturbances. Patients were considered responsive to treatment if they 
showed substantial clinical improvement within four weeks after the start of treatment, 
as judged by the treating physicians.  
 Brain MRIs performed during and after disease were re-evaluated by an 
independent experienced neuroradiologist (ES), mixed with control MRIs from 
antibody-negative epilepsy patients for blinding. Visual assessment of hippocampal 
volume and FLAIR or T2-weighted signal intensity changes within the hippocampus 
were performed. The evaluation was performed on coronal plane images at the level of 
the hippocampus (or axial plane when coronal images were absent). 
 Long-term cognitive outcome was analyzed in patients with disease onset 
over two years ago. Neuropsychological assessment was performed using Cambridge 
Neuropsychological Test Automated Battery (CANTAB Research Suite 6.0, Cambridge 
Cognition Ltd., Cambridge, UK). We expected most relevant residual deficits in domains 
of memory, spatial orientation and executive functioning. Therefore, our primary 
outcomes were the Spatial Recognition Memory (SRM) and Intra-Extra Dimensional 
set shift (IED, total errors) test results. Seven tests of different cognitive domains were 
added for wider exploration of cognitive outcome (Suppl. Table e-1). 
Standard protocol approvals, registrations and patient consents
The study was approved by the Institutional Review Board of the Erasmus University 
Medical Center, Rotterdam. Informed consent was obtained in all patients. 
Statistical analysis
Incidence rate was calculated with 95% confidence intervals (CI) based on a Poisson 
distribution, using available population data (http://statline.cbs.nl/statweb/). 
Categorical data were analyzed with Fisher-Freeman-exact test, numerical data with 
Mann Whitney-U test, and correlation by Spearman’s rho, with p-values <0.05 
considered significant. CANTAB results were expressed as z-scores, based on normative 
data (age and gender specific) obtained by the company and analyzed with one-sample 
T-tests (Test Value=0). Primary outcome measures (SRM and IED) were considered 
significant if p<0.025 (Bonferroni). Secondary outcome measures were exploratory, 
29
2
Clinical syndrome of anti-LGI1 encephalitis
without correction for multiple testing. These p-values should be considered carefully. 
SPSS Statistics 21 (IBM Corp., Armonk, NY) was used for analysis.
Results
Thirty-nine anti-LGI1 encephalitis patients were identified, of whom 38 patients were 
available for inclusion (19 prospectively; Table 1). Twenty-five patients were male 
(66%). Median age at onset of disease was 64 years.  Median follow-up was 27 months. 
Long-term outcome was analyzed in 21 patients with follow-up ≥2 years. 
Incidence
Fourteen patients were clinically diagnosed with anti-LGI1 encephalitis in the last year, 
resulting in an annual incidence of 0.83/million (95%-CI 0.45-1.40),  an increase 
compared to only 11 patients diagnosed in the three-year period earlier (annual incidence 
0.22/million; 95%-CI 0.11-0.39; p=0.002). 
Clinical phenotype
Thirty-four patients had limbic encephalitis, three patients had Morvan’s syndrome 
(limbic encephalitis and peripheral nerve hyperexcitability and insomnia/dysautonomia) 
and one patient had only seizures. Most common initial symptoms were seizures (53%) 
or cognitive disorder (42%; Figure 1A). Typical disease course is shown in Figure 
1B. Median time from onset to nadir of disease was 22 weeks. At maximum disease 
severity, 76% had mRS ≥3. Almost all patients evolved disturbance of memory (97%) 
or behavior (90%). Behavioral changes included apathy (53%), disinhibition (excessive 
eating, missing social cues, 40%), egocentrism (38%), or compulsive behavior (clean 
up, hoarding, 29%). Over half of the patients had spatial disorientation, often reported 
as getting lost walking to the supermarket or at the ward. 
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Table 1. Patient characteristics (n = 38)
Male gender 25/38 (66%)
Age at onset in years, median (IQR, range) 64 (60 – 69, 31 to 84)
Time to maximum disease severity in weeks (IQR, range) 22 (8 – 32, 2 to 150)
Clinical syndrome
- Limbic encephalitis
- Morvan’s syndrome #
- Epilepsy
34 (90%)
  3 (8%)
  1 (3%)
Seizures 34 (90%)
Memory deficit 37 (97%)
Disorder of behavior 34 (90%)
Spatial disorientation 17/33 (52%)
Insomnia 20/31 (65%)
Weight loss   9/33 (27%)
Autonomic dysfunction 15/32 (47%)
Pain   3/34 (9%)
Peripheral nervous system symptoms   5/32 (16%)
Hyponatremia 24/37 (65%)
CSF 
- Cell count > 5 cells/uL
- Protein > 0.58 g/L
- 5/32 (16%) (max 88 cells /µL)
- 5/32 (16%)
EEG 
- Focal slowing
- Epileptic
- 9/36 (25%)
- 11/36 (31%)
MRI, at presentation
- Unilateral hippocampal lesion
- Bilateral hippocampal lesion
- Normal
- 21/35 (60%)
-  5/35 (14%)
-  9/35 (26%)
MRI, at follow-up (with initial hippocampal lesions)
- Mesotemporal sclerosis
- Hippocampal T2 hyperintensity
- Normal
- 7/17 (41%)
- 6/17 (35%)
- 4/17 (24%)
- Tumor - 4/36 (11%)
- VGKC RIA median (IQR, range) - 720 (457 – 971, 245 to 1314)
- Cell-based assay LGI1. Serum; CSF† - 38/38 (100%); 9/17 (53%)
- Immunohistochemistry LGI1. Serum; CSF†† - 38/38 (100%); 15/17 (88%)*
# Morvan’s syndrome was defined as limbic encephalitis with peripheral nerve hyperexcitability and sleep disorder or 
dysautonomia; †p= 0.008, McNemar’s test comparing serum with CSF. ††p = 0.50, McNemar’s test comparing serum 
with CSF. *Both negative scored samples were negative on cell-based assay as well. IQR = interquartile range, FBDS = 
faciobrachial dystonic seizures, RIA = radioimmunoassay.
During the course of disease, 33 patients (89%) developed one or more types of seizures 
(Table 2, case descriptions in Supplement). FBDS (47%) started mostly several weeks 
before the onset of cognitive symptoms. Median frequency was 40 FBDS per day. Focal 
seizures with mainly dyscognitive (n=15), autonomic (n=9), motor (n=3) or gelastic 
(n=2) features or aura (n=1) were present in 25 patients (66%). Focal seizures lasted 
longer than FBDS and the median frequency was 12 per day. Tonic-clonic seizures 
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occurred in 63% of the patients, mostly simultaneous with or after onset of cognitive 
decline. Most patients had only a single or a few tonic-clonic seizures (median 3). This 
last type of seizures was often the trigger to start or extend ancillary testing. 
Other common symptoms were insomnia (65%) and autonomic dysfunction (47%, 
mainly hyperhidrosis). Sexual dysfunction was not systemically questioned but 5 male 
patients (21%) reported it spontaneously. One patient had marked chorea. One patient 
evolved bulbar symptoms of myasthenia gravis, concomitant with the start of limbic 
encephalitis (AChR antibodies positive, no thymoma). 
65% hyponatremia
74% T2 hyperintensity limbic system
75% normal CSF
89% no tumor
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Figure 1. Presenting symptoms and disease course.  A. First symptom in 38 patients with anti-LGI1 encephalitis. B. 
Disease course in anti-LGI1 encephalitis. Timeline: median disease progression 22 weeks, median treatment delay 25 
weeks, median start of improvement 2 weeks after treatment, median time of recovery 33 weeks. FBDS = faciobrachial 
dystonic seizures. TC-seizure = tonic-clonic seizure.
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Table 2. Seizure characteristics in 38 patients
FBDS Focal seizures
(other than FBDS)
Tonic-clonic seizures
Number of patients 18 (47%) 25 (66%) 24 (63%)
Duration of seizure < 15 seconds Median: 25 sec (range 
1 – 600)
Seizure frequency Median: 40/day 
Range: 10-100/day
IQR: 20 – 80 
Median: 12/day 
Range: 1-150/day
IQR: 3 – 40 
Median: 3 in total
Range: 1-100 in total
IQR: 1 – 5 
Relation to onset of 
cognitive symptoms
Before (67%)
Median 3 weeks before
Before or simultaneous 
(90%)
Median 1.5 weeks before 
Simultaneous or after 
(78%)
Median 0.5 weeks after
FBDS = faciobrachial dystonic seizures, IQR = interquartile range
Ancillary testing
In the acute symptomatic phase, hyponatremia was found in 65% of the patients. CSF 
cell count and protein were unremarkable in 75%. Initial brain MRI was available for 
revision in 35 patients (Suppl. Figure e-2A). Median time from onset to first MRI was 
11 weeks (IQR 5–24, range 0-55 weeks). Hippocampal lesions were seen in 74%, of 
which 81% were unilateral. 40% had swelling of the hippocampus with increased T2-
signal intensity. 14% had a hyperintensity on T2-images with normal hippocampal 
volume. Seven (20%) patients had loss of hippocampal volume on initial MRI. Six of 
these seven patients had increased T2-signal intensity, of which four fulfilled criteria for 
mesotemporal sclerosis (MTS). Median time from onset was 6.5 weeks in patients with 
swelling and 18.5 weeks in patients with loss of hippocampal volume (p=0.052). In 
23%, hyperintensities extended to the amygdala (n=6), insula (n=1) or striatum (n=1).
 
Follow-up MRI’s were available in 19 patients (Suppl. Figure e-2B). Median time 
from symptom onset was 27 weeks (range 7-149 weeks). 16 patients had hippocampal 
lesions on first MRI, of which seven patients (44%) had MTS at follow-up (three with 
MTS at initial MRI). 86% of patients with MTS had multiple seizures daily during 
maximal disease severity, compared to 50% in patients without MTS (p=0.17). 38% 
had persistent high signal without loss of volume. Brain MRI had normalized in the 
other three patients (19%) and three patients with initial normal MRI still had normal 
MRI at follow-up.
 Electroencephalography (EEG) showed epileptic discharges (31%) or focal 
slowing (25%) in half of the patients. 13 patients had clinical manifestations of seizures 
during EEG recordings. FBDS had no EEG correlate (n=7), while 16/17 dyscognitive, 
autonomic, gelastic or motor focal seizures were associated with epileptic discharges. 
Tumor analysis showed malignancy in three patients: neuroendocrine pancreas tumor, 
thymoma with metastasis and abdominal mesothelioma. An additional patient had 
rectal carcinoma in situ detected two months before onset of neurological disease. A 
fifth patient had metastatic breast cancer for seven years and was excluded from tumor 
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analysis.11 Although unknown if all tumors were related, we calculated tumor incidence 
as 4/36 (11%). 
 Median VGKC-RIA result was 720 pM, ranging from 245 to 1314 pM (positive 
>100pM). All sera tested positive for LGI1-antibodies on both CBA and IHC (Suppl. 
Figure E-1). CSF was available for testing in 17 patients, of which 88% showed typical 
LGI1-antibody staining on rat brain. Only 9/17 CSF samples (53%) were positive for 
LGI1 by CBA.  
 In all tested patients, no antibodies to Caspr2 (n=38), NMDA-receptor (n=32) 
or onconeural antibodies (n=29) were found. 
Treatment
Initial disease episode was treated with immunotherapy in 32 patients, with a median 
delay of 25 weeks (IQR 9-46, range 1 week to 2.5 years). 30 patients were treated with 
corticosteroids (oral n=8, intravenous n=6 or both n=16), of which 18 were additionally 
treated with intravenous immunoglobulins or plasma exchange. Two patients received 
only immunoglobulins. First-line treatment was considered effective in 80% of the 
patients. Median time to start of improvement was two weeks. Improvement started 
with decrease of seizures in 58% or decrease of seizures simultaneous with cognitive 
improvement in 42%. 
 Six patients were not treated with immunotherapy. Three patients, two diagnosed 
retrospectively, mainly suffered from seizures, with only minor cognitive symptoms, and 
improved on anti-epileptic drugs. A fourth patient was initially diagnosed with complex 
partial seizures, but when she developed behavioral problems she was suspected to have 
psychiatric disease. She remained untreated until diagnosis at relapse. Two patients had 
severe limbic encephalitis and died untreated without diagnosis.  
Long-term follow-up 
Follow-up over two years was available in 21 patients. Median follow-up was 42 
months. 67% had a favorable outcome (mRS 0-2, Figure 2). Two patients (10%) were 
moderately affected (mRS=3) due to a relapse. Two patients initially showed partial 
recovery, but died due to comorbidities aggravated by steroids (spinal cord injuries due 
to thoracic fracture and diverticular perforation) and three patients died without initial 
improvement. Two-year case fatality rate was 19%.
 In recovering patients, median time between start of improvement and end of 
recovery was 33 weeks (IQR 18-52, range 13-108). Seizures were reported to recover 
early. At final follow-up, 28% of the patients were still on anti-epileptic drugs and only 
14% had seizures in the last year. Residual symptoms reported by patients or relatives were 
mostly memory deficits, apathy and difficulties with spatial orientation. 86% suffered 
from persistent amnesia for the disease period. These patients did not remember visits 
and admissions to the hospital, and lacked memories of life events happening during 
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Figure 2. Outcome in patients with follow-up ≥ 2 years (n = 21). A. Modified Rankin Scale (mRS) at follow-up. 
Fourteen patients (67%) had a favorable outcome (mRS 0-2). Five patients had died (24%), of which four died within 
two years (2-year case fatality rate 19%). B. Current cognitive deficits, only including living patients without recent relapse. 
C. Seizures in the last 12 months, only including living patients without recent relapse. AED = anti-epileptic drugs.
35
2
Clinical syndrome of anti-LGI1 encephalitis
disease. Retrograde amnesia was reported as well, often expressed as lack of memories 
of holidays. Three patients (21%) reported persistent insomnia, with sleep disorder 
confirmed with PSQI>5. No patient had increased ESS indicating daytime sleepiness. 
Overall, median time from symptom onset to maximum recovery was 67 weeks (IQR 
50-115, range 36-269 weeks). There was no relation between treatment delay and time 
to maximum improvement or final mRS (p=0.76 and p=0.86 respectively). 
 Fifteen patients were eligible for neuropsychological assessment (follow-up ≥2 
years), of which twelve agreed to participate. Assessment was performed after median 
follow-up of 44 months (range 25-95). Residual behavioral problems precluded reliable 
assessment in one patient (mRS=3), allowing analysis of eleven patients only, all mRS 
0-2. Results for spatial recognition (SRM) were inferior to normative data (mean z-score 
-1.05, 95%-CI -1.89 to -0.23, p=0.018), while patients had normal scores on the other 
tests for visual memory. Patients had normal scores on the other primary outcome 
measure executive function (IED) and the secondary outcome measures. (Table 3)
 Relapse rate was analyzed in the 17 patients with at least two years follow-
up alive. Six patients (35%) had a relapse. Two patients were initially untreated and 
LGI1-antibodies were only tested at relapse. In four, relapses occurred despite being 
treated with immunotherapy in the acute phase. None of these patients used long-term 
immunosuppressive drugs when relapse occurred. In those tested (n=2), antibodies were 
absent in between the episodes and had reoccurred at relapse. Median time from onset 
of initial disease to relapse was 35 months (range 21-98).
Table 3: results of neuropsychological assessment performed with CANTAB
Test Outcome measure n Z-score 
(mean, SD)
p-value 95% CI
Verbal memory
Graded naming task (GNT) Percent correct 11 0.21 (0.65)  0.30 -0.22 – 0.65
Visual memory
Delayed matching to sample (DMS)
Pattern recognition memory (PRM)
Spatial recognition memory (SRM)
Percent correct (all delays)
Percent correct
Percent correct 
10
11
11
0.07 (0.64)
0.06 (0.98) 
-1.06 (1.24)
0.75
0.85
0.018 *
-0.39 – 0.53
-0.39 – 0.53
-1.89 – -0.23
Executive function
Intra-extra dimensional set shift (IED)
Spatial working memory (SWM) 
Spatial span (SSP)
Total errors
Between errors
Span length
11
11
11
0.25 (0.68)
0.36 (1.14)
-0.46 (1.72)
0.25
0.32
0.40
-0.21 – 0.70
-0.40 – 1.13
-1.61 – 0.70
Attention
Matching to sample (MTS) 
Reaction time (RTI)
Percent correct
Mean simple reaction time
11
10
-0.67 (0.95)
-0.48 (1.54)
0.041 †
0.36
-1.31 - -0.03
-1.58 – 0.63
CANTAB = Cambridge Neuropsychological Test Automated Battery. 
Cursive tests were upfront defined as primary outcome measures. 
*p<0.025 (cut-off value for primary outcome measures, Bonferroni correction)
† p<0.05 (cut-off value for secondary outcome measure, uncorrected p-value should be considered carefully)
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Discussion
We provide detailed clinical information of 38 patients with antibodies directed to 
LGI1 and report important incidence rates and long-term outcome. More insight in 
the course and semiology of seizures is essential to improve diagnosis. Seizures respond 
quickly to immunotherapy, but long-term follow-up showed cognitive improvement 
as well. Other important results of long-term follow-up were remarkable persistent 
amnesia for the disease period, a high relapse rate and the evolvement of MTS. 
 Annual incidence of anti-LGI1 encephalitis in the Netherlands was 0.83 per 
million, which is in the same order of magnitude as Creutzfeldt-Jakob disease12 or 
Lambert-Eaton myasthenic syndrome.13 The increase of the incidence of LGI1 diagnosis 
is probably due to better disease recognition, but underdiagnosis is still suspected. 
 The recognition of seizures is a clue for early diagnosis. 47% of the patients 
had FBDS, an early symptom comparable to 40-71% in other series.14,15 Recognition 
of these short seizures might be complicated by the common absence of ictal EEG 
abnormalities, which has been reported before.8 66% of our patients had focal seizures 
with mainly dyscognitive or autonomic features, also early in disease course. A few 
cases presenting with pilomotor seizures have been reported before.16 These cases also 
support our finding that focal seizures and FBDS were initially not recognized by 
treating physicians, including neurologists. Special attention should be paid to repeated 
attacks which patients describe as ‘indefinable feeling’, ‘thoughts being pulled away’ 
or autonomic features including goose bumps. Tonic-clonic seizures are more easily 
recognized, but usually occur later in disease course.  
 Almost 90% of surviving patients had a favorable outcome. Patients were 
left with persistent amnesia for the entire disease process and the preceding months 
or years. During interviews with patients and their relatives this symptom emerged to 
be very stressful to them, and was often misinterpreted as an expression of ongoing 
disease. Persistent amnesia for the period of disease has been recognized in anti-NMDA 
receptor encephalitis before17 and was thought to be caused by disturbance of long-term 
potentiation (LTP), which is the key cellular mechanism in learning and memory.17-19 
A similar mechanism can be hypothesized in LGI1-encephalitis, because LGI1-
ADAM22-AMPAR interaction is thought to influence both long-term depression 
(LTD) and LTP.4,20 As LTD is essential for spatial memory as well,21 disturbance of 
this process might be an explanation for spatial disorientation in LGI1-encephalitis. 
Neuropsychological assessment showed disturbed spatial recognition memory with 
normal performance on other memory tasks (in our limited sample size), implying 
a persistent disorder of spatial orientation, similarly as reported by the patients and 
their relatives. Apathy was also frequently reported, but was not tested formally by our 
computerized assessment. 
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 Case fatality rate at two years was 19%. Another study reports 3/57 deaths 
(6%) after follow-up ranging from 2 to 60 months.2 In our study, 2/5 deaths occurred in 
untreated patients, before LGI1-antibodies were recognized. Assuming immunotherapy 
is effective, better recognition and treatment of anti-LGI1 encephalitis is expected to 
decreases case fatality rate in the future. 
 Clinical relapses occurred more frequently than anticipated. In two patients, 
diagnosis was first made at relapse. Underdiagnoses of patients with a single disease 
episode might result in an overestimation of the relapse rate, similarly as reported in 
anti-NMDAR22,23 and anti-AMPAR encephalitis.24,25 Earlier series report relapses in 
0-18% of the anti-LGI1 patients, but follow-up was shorter, whereas relapses tend to 
occur years after the initial disease episode.2,14,26 
 Patients with MTS had frequent seizures during disease course. MTS might be 
caused by seizure activity, or directly by inflammation. The development of MTS after 
limbic encephalitis was reported before in anti-LGI1 patients.27 Similar hippocampal 
changes are reported after anti-GAD65 or anti-NMDAR encephalitis.28,29  
 Diagnosis of LGI1-antibodies can be complicated by low sensitivity of the CBA 
with CSF. Only 53% of the samples tested positive, resulting in significant delays in 
two patients until serum was tested. 6/8 CBA-negative CSF samples showed typical 
LGI1-antibody staining on rat hippocampal tissue, indicating that antibodies are 
actually present in the CSF. The need for serum analysis to detect LGI1-antibodies is 
just opposite from anti-NMDAR,30 anti-GABAbR31 or anti-AMPAR encephalitis.24 
Median time from onset to recovery was more than a year, and time to relapse was 
almost three years. This underlines the need for long follow-up time in studies assessing 
outcome. To allow the inclusion of a considerable number of patients, this study was 
conducted retrospectively, with the associated limitations. We obtained most reliable data 
by analyzing patients’ files and interviewing patients, relatives and treating physicians. 
All MRI’s were blindly reviewed by one specialized neuroradiologist. However, variable 
scan protocols and lack of coronal images in some patients limited analyses.  
 Recognizing the clearly defined clinical syndrome of anti-LGI1 encephalitis 
is essential for early treatment. Disease course can be relatively slow, resembling 
dementia, and attention should be paid to seizures with subtle manifestations early in 
disease course. Long-term outcome of surviving patients is mostly favorable, although 
persistent amnesia for the disease period is disturbing for patients. Relapses are common 
and physicians should be aware that these can occur up to years after the initial disease 
episode.
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Supplemental material
Seizure and EEG description of two patients with anti-LGI1 encephalitis
Patient 1 presents with painful legs and hyperhidrosis. After six months paroxysmal 
symptoms started, consisting of faciobrachial dystonic seizures and focal seizures 
with dyscognitive and autonomic features, as described below. Progressive cognitive 
impairment evolved, followed by tonic-clonic seizures. Two different attacks occurred 
during 24-hours EEG:
•	 Up to seventy attacks lasting for several seconds with a tonic posture of the right 
hand, arm, neck and the right corner of the mouth. Patient is able to push the 
button to report these events. Ictal EEG recordings show no abnormalities besides 
muscle artifacts.
•	 Up to twenty episodes characterized by pupillary dilation, heavy breathing and an 
anxious facial expression. The patient reports nausea and an urge to vomit. Consciousness 
seems to be retained and after the attack patient immediately responds appropriately. 
During the attack, EEG shows theta or delta activity, followed by sharp waves and spike 
and wave complexes over the midfrontal and left frontal areas, with rapid recovery. 
Patient 2 presents with mild behavioral problems. A few months later, memory 
declined and seizures started. Patient reports autonomic attacks lasting only seconds, 
occurring several times a day. These attacks consist of goose bumps and a shiver, 
sometimes accompanied by smelling a strange odor. Spouse described an early attack 
with dyscognitive features while the patient was driving a car. Patient was told to stop 
the car and they changed seats. After a few minutes, patient asked ‘how did I get in the 
passenger’s seat?’. Forty attacks similar occurred during 24-hours EEG registration: 
•	 Attacks start with a shiver, sniffing and a pale face. Patient stops talking but is able 
to follow commands, without remember these afterwards. EEG started to become 
slow and irregular, followed by sharp waves and spike and wave complexes with a 
maximum over the frontal-temporal areas. 
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Table e-1. Description of CANTAB tests included in neuropsychological assessment
Test Cognitive domain Description
Graded naming task (GNT) Verbal memory Objects appear on the screen. Participants are 
instructed to name the object.
Delayed matching to sample (DMS) Visual memory A complex pattern appears on the screen. After a brief 
delay, four patterns appear. Participants must touch 
the pattern that matches the sample. 
Pattern recognition memory (PRM) Visual memory Learning phase: several patterns appear, one at a time. 
Recognition phase: participants choose which of two 
patterns they have seen before
Spatial recognition memory (SRM)* Visual memory Learning phase: a white square is shown in various 
locations. Recognition phase: participants choose 
which of two boxes is in a location previously 
presenting a square.
Intra-extra dimensional set shift 
(IED)*
Executive function Participants must first use feedback to learn a rule 
involving two dimensions. When feedback implies 
that the rule has changed, the participant must shift 
attention to the previously irrelevant dimension. 
Derived from the Wisconsin Card Sorting Test. 
Spatial working memory (SWM) Executive function Participants search for blue tokens by touching 
colored boxes throughout the screen, without 
returning to a box where a blue token was previously 
found. 
Spatial span (SSP) Executive function White squares on the screen briefly change color in a 
variable sequence.  Participants must remember the 
sequence and touch squares in the same order, with 
growing sequence length throughout the test. 
Matching to sample (MTS) Attention A test pattern is shown. Participants have to choose 
the matching pattern from a possible 8 patterns, 
measuring speed and accuracy. 
Reaction time (RTI) Attention The participant must hold down a button until a 
yellow spot appears on the screen, and then touch the 
yellow spot.
CANTAB = Cambridge Neuropsychological Test Automated Battery 
*Primary outcome measures
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Figure e-1. Immunohistochemistry on rat brain. A) LGI1-antibody staining pattern. The hippocampus is stained, 
including the hilus and the outer 2/3rd of the dentate gyrus. Lack of staining of the inner 1/3rd of the dentate gyrus 
results in a pale line (blue arrow). B) Negative sample.
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Figure e-2. A. Revision of initial MRI brain in 35 patients. B. Revision of serial MRI brain in 19 patients. MTS = 
mesotemporal sclerosis.
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Abstract
Leucine-rich glioma-inactivated1 (LGI1)-encephalitis is an antibody-associated 
inflammation of the limbic area. An autoimmune etiology is suspected but not proven 
yet. We performed HLA-analysis in 25 non-tumor anti-LGI1 patients and discovered 
a remarkably strong HLA-association. HLA-DR7 was present in 88% compared to 
19.6% in healthy controls (p=4.1*10-11). HLA-DRB4 was present in all patients and in 
46.5% controls (p=1.19*10-7). These findings support the autoimmune hypothesis. An 
exploratory analysis was performed in a small group of four tumor-LGI1 patients. The 
strong HLA association seems not applicable in these patients. Therefore, the absence of 
HLA-DR7 or HLA-DRB4 could raise tumor suspicion in anti-LGI1 patients.
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Introduction
Leucine-rich glioma-inactivated1 (LGI1)-encephalitis is an antibody associated 
inflammation of the limbic area of the brain. Approximately 300 patients have been 
reported and annual incidence is 0.83 per million.1 Patients exhibit a subacute onset of 
frequent short seizures, tonic clonic seizures and disturbance in memory and behavior. 
Tumors are present in 5-10% of the patients,1-3 most commonly thymoma. 
 LGI1-antibodies are specific and thought to be pathogenic, although this has 
not been proven by passive transfer, as required according to the adapted Koch-Witebsky 
postulates.4 Anti-LGI1 encephalitis shows resemblance to the phenotype linked to 
genetic disruption of LGI1 proteins, which serves as indirect evidence of autoimmunity. 
Circumstantial evidence is provided by the favorable response to immunotherapy in 
observational studies. A human leukocyte antigen (HLA) association would further support 
the autoimmune hypothesis.4 HLA encodes for the major histocompatibility complex 
(MHC). MHC-class I restricted recognition by CD8+ T-cells leads mainly to a cytotoxic 
T-cell response, while MHC-class II restricted recognition by CD4+ T-cells often leads 
to a B-cell immune response. As the antibodies in anti-LGI1 encephalitis are considered 
pathogenic, a B-cell mediated immune disease is suspected. Therefore, a possible HLA-
association is most likely to involve HLA-DR or HLA-DQ, encoding MHC-class II.
 Specific HLA alleles have been linked to predisposition for autoimmune 
diseases, like myasthenia gravis (MG)5, multiple sclerosis (MS)6 and Lambert-Eaton 
myasthenic syndrome (LEMS).7 Interestingly, the association of LEMS with HLA-
B8-DR3-DQ2 was only found in patients without a tumor, suggesting a distinct 
immunopathogenetic route for paraneoplastic LEMS.7 An HLA-association with 
antibody-mediated encephalitis has not been reported before. 
 In the clinical setting, we noticed a common HLA-DRB1*07 (DR7) allele in 
our anti-LGI1 patients. For systematic analysis, we performed HLA-phenotyping in 
a larger group of anti-LGI1 patients. The aim was to analyze the association between 
HLA-type and predisposition for anti-LGI1 encephalitis in non-tumor patients. 
Methods
The study was performed in unrelated Dutch anti-LGI1 encephalitis patients from 
Caucasian descent. LGI1-antibodies were detected in serum, using a commercially 
available cell-based immunofluorescence assay (CBA)(Euroimmun, Lübeck, Germany) 
and confirmed with immunohistochemistry (IHC) on rat brain, as reported before.8 
Tumor screening had been performed with thoracic and abdominal CT or whole body 
FDG-PET, in line with recommendations.9 The frequency of the HLA-alleles in the 
study group was compared to the frequency in 5,604 healthy Caucasian Dutch blood 
donors.10   
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 The study was approved by the Institutional Review Board of the Erasmus 
Medical Center, Rotterdam. Patients were included in the study after their informed 
consent. 
HLA analysis
HLA-class I typing was performed by the reverse SSO method on a suspension array 
platform using microspheres as a solid support to immobilize oligonucleotide probes 
(Luminex bead technology Immunocor Transplant Diagnostics Inc. Stamford, CT, 
USA). HLA-class II (DRB1, DQB1, DRB3/4/5) was genotyped using the sequence-
specific oligonucleotide probe (PCR/SSOP) technique.11 This results in medium-
low resolution subtyping. The HLA-types are given as serotypes, according to the 
most common nomenclature. The serotypes are the protein products of various gene 
products. For example, the HLA-DR7 serotype comprises the gene products of HLA 
DRB1*07:01 to DRB1*07:05. 
Tissue analysis
Formalin-fixed paraffin-embedded (FFPE) tumor tissue of a mesothelioma, resected from 
a patient with anti-LGI1 encephalitis, was analyzed for the presence of LGI1 proteins. 4 
µm thick sections were stained with the Ventana Benchmark Ultra automated staining 
system (Ventana Medical System, Tuscon, AZ, USA). Briefly, after deparaffination 
the sectioned specimens were processed for 64 minutes antigen retrieval using Cell 
Conditioning Solution (CC1 Ventana-Ref.:950-124). After 32 minutes incubation with 
the primary antibody (LGI1, ab30868, Abcam, Massachusetts, USA. Dilution 1:250) 
at 360C, detection was performed using OptiView DAB IHC Detection Kit (760-
700) after amplification with OptiView Amplification Kit (Ventana-ref.:760-099). The 
sections were counterstained with hematoxylin II (Ventana-Ref.:790-2208).
Statistical analysis
Differences in phenotype frequencies were analyzed with Fisher’s Exact-Test. P-values 
were corrected for multiple testing (Sidak’s method) and standardized for sample size 
disparity between the patient and control group (Good’s method, adjusted to 1:3 
ratio). Pcorrected< 0.05 was considered significant. Odds ratios (OR) were calculated using 
Haldane’s modification of Woolf ’s method. The main study group consisted of patients 
without a tumor. Analysis of HLA-subtype in anti-LGI1 patients with a tumor was 
exploratory.
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Table 1: Patient characteristics and HLA-results. 
Case Gender Age Clinical 
subtype
Tumor FU 
(mo)
DRB3,4,5 DRB1 DQB1
1 F 29 LE No 7 DRB4  DRB1*08
DRB1*09
DQB1*03 DQB1*03
2 M 43 LE No 6 DRB4  DRB1*01 DRB1*04 DQB1*03 DQB1*05
3 M 49 LE No 4 DRB4 DRB3 DRB1*07 DRB1*12 DQB1*02 DQB1*03
4 F 51 LE No 14 DRB4  DRB1*07 DRB1*04 DQB1*03 DQB1*03
5 M 54 LE No 9 DRB4 DRB3 DRB1*07 DRB1*03 DQB1*02 DQB1*02
6 M 58 LE No 15 DRB4 DRB5 DRB1*07 DRB1*15 DQB1*03 DQB1*06
7 F 58 LE No 81 DRB4  DRB1*07 DRB1*01 DQB1*02 DQB1*05
8 M 59 LE No 1 DRB4  DRB1*07 DRB1*04 DQB1*02 DQB1*03
9 F 60 MoS No 95 DRB4  DRB1*07 DRB1*04 DQB1*03 DQB1*02
10 F 60 LE No 42 DRB4  DRB1*07 DRB1*04 DQB1*02 DQB1*03
11 M 61 LE No 79 DRB4  DRB1*07 BRB1*04 DQB1*02 DQB1*03
12 M 62 MoS No 0 DRB4 DRB5 DRB1*07 DRB1*15 DQB1*02 DQB1*06
13 F 62 LE No 6 DRB4 DRB3 DRB1*07 DRB1*03 DQB1*02 DQB1*03
14 M 63 LE No 9 DRB4 DRB3 DRB1*07 DRB1*12 DQB1*02 DQB1*03
15 M 64 LE No 0 DRB4  DRB1*07 DRB1*07 DQB1*02 DQB1*02
16 F 64 LE No 85 DRB4  DRB1*07 DRB1*07 DQB1*02 DQB1*02
17 M 66 LE No 4 DRB3 DRB4 DRB1*07 DRB1*11 DQB1*02 DQB1*03
18 M 68 LE No 81 DRB4 DRB5 DRB1*07 DRB1*15 DQB1*02 DQB1*06
19 M 69 LE No 26 DRB4  DRB1*07 DRB1*01 DQB1*02 DQB1*05
20 M 69 LE No 8 DRB4  DRB1*07 DRB1*04 DQB1*02 DQB1*03
21 M 72 LE No 9 DRB4  DRB1*07 DRB1*01 DQB1*02 DQB1*05
22 M 72 LE No 18 DRB4  DRB1*07 DRB1*01 DQB1*02 DQB1*05
23 F 77 LE No 73 DRB4  DRB1*07 DRB1*07 DQB1*02 DQB1*03
24 M 78 LE No 18 DRB5 DRB5 DRB1*09 DRB1*16 DQB1*03 DQB1*05
25 M 80 LE No 28 DRB4  DRB1*07 DRB1*04 DQB1*02 DQB1*03
26 M 60 LE Rectum 
carcinoma 
(2 mo before)
79 DRB4  DRB1*07 DRB1*04 DQB1*02 DQB1*03
27 M 60 MoS Neuroendocrine 
pancreas tumor 
(9 mo before)
34 DRB4  DRB1*07 DRB1*01 DQB1*02 DQB1*05
28 F 66 LE Thymoma 
(2 mo after)
3 DRB3  DRB1*11 DRB1*13 DQB1*03 DQB1*06
29 M 67 LE Mesothelioma 
(At relapse)
72 DRB4 DRB5 DRB1*04 DRB1*15 DQB1*03 DQB1*06
FU = follow up. Mo = months. LE = limbic encephalitis. MoS = Morvan’s syndrome
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Results
25 non-tumor and 4 tumor patients were included, 17/25 (68%) and 3/4 (75%) were 
male, respectively. Median age at disease onset was 62 years (IQR 58.5-68.5, range 29-
80). 26 patients had a limbic encephalitis (LE). Three patients had LE with additional 
features, fulfilling criteria for Morvan’s syndrome. In the course of disease, all patients 
had memory deficits and 25 patients (86%) had seizures. Median follow up was 15 
months. (Table 1)
Non-tumor anti-LGI1 patients vs healthy controls
HLA-DR7 allele was present in 22/25 non-tumor anti-LGI1 patients (88%) 
and in 1,098/5,604 (19.6%) healthy controls (OR 26.37, 95%-CI 8.54–81.49, 
pcorrected=4.1*10
-11). Three anti-LGI1 patients (12%) were homozygous for HLA-DR7, 
compared to 1.0% in the control population (p=0.0021). The three HLA-DR7 negative 
patients did not differ from HLA-DR7 positive patients with regard to age and gender 
(p=0.84 and p=1.00, respectively) and they all presented with typical features of anti-
LGI1 encephalitis.1 
 HLA-DR7 is known be linked to DRB4, which was present in all 25 patients, 
compared to 46.5% of the controls (OR 58.59, 95%-CI 3.57–962.84, pcorrected=1.19*10
-7). 
The high incidence of DQ2 is explained by its link with DR7. No positive association 
with other class I or class II HLA alleles was found. (Table 2 and Supplementary Table)
Table 2: The frequency of HLA-alleles in non-tumor anti-LGI1 patients and controls. 
Cases Controls Woolf-
Haldane
95% C.I. Fishers Exact Test (2-sided)
pos neg % pos neg % OR lower upper P Pc Pc2
B*13 6 19 24,0 229 5375 4,1 7,81 3,182 19,155 0,0005 0,0179   0,1340
DRB1*07 22 3 88,0 1098 4506 19,6 26,37 8,535 81,489 0,0000 0,0000 <0,0001*
DRB1*13 0 25 0,0 1393 4211 24,9 0,06 0,004 0,974 0,0016 0,0222   0,1667
DRB3 5 20 20,0 3744 1860 66,8 0,13 0,052 0,342 0,0000 0,0000   0,0001*
DRB4 25 0 100,0 2608 2996 46,5 58,59 3,565 962,842 0,0000 0,0000 <0,0001*
DQB1*02 20 5 80,0 2204 3400 39,3 5,75 2,240 14,759 0,0000 0,0003   0,0024*
DQB1*06 3 22 12,0 2470 3134 44,1 0,20 0,064 0,609 0,0009 0,0064   0,0481*
The table shows the major overpresentation of DRB1*07 and DRB4 in anti-LGI1 patients. As a result, the frequency of DRB3 
and DQB1*06 are significantly reduced. The high frequency of DQB1*02 in patients is probably due to its common linkage with 
DRB1*07. Within the DRB1*07 positive patients, DQB1*02 is present in 91%, compared to 74% in the DQB1*07 positive controls 
(p = 0.0857). CI = confidence interval; neg = negative; OR = odds ratio; pos = positive.
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Tumor anti-LGI1 patients
The DR7 allele was present in 2/4 tumor patients and 3 were DRB4 positive. One 
patient was negative for DR7 and DRB4 and had a thymoma detected 2 months 
earlier. Recently, tissue analyses confirmed the presence of LGI1 proteins in a LGI1-
patient’s thymoma.12 The other DR7 negative patient had a mesothelioma, detected 
with screening at relapse (no tumor screening at initial disease episode). Tissue analysis 
confirmed the presence of LGI1-protein in the patient’s mesothelioma (Fig 1). The two 
DR7 positive patients had a rectum carcinoma in situ and a neuroendocrine pancreas 
tumor, of which the relation with encephalitis remains questionable.
A CB
D E F
Figure 1. Tissue staining showing the presence of LGI1-protein in patient’s mesothelioma. 
A. Mesothelioma tissue from a patient with anti-LGI1-encephalitis. The positive staining with commercial LGI1 antibody 
(brown color) confirms the presence of LGI1 protein in the tumor. B. Hippocampal tissue, positive control. C. Ovarium 
tissue, negative control. D-F. Mesothelioma tissue from patients without LGI1 antibodies. Some mesothelioma contain 
LGI1 protein, showing positive staining (D, E), while others lack LGI1 protein (F). Figures are at x200 magnification. 
Discussion
We report a remarkably strong association of non-tumor anti-LGI1 encephalitis with 
HLA-DR7 and HLA-DRB4. This is the first report of a genetic predisposition for 
antibody-mediated limbic encephalitis and supports the autoimmune hypothesis. The 
strong HLA association seems not to apply to the small group of four tumor patients, 
suggesting two different immunopathogenic pathways. Considering the small size, 
absence of HLA-DR7 or HLA-DRB4 in anti-LGI1 patients could raise tumor suspicion. 
In non-tumor anti-LGI1 patients, HLA-DRB4 was present in 100% and HLA-DR7 
in 88%, comparable to the strong association of HLA-B27 in patients with ankylosing 
spondylitis13. HLA-DR53 (the molecule encoded by HLA-DRB4) is associated with 
several diseases, such as Crohn’s disease,14 rheumatoid arthritis,15 and celiac disease.16 
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Little is known about DR7 associations. Limited data suggest an association with 
polyarthritis in psoriasis patients.17 Functional studies are needed to establish whether 
DRB4 or DR7 is responsible for antigen presentation. Our results enable further studies, 
including the possibility to culture disease-specific T-cells from patient’s peripheral 
blood. In addition, the target epitopes for LGI1-antibodies can possibly be detected 
by analyzing which fragment of LGI1-protein fits to the unique characteristics of the 
involved MHC-II molecule. 
 LGI1-antibodies are mainly IgG4 subclass antibodies.18 An HLA-association 
was earlier described in IgG4-mediated diseases: MuSK-antibody mediated MG 
and pemphigus vulgaris are both associated with HLA-DR14-DQ5 and IgLON5 is 
associated with DR1-DQ5.19,20 Anti-LGI1 encephalitis is the first IgG4-associated 
disease with a different HLA-type than DQ5. 
 Contrary to non-tumor-LGI1 patients, the strong HLA associations were 
not seen in the four anti-LGI1 patients with a tumor. This suggests two separate 
immunopathogenic routes leading to one disease, as described in LEMS before. HLA-
B8-DR3 was only linked to non-tumor LEMS, while no HLA-association was found in 
LEMS associated to small-cell lung cancer.7 In both LEMS and anti-LGI1 encephalitis, 
a direct autoimmune etiology is supported by the HLA-link in non-tumor patients, 
while a paraneoplastic etiology is likely in tumor patients. Our results support the latter 
by the demonstration of LGI1-proteins in a patient’s tumor. This suggests that the 
tumor directly triggers the immune response, similar to LEMS.21 Considering our small 
sample size we cannot draw firm conclusion in anti-LGI1 encephalitis, but the absence 
of HLA-DR7 or DRB4 seems to increase the probability of a tumor, and should lead to 
extensive screening.9 Importantly, the presence of HLA-DR7 and DRB4 is insufficient 
to exclude a tumor in anti-LGI1-patients. 
 This study has some limitations. First, follow up in most patients was less 
than the four years needed to exclude a tumor.9 However, the current HLA-DRB4 and 
DR7 associations are remarkably strong. Detecting a tumor in coming years will only 
slightly change the strength of these associations. Our study was limited by small sample 
size, especially of anti-LGI1 patients with a tumor, and confirmation of our results is 
mandatory.   
 Non-tumor anti-LGI1 encephalitis is strongly associated with the presence of 
HLA-DR7 and HLA-DRB4, underlining the autoimmune hypothesis. Our HLA results 
and the results of tumor tissue analysis suggest an alternative immunopathogenetic route 
in tumor patients. We recommend HLA subtyping in anti-LGI1 patients. If HLA-DR7 
or DRB4 is absent, extended tumor search including follow up is indicated. 
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Supplemental material 
Supplementary Table: The frequency of all HLA-alleles in non-tumor anti-LGI1 patients and controls
Cases Controls Woolf-
Haldane
95% C.I. Fishers Exact Test (2-sided)
pos neg % pos neg % OR lower upper P Pc Pc2
A*01 6 19 24,0 1887 3717 33,7 0,66 0,270 1,598 0,3979 1,0000 0,5000
A*02 14 11 56,0 2745 2859 49,0 1,31 0,605 2,853 0,5503 1,0000 0,5000
A*03 8 17 32,0 1640 3964 29,3 1,17 0,516 2,669 0,8260 1,0000 0,5000
A*11 1 24 4,0 649 4955 11,6 0,47 0,090 2,434 0,3519 0,9998 0,5000
A*23 1 24 4,0 134 5470 2,4 2,49 0,475 13,063 0,4557 1,0000 0,5000
A*24 2 23 8,0 921 4683 16,4 0,54 0,147 1,995 0,4138 1,0000 0,5000
A*25 0 25 0,0 122 5482 2,2 0,88 0,053 14,498 1,0000 1,0000 0,5000
A*26 2 23 8,0 248 5356 4,4 2,29 0,619 8,499 0,3057 0,9993 0,5000
A*29 3 22 12,0 299 5305 5,3 2,76 0,888 8,549 0,1477 0,9591 0,5000
A*30 2 23 8,0 276 5328 4,9 2,05 0,553 7,594 0,3521 0,9998 0,5000
A*31 3 22 12,0 314 5290 5,6 2,62 0,844 8,116 0,1637 0,9720 0,5000
A*32 2 23 8,0 355 5249 6,3 1,57 0,425 5,812 0,6707 1,0000 0,5000
A*33 0 25 0,0 113 5491 2,0 0,95 0,057 15,680 1,0000 1,0000 0,5000
A*34 0 25 0,0 17 5587 0,3 6,26 0,367 106,936 1,0000 1,0000 0,5000
A*36 0 25 0,0 9 5595 0,2 11,55 0,655 203,762 1,0000 1,0000 0,5000
A*66 0 25 0,0 33 5571 0,6 3,26 0,194 54,679 1,0000 1,0000 0,5000
A*68 1 24 4,0 517 5087 9,2 0,60 0,115 3,137 0,7237 1,0000 0,5000
A*69 0 25 0,0 9 5595 0,2 11,55 0,655 203,762 1,0000 1,0000 0,5000
A*74 0 25 0,0 5 5599 0,1 19,96 1,075 370,551 1,0000 1,0000 0,5000
A*80 0 25 0,0 2 5602 0,0 43,94 2,058 938,319 1,0000 1,0000 0,5000
B*07 4 21 16,0 1391 4213 24,8 0,63 0,229 1,754 0,3633 1,0000 0,5000
B*08 5 20 20,0 1436 4168 25,6 0,78 0,303 1,999 0,6493 1,0000 0,5000
B*13 6 19 24,0 229 5375 4,1 7,81 3,182 19,155 0,0005 0,0179 0,1340
B*14 1 24 4,0 217 5387 3,9 1,52 0,290 7,929 1,0000 1,0000 0,5000
B62 8 17 32,0 837 4732 15,0 2,74 1,206 6,249 0,0427 0,8254 0,5000
B63 0 25 0,0 44 5525 0,8 2,43 0,146 40,618 1,0000 1,0000 0,5000
B75 0 25 0,0 16 5553 0,3 6,60 0,385 112,991 1,0000 1,0000 0,5000
B76 0 25 0,0 1 5568 0,0 72,79 2,896 1829,526 1,0000 1,0000 0,5000
B77 0 25 0,0 9 5560 0,2 11,48 0,650 202,487 1,0000 1,0000 0,5000
B*18 1 24 4,0 414 5190 7,4 0,77 0,147 3,999 1,0000 1,0000 0,5000
B*27 1 24 4,0 405 5199 7,2 0,79 0,151 4,095 1,0000 1,0000 0,5000
B*35 4 21 16,0 1090 4514 19,5 0,87 0,313 2,399 0,8040 1,0000 0,5000
B*37 0 25 0,0 181 5423 3,2 0,59 0,036 9,662 1,0000 1,0000 0,5000
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B*38 0 25 0,0 186 5418 3,3 0,57 0,035 9,394 1,0000 1,0000 0,5000
B*39 2 23 8,0 229 5375 4,1 2,49 0,672 9,240 0,2739 1,0000 0,5000
B60 0 25 0,0 676 4832 12,3 0,14 0,009 2,303 0,0644 0,9303 0,5000
B61 1 24 4,0 198 5310 3,6 1,64 0,313 8,569 0,6006 1,0000 0,5000
B*41 2 23 8,0 86 5518 1,5 6,79 1,811 25,434 0,0575 0,9062 0,5000
B*42 0 25 0,0 9 5595 0,2 11,55 0,655 203,762 1,0000 1,0000 0,5000
B*44 8 17 32,0 1257 4347 22,4 1,68 0,738 3,820 0,2378 1,0000 0,5000
B*45 0 25 0,0 60 5544 1,1 1,80 0,108 29,858 1,0000 1,0000 0,5000
B*46 0 25 0,0 9 5595 0,2 11,55 0,655 203,762 1,0000 1,0000 0,5000
B*47 0 25 0,0 29 5575 0,5 3,71 0,220 62,309 1,0000 1,0000 0,5000
B*48 0 25 0,0 5 5599 0,1 19,96 1,075 370,551 1,0000 1,0000 0,5000
B*49 1 24 4,0 84 5520 1,5 4,00 0,759 21,090 0,3170 1,0000 0,5000
B*50 0 25 0,0 84 5520 1,5 1,28 0,077 21,217 1,0000 1,0000 0,5000
B*51 2 23 8,0 590 5014 10,5 0,90 0,245 3,337 1,0000 1,0000 0,5000
B*52 0 25 0,0 50 5554 0,9 2,16 0,130 35,915 1,0000 1,0000 0,5000
B*53 0 25 0,0 40 5564 0,7 2,69 0,161 45,013 1,0000 1,0000 0,5000
B*54 0 25 0,0 2 5602 0,0 43,94 2,058 938,319 1,0000 1,0000 0,5000
B*55 0 25 0,0 239 5365 4,3 0,44 0,027 7,237 0,6245 1,0000 0,5000
B*56 0 25 0,0 77 5527 1,4 1,40 0,084 23,179 1,0000 1,0000 0,5000
B*57 2 23 8,0 368 5236 6,6 1,51 0,409 5,592 0,6783 1,0000 0,5000
B*58 0 25 0,0 93 5511 1,7 1,16 0,070 19,128 1,0000 1,0000 0,5000
B*67 0 25 0,0 1 5603 0,0 73,25 2,914 1841,024 1,0000 1,0000 0,5000
B*71 0 25 0,0 19 5550 0,3 5,58 0,328 94,955 1,0000 1,0000 0,5000
B72 0 25 0,0 26 5543 0,5 4,10 0,243 69,146 1,0000 1,0000 0,5000
B*73 0 25 0,0 2 5602 0,0 43,94 2,058 938,319 1,0000 1,0000 0,5000
B*78 0 25 0,0 3 5601 0,1 31,38 1,580 623,201 1,0000 1,0000 0,5000
B*81 0 25 0,0 3 5601 0,1 31,38 1,580 623,201 1,0000 1,0000 0,5000
C*01 2 23 8,0 323 5281 5,8 1,74 0,469 6,429 0,6532 1,0000 0,5000
C*02 3 22 12,0 575 5029 10,3 1,36 0,439 4,206 0,7379 1,0000 0,5000
C*03 7 18 28,0 1665 3939 29,7 0,96 0,410 2,244 1,0000 1,0000 0,5000
C*04 6 19 24,0 1287 4317 23,0 1,12 0,459 2,722 0,8159 1,0000 0,5000
C*05 1 24 4,0 764 4840 13,6 0,39 0,074 2,019 0,2408 0,9789 0,5000
C*06 8 17 32,0 898 4706 16,0 2,54 1,118 5,791 0,0492 0,5067 0,5000
C*07 14 11 56,0 3140 2464 56,0 0,99 0,456 2,149 1,0000 1,0000 0,5000
C*08 1 24 4,0 233 5371 4,2 1,41 0,269 7,362 1,0000 1,0000 0,5000
C*12 0 25 0,0 466 5138 8,3 0,22 0,013 3,554 0,2622 0,9858 0,5000
C*14 1 24 4,0 117 5487 2,1 2,86 0,544 15,018 0,4119 0,9994 0,5000
C*15 0 25 0,0 287 5317 5,1 0,36 0,022 5,972 0,6364 1,0000 0,5000
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C*16 4 21 16,0 343 5261 6,1 3,21 1,154 8,908 0,0643 0,6059 0,5000
C*17 2 23 8,0 97 5507 1,7 6,01 1,607 22,477 0,0707 0,6418 0,5000
C*18 0 25 0,0 2 5602 0,0 43,94 2,058 938,319 1,0000 1,0000 0,5000
 
DRB1*01 5 20 20,0 1234 4370 22,0 0,95 0,370 2,440 1,0000 1,0000 0,5000
DR17 2 23 8,0 1524 3990 27,6 0,28 0,075 1,027 0,0250 0,2988 0,5000
DR18 0 25 0,0 8 5506 0,1 12,70 0,714 225,974 1,0000 1,0000 0,5000
DRB1*04 8 17 32,0 1557 4047 27,8 1,26 0,555 2,870 0,6563 1,0000 0,5000
DRB1*07 22 3 88,0 1098 4506 19,6 26,37 8,535 81,489 0,0000 0,0000 0,0000*
DRB1*08 1 24 4,0 361 5243 6,4 0,89 0,170 4,633 1,0000 1,0000 0,5000
DRB1*09 2 23 8,0 160 5444 2,9 3,61 0,971 13,419 0,1609 0,9142 0,5000
DRB1*10 0 25 0,0 132 5472 2,4 0,81 0,049 13,374 1,0000 1,0000 0,5000
DRB1*11 1 24 4,0 930 4674 16,6 0,31 0,059 1,602 0,1071 0,7951 0,5000
DRB1*12 2 23 8,0 210 5394 3,7 2,73 0,735 10,116 0,2422 0,9794 0,5000
DRB1*13 0 25 0,0 1393 4211 24,9 0,06 0,004 0,974 0,0016 0,0222 0,1667
DRB1*14 0 25 0,0 373 5231 6,7 0,27 0,017 4,520 0,4073 0,9993 0,5000
DRB1*15 3 22 12,0 1356 4248 24,2 0,49 0,158 1,505 0,2389 0,9781 0,5000
DRB1*16 1 24 4,0 165 5439 2,9 2,01 0,384 10,539 0,5276 1,0000 0,5000
DRB3 5 20 20,0 3744 1860 66,8 0,13 0,052 0,342 0,0000 0,0000 0,0001*
DRB4 25 0 100,0 2608 2996 46,5 58,59 3,565 962,842 0,0000 0,0000 0,0000*
DRB5 4 21 16,0 1508 4096 26,9 0,57 0,205 1,573 0,2645 0,6021 0,5000
DQB1*02 20 5 80,0 2204 3400 39,3 5,75 2,240 14,759 0,0000 0,0003 0,0024*Ϯ
DQ7 6 19 24,0 1641 3894 29,6 0,79 0,325 1,925 0,6632 0,9995 0,5000
DQ8 6 19 24,0 1073 4462 19,4 1,39 0,569 3,375 0,6105 0,9986 0,5000
DQ9 6 19 24,0 504 5031 9,1 3,32 1,362 8,115 0,0226 0,1480 0,5000
DQB1*04 0 25 0,0 340 5264 6,1 0,30 0,018 4,991 0,3993 0,9718 0,5000
DQB1*05 6 19 24,0 1840 3764 32,8 0,68 0,280 1,659 0,4008 0,9723 0,5000
DQB1*06 3 22 12,0 2470 3134 44,1 0,20 0,064 0,609 0,0009 0,0064 0,0481*
*pcorrected < 0.05. 
ϮThe high frequence of DQB1*02 in patients is probably due to its linkage with DRB1*07. Within 
the DRB1*07 positive patients, DQB1*02 is present in 91%, compared to 74% in the DQB1*07 positive controls 
(p = 0.0857). 
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Abstract
Objectives 
To report a large cohort of patients with antibodies against contactin-associated protein-
like 2 (Caspr2) and provide the clinical spectrum of this disorder. 
Methods 
Serum and CSF samples were assessed at two neuroimmunology centers in Barcelona 
and Rotterdam. Patients were included if Caspr2-antibodies were confirmed with two 
independent techniques, including brain immunohistochemistry and cell-based assay. 
Clinical information was obtained by the authors or provided by treating physicians 
after patients’ informed consent.
Results 
Median age at symptom onset was 66 years. 34/38 patients were male. Median time to 
nadir of disease was 4 months (in 30% >1 year). The most frequent syndromes included 
limbic encephalitis (42%) and Morvan’s syndrome (29%). 77% of the patients had 
≥3 of the following symptoms: encephalopathy (cognitive deficits/seizures), cerebellar 
dysfunction, peripheral nervous system hyperexcitability, dysautonomia, insomnia, 
neuropathic pain or weight loss. A tumor, mostly thymoma, occurred in 19% of the 
patients. IgG4 subclass antibodies were present in all patients, 63% also had IgG1 
antibodies. Treatment-response occurred in 93% of the patients and 25% had clinical 
relapses. 
Conclusions 
Caspr2-antibodies associate with a treatable disorder that predominantly affects elderly 
men. The resulting syndrome may vary among patients but it usually includes a set of well-
established symptoms. Recognition of this spectrum of symptoms and consideration of 
the protracted clinical course are important for early diagnosis of this disorder. Prompt 
immunotherapy and tumor therapy (if needed) often result in improvement.
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Introduction
Contactin-associated protein-like 2 (Caspr2) is a membrane protein expressed in the 
central and peripheral nervous system. It is essential for proper localization of voltage-gated 
potassium channels (VGKC). Antibodies to VGKC were initially reported in patients with 
neuromyotonia, Morvan’s syndrome and limbic encephalitis (LE).1-3 However, while the 
clinical spectrum emerged, it became clear that the antibodies were not directed against 
the VGKC subunits but to associated proteins. Two of these proteins were identified in 
2010: leucine-rich glioma-inactivated1 (LGI1) and Caspr2.4, 5 Antibodies to LGI1 are 
mainly associated with LE and faciobrachial dystonic seizures, but the clinical spectrum 
of Caspr2-antibodies is more diverse. Most reports on Caspr2 autoimmunity consist 
of clinically pre-selected groups of patients with Morvan’s syndrome6, epilepsy7 or pain 
syndromes.8 In other reports, patients with Caspr2-antibodies were analyzed along with 
patients with antibodies to LGI1 or unknown proteins considered within the VGKC-
complex.9,10 Overall the clinical spectrum of Caspr2-autoimmunity remains not well 
defined. We report here the largest series of patients with Caspr2 antibodies and provide 
a framework for the clinical recognition of this disorder. 
Methods
Patients 
The study population consisted of patients suspected to have autoimmune or 
paraneoplastic neurological disorders whose serum or cerebrospinal fluid (CSF) were 
analyzed at two referral centers (Center of Experimental Neuroimmunology, Institut 
d’Investigacions Biomèdiques August Pi i Sunyer [IDIBAPS], Hospital Clinic, 
University of Barcelona, and Department of Immunology, Erasmus University Medical 
Center, Rotterdam) between 1994 and 2015. Patients with confirmed Caspr2-
antibodies were included in the study. Serum and CSF (if available) were tested using 
brain immunohistochemistry (IHC) and cell-based assays (CBA) in parallel in both 
institutions. Patients were considered to have Caspr2-antibodies if both tests were 
positive in at least one of the samples. Clinical information was obtained from the 
treating physicians in a standardized fashion after patient’s informed consent, or patients 
were seen by one of the authors (n = 15). Peripheral nerve hyperexcitability (PNH) was 
defined as spontaneous muscle overactivity (i.e. myokymia, fasciculations) identified 
by the treating neurologist during physical examination or with electrophysiological 
studies.11 Morvan’s syndrome was defined as a combination of a) cognitive symptoms 
or seizures, and b) peripheral nerve hyperexcitability and c) dysautonomia and/
or insomnia. Limbic encephalitis was defined as an encephalitis with predominant 
clinical involvement of the limbic system (short-term memory loss, difficulty forming 
new memories, behavioral disorder) or MRI FLAIR/T2 abnormalities in the medial 
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temporal lobes. Pain was considered of neuropathic origin if it was described as ‘burning’ 
sensation, ‘painful pins and needles’ or had a compatible nerve distribution. Relapse 
was defined as reoccurrence of symptoms after full or partial recovery, with sustained 
improvement for at least two months. 
Laboratory studies
The cell-based assays for determination of Caspr212 and other antibodies, brain tissue 
immunohistochemistry13, radioimmunoassay to determine VGKC-complex antibodies, 
and immunoblot studies14 have been previously reported, and are described in 
Supplemental material.
Statistical analysis
Fisher exact test was used for categorical data. Mann Whitney U was used for the 
comparison of continuous data. 
Approval 
The study was approved by the Institutional Review Boards of the University of Barcelona 
and the Erasmus University Medical Center, Rotterdam. 
Results
Thirty-eight patients fulfilled the criteria of having Caspr2-antibodies confirmed with 
more than one test (Suppl. Figure e-1, Suppl. Table e-1); 10 additional cases had 
antibodies detected only with CBA but without confirmation with brain IHC (Suppl. 
Table e-2). The clinical features of patients with confirmed Caspr2-antibodies are shown 
in Table 1. Thirty-four of 38 (89%) were male; the median age at symptom onset was 
66 years. Female patients were younger than male patients (median 49 vs 68 years, p = 
0.008). The median time to nadir was four months; in 10/33 (30%) patients the nadir 
of the disease was reached ≥12 months after symptom onset. Morvan’s syndrome was 
related to longer time to nadir than other syndromes (p=0.016).
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Table 1. Patient characteristics and clinical features (n = 38)
Male gender 34/38 (89%)
Age in years (median; IQR; range) 66; 58-72; 25-77
Time to nadir in months (median; IQR; range) 4; 2.5-12; 0.2-42
Clinical syndrome
- Limbic encephalitis
- Morvan’s syndrome
- Peripheral nerve hyperexcitability syndrome
- Cerebellar syndrome
- Other
- 16 (42%) (10/16 LE ‘plus’) 
- 11 (29%)
-   5 (13%)
-   3   (8%)
-   3   (8%) 
Presenting symptom
- Cognitive disturbance
- Epilepsy
- Peripheral nerve hyperexcitability
- Neuropathic pain
- Cerebellar symptoms
- 9/34 (26%)
- 8/34 (24%)
- 7/34 (21%)
- 6/34 (18%)
- 4/34 (12%)
Symptoms during course of disease
Cognitive disturbance
- Amnesia
- Behavioral disorder
- Hallucinations
- Psychosis
30/38 (79%) 
- 24/35 (69%)
- 21/33 (64%)
- 10/30 (33%)
-   6/32 (19%)
Epilepsy 19/36 (53%)
Peripheral nerve hyperexcitability 20/37 (54%)
Sleep disorder
- Insomnia
19/28 (68%)
16/28 (57%)
Autonomic dysfunction, ≥ 1 of the following:
- Hyperhydrosis
- Tachycardia
- Urinary retention or hesitation
- Constipation
- Orthostatic hypotension
- Adie’s pupil
- Erectile dysfunction
14/32 (44%)
- 7/14 (50%)
- 4/14 (29%)
- 3/14 (21%)
- 2/14 (14%)
- 2/14 (14%)
- 2/14 (14%)
- 1/14 (7%)
Weight loss 18/31 (58%)
Pain
Subtype specified (n = 14)
- Neuropathic
- Muscles / joints
20/33 (61%)
- 12/14 (86%)
-   2/14 (14%)
Cerebellar symptoms 12/34 (35%)
Clinical phenotype
Sixteen patients (42%) developed LE. Ten of them had additional symptoms beyond the 
limbic system, such as cerebellar dysfunction or pain (‘LE plus’, 26%) and the other 6 
had ‘pure’ LE (16%). Morvan’s syndrome occurred in 11 (29%) patients, and PNH in 
5 (13%). Two of these 5 patients also had insomnia, and another two had autonomic 
dysfunction. Three additional patients (8%) had predominant cerebellar symptoms, and 
the remaining 3 patients had a single seizure followed by pain syndrome (n = 1), painful 
polyneuropathy (n = 1) or mild amnestic syndrome with frontal lobe dysfunction (n = 1). 
 Most common presenting symptoms were cognitive disturbance (26%), 
seizures (24%), PNH (21%) or neuropathic pain (18%). During the course of disease, 
cognitive dysfunction was reported by the treating neurologist in 79% of the patients 
and 53% had seizures. In addition to cerebral symptoms, sleep disorder (68%), pain 
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(61%), weight loss (58%, median 10 kg), PNH (54%), autonomic dysfunction (44%) 
and cerebellar symptoms (35%) were common. The type of pain most frequently 
reported was neuropathic (86%), usually described as a burning sensation in the 
hands or feet; other types of pain included joint and muscle pain, thoracic pain, and 
lumbocoxalgia. The repertoire of seven symptoms comprise the spectrum of Caspr2 
clinical manifestations (Table 2). In 77% of the patients ≥ 3 core symptoms were present 
and 61% had ≥ 4. Although mainly contributive to patient recognition, these symptoms 
possibly differentiate Caspr2-patients from patients with other antibodies. Among 35 
LGI1 patients and 62 NMDAR patients, only 6 (17%) and 2 patients (3%) had ≥ 4 core 
symptoms (both p < 0.001), respectively. 
Table 2. Caspr2 core symptoms and signs
Cerebral symptoms (cognition, epilepsy)
Cerebellar symptoms
Peripheral nerve hyperexcitability
Autonomic dysfunction
Insomnia
Neuropathic pain
Weight loss
Diagnostic tests 
Cerebrospinal fluid was normal in 65% of the patients (Table 3). Seven patients had 
mild pleocytosis ranging from 6-20 cell/µL. Four of 6 patients with neuropathic pain 
had unremarkable nerve conduction studies. Needle EMG showed hyperexcitability in 
all patients with clinical features of PNH. In patients with cognitive decline and/or 
seizures, 70% had unremarkable MRI, while 24% showed bilateral T2 hyperintensity of 
the medial temporal lobes. One patient presenting with ataxia and dysarthria had an area 
of increased FLAIR/T2 signal in the brainstem. A patient with subacute cerebellar ataxia 
followed by limbic encephalitis had cerebellar atrophy on the MRI at presentation. 
 Caspr2-antibodies were detected in serum with both CBA and IHC in 
all patients. CSF brain IHC was negative in three patients, all with a tumor (and 
presenting with Morvan’s syndrome). Possibly, CSF antibody titer was lower due to the 
predominant initial peripheral involvement in this syndrome and the presence of a clear 
systemic trigger of the immune response. Twenty eight serum samples were available for 
VGKC-complex RIA. The median titer was 414 pM; 25 patients (89%) had a positive 
result (titer >100 pM).
IgG subtype classification was available in 19 patients.  All sera were IgG4 positive 
(100%) and twelve were also positive for IgG1 subclass antibodies (63%) (Fig 1). No 
clinical correlation with the presence of IgG1 antibodies was detected. 
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Table 3. Ancillary testing and laboratory results
Hyponatremia 4/31* (13%)
CSF 
- Normal
- Cell count > 5 cell/µL
- Protein > 0.58 g/L
- Unmatched oligoclonal bands
- 22/34 (65%)
-   7/34 (21%)
-   9/34 (26%)
-   3/12 (25%)
EEG
- Normal
- Epileptic
- Slow
-   8/27 (30%)
- 11/27 (41%)
-   9/27 (33%)
EMG: PNP on nerve conduction studies
- Patients with neuropathic pain 2/6 (33%) 
EMG: hyperexcitability on needle EMG 
- Patients with PNH symptoms
- Patients without PNH symptoms 
- 15/15 (100%)
-   1/8     (13%)
MRI brain (only patients with CNS symptoms) 
- Normal
- Hyperintensity medial temporal lobes
- Other abnormalities
- 23/33 (70%)
-   8/33 (24%; all bilateral)
-   2/33   (6%)
Tumor  7/37 (19%)
Immunological testing
Serum Caspr2 CBA positive 34/34 (100%)
Serum IHC positive (staining matching Caspr2 antibodies) 34/34 (100%)
CSF Caspr2 CBA positive 22/22 (100%)
CSF IHC positive (staining matching Caspr2 antibodies) 19/22   (86%)
LGI1 positivity  4/36    (11%)
VGKC RIA, picomol (n = 28). Median, range 414, 50-815
Immunoglobulin subtype
- IgG1
- IgG4
- 12/19   (63%)  
- 19/19 (100%) 
*2/4 patients with hyponatremia had LGI1-antibodies in addition to their Caspr2-antibodies.
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Figure 1: IgG subtyping by cell-based immunofluorescence assay. 
Serum from patient 1 shows IgG1 and IgG4 reactivity with HEK cells expressing Caspr2. Serum from patient 2 shows 
only IgG4 reactivity. The control serum is from a healthy participant showing absence of IgG1 and IgG4 reactivity with 
Caspr2.
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Co-morbidities
Seven (2 female, 5 male) of 37 (19%) patients had a tumor, including 4 thymoma, 1 
adenocarcinoma of the lung, 1 carcinoma in situ of sigmoid, and 1 thoracic mass without 
pathological diagnosis (the patient died shortly after presenting neurological symptoms). 
Among the 4 patients with thymoma, 1 had tumor resection two months before onset 
of neurological symptoms, another had an unresectable thymoma that had been stable 
for several years, and two had a tumor relapse by the time of neurological disease 
onset. Interestingly, 6/7 tumor patients had PNH-syndrome with several additional 
‘core symptoms’ or Morvan’s syndrome, as compared to 10/30 non-tumor patients 
(uncorrected p = 0.029). Patients with a tumor had a similar progressive disease course 
as those without tumor (median time to peak of disease 3 versus 4.5 months, p = 0.72). 
 In addition to anti-Caspr2 associated symptoms, 3 patients (2 female) had 
myasthenia gravis (MG). Their anti-Caspr2-related syndromes included Morvan’s 
syndrome (n = 2) and PNH syndrome (n = 1). Two of them had recurrent thymoma at 
the time of presentation and the third had thymic hyperplasia without thymoma.
 Four patients (11%) had additional LGI1 antibodies: one had LE, one PNH 
syndrome, and two Morvan’s syndrome. Co-occurrence of LGI1-antibodies was present 
in 2/7 tumor patients (both with thymoma) and in 2/30 non-tumor patients (p = 0.15). 
Serum sodium levels were available in three patients with LGI1-antibodies, two of them 
had hyponatremia. Caspr2-antibodies and LGI1-antibodies co-occurred in 2/4 female 
patients, but this was not different from male patients (2/32, p = 0.053).
Treatment and outcome
Twenty-eight of 30 patients without tumor were treated with immunotherapy, and the 
treatment effects in the first month were obtained in 23. The median delay between 
symptom onset and treatment was 6 months, ranging from 10 days to 9 years. Treatments 
included intravenous immunoglobulin (IVIg) only (n = 4), intravenous and/or oral 
steroids only (n = 7), plasma exchange only (n = 1), combination of IVIg and steroids 
(n = 7), combination of IVIg, steroids and plasma exchange (n = 2), or combination 
of steroids and plasma exchange (n = 2).  Additionally, one patient was treated with 
azathioprine, and seven with second line immunotherapy (cyclophosphamide (n = 2) or 
rituximab (n = 5)). Full recovery was obtained in 9 patients (39%) and partial response 
in 12 (52%). Two patients (9%) did not respond to immunotherapy (Figure 2A). Six 
patients required repeated cycles of immunotherapy because symptoms progressed days 
to weeks after initial response (treatment related fluctuations). The various therapeutic 
strategies could not be compared, due to small numbers and selection. 
 Two patients were not treated; one of them had Morvan’s syndrome and died 
before treatment could be started. The other patient was diagnosed recently. He had 
minor cognitive impairment and refused treatment. 
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Four of the 7 patients with a tumor were initially treated only with immunotherapy. 
Two showed transient improvement and the other two did not respond. However, all 
4 patients had full neurological recovery after the tumor was identified and successfully 
treated with surgery or chemotherapy (Fig 2A).  The effect of tumor treatment was 
unknown for the other 3 tumor patients. 
Figure 2: Treatment effect and outcome A. Effect of treatment in 27 patients. B. Modified Rankin Scale at follow-
up in 33 patients. 0 - No symptoms. 1 - No significant disability. Able to carry out all usual activities, despite some 
symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous 
activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. 
Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires 
constant nursing care and attention, bedridden, incontinent. 6 - Dead.(26)
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The median follow up was 36 months (range 3-168).  Twenty-four of 33 patients (73%) 
had a favorable outcome at the last follow up (mRS ≤2)(Figure 2B). Four patients died: 
two died at initial stages of the neurological disease, and one during a relapse. The 
fourth patient died after four years in a nursing home (with serious cognitive residual 
symptoms and cardiac disease). Case fatality rate was 3% after one year and 10% after 
two years. 
 Seven of 28 (25%) patients with a ≥ 1 year follow up had clinical relapses. 
Relapses occurred in 3/3 initially untreated patients and 4/26 treated patients (p = 
0.010), and presented 8 to 72 months after the initial episode (median 19 months; IQR 
9 to 33). In 3 of these 7 patients the diagnosis of Caspr2 antibody-associated syndrome 
was during the relapse.  At relapse, five patients had symptoms similar to those of the 
first episode, but the other two developed different core symptoms of the disease. A 
clarifying case is a man who presented at age 61 with visual hallucinations, behavioral 
problems, seizures and ataxia. Six year later he returned with PNH and dysarthria. The 
relapse rate did not differ between tumor and non-tumor patients (20% vs 25%, p = 
1.00). 
Discussion
We report 38 patients with Caspr2-antibodies. This is the largest and most detailed 
description of patients with this disorder and provides several relevant findings, 
1) there is a well-defined spectrum of symptoms related to Caspr2-antibodies and 
most patients have symptoms affecting multiple areas of the nervous system, 2) the 
symptom development and course of the disease are often less rapid than those of other 
autoimmune encephalitis, 3) the disorder predominates in males, 4) approximately 25% 
of the patients had relapses, and 5) all patients had IgG4 subclass Caspr2-antibodies.  
 The diagnosis of this immune disorder can be complicated by the presentation 
with a combination of symptoms involving the central and peripheral nervous system. 
Although the clinical picture may vary among patients it usually includes a set of well-
established symptoms. In 77% of the patients three or more core symptoms were 
present, including cognitive deficits/epilepsy, cerebellar dysfunction, peripheral nerve 
hyperexcitability, insomnia, autonomic dysfunction, neuropathic pain or weight loss. 
This repertoire of symptoms is consistent with the syndromes previously ascribed to this 
autoantibody in two series including 19 and 8 patients.4,12 
 Two frequent symptoms included neuropathic pain (61%) and cerebellar 
dysfunction (35%).  Pain was previously described in patients with Morvan’s syndrome 
and Caspr2-antibodies6,15 and it was attributed to small fiber polyneuropathy.15 
Unremarkable nerve conduction studies in 67% of our patients support this hypothesis. 
Most patients with cerebellar symptoms had other additional clinical features, such 
as LE.12,16,17 Our findings suggest that cerebellar symptoms in patients with limbic 
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encephalitis should raise suspicion of Caspr2-antibodies, although similar clinical 
features can occur in patients with antibodies to GABAb receptor18, Hu19 or in children 
with NMDAR-antibodies.20 
 In 30% of the patients the disease evolved in more than 1 year, which is in 
contrast to the subacute onset of most antibody-associated encephalitis.21 This protracted 
course of the disease can lead to diagnostic delays or to misdiagnosing the disorder as 
a primarily neurodegenerative disease, preventing the early use of immunotherapy. The 
low sensitivity of CSF pleocytosis adds to this difficult distinction. The VGKC-RIA does 
not always test positive either, so Caspr2 should be specifically requested.
 Most patients with confirmed Caspr2-antibodies were male (89%), which is in 
line with earlier reports (84-88%).4,12 Autoimmune diseases are generally considered to 
be more frequent in women, but male predominance is also seen in late onset myasthenia 
gravis.22 The reason for this male predominance is unclear. Although the expression of 
Caspr2 mRNA in the prostate was suggested6, Caspr2 mRNA is also expressed in the 
ovaries23. Interestingly, the few women of our study were younger than men, frequently 
had an underlying tumor (none of them of the ovary), and showed high propensity to 
autoimmunity (MG and LGI1-antibodies). 
Twenty-five percent of the patients had relapses, some of which occurring up to 7 years 
after the initial episode of the disease. Considering that the overall median follow-up 
was 3 years, the late relapses of some patients may suggest an even higher relapse rate. In 
almost half of the cases with relapses the initial diagnosis of the disease was made during 
the relapse, suggesting that patients with a monophasic disease may be missed at disease 
onset leading to an overestimation of relapse rates. This occurred in other autoimmune 
encephalitis such as anti-AMPAR24 and anti-NMDAR in which a drop of relapse rate 
was noted after these disorders were better recognized and promptly diagnosed.20 Similar 
to these encephalitides, about half of the relapsing cases with Caspr2-antibodies were not 
appropriately treated in the first episode. The lower relapse rate in treated patients versus 
untreated patients is similar to that seen in anti-NMDAR encephalitis.20 One should 
be aware that in patients with Caspr2-antibodies the symptoms at relapse may involve 
different parts of the nervous system than those involved in the initial episode (e.g. CNS 
or peripheral nervous system). 
 A limited number of autoimmune disorders are associated with IgG4 antibodies. 
Recently, IgG4 antibodies were demonstrated in several anti-LGI1 patients and in 
three out of seven anti-Caspr2 patients.6 All our patients had IgG4 antibodies against 
Caspr2; this finding is important for a better understanding of the pathophysiology 
of the disease and has treatment implications. IgG4 antibodies have the property of 
being functionally monovalent through the in vivo exchange of IgG half-molecules 
(one H- plus one L-chain).25 Therefore, in contrast to IgG1 antibodies (as in anti-
NMDAR encephalitis) IgG4 antibodies are unable to crosslink the target leading to its 
The clinical spectrum of Caspr2-antibodies
71
4
internalization. Moreover, IgG4 antibodies show low affinity for the Fcγ receptor, and 
are inadequate in activating cellular immune responses and complement. We postulate 
that IgG4 Caspr2-antibodies may be directly pathogenic by altering Caspr2-related cell-
to-cell interactions. 
 A limitation of this study is the retrospective collection of data obtained from 
medical records. Therefore, we possibly overestimated the true frequency of some 
symptoms, as missing information was not taken into account. Nevertheless, the current 
findings will improve the recognition of the core symptoms associated to Caspr2-antibodies 
as well as the frequent protracted clinical course and high relapse rate. Early recognition 
is important because our data confirm that immunotherapy and tumor treatment 
(if needed) are often effective in this disease.
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Supplemental material
Laboratory Studies
Cell based assay (CBA) was performed with an in-house test at Hospital Clinic, 
whereas the Erasmus Medical Center used a commercially available test (Euroimmun, 
Lübeck, Germany). For both tests, fixed human embryonic kidney 293 cells had been 
transfected with cDNA encoding Caspr2 protein. The in-house test was performed with 
serum diluted 1:40 and CSF 1:5, and Alexa Fluor 488 goat anti-human IgG (1:1000; 
Invitrogen) to detect bound IgG. Dilutions for the commercial CBA were serum 1:10 
and CSF undiluted, with fluorescein isothicyanate (FITC)-conjugated goat-anti-human 
IgG to detect bound IgG, according to manufacturer’s instructions. Serum IgG subtyping 
was performed using CBA and FITC conjugated sheep anti–human IgG1 (1:400) or 
IgG4 (1:1000) as secondary antibodies (The Binding Site, Birmingham, England). All 
assays were examined with a fluorescence microscope by two of the investigators. 
 IHC was performed according to similar protocols in both laboratories. In 
brief, paraformaldehyde fixed rat brain was prepared as previously reported1, and 7 µm 
thick sagittal sections were serially incubated with 0,3% H2O2 for 15 minutes, 5% 
goat serum for 60 minutes, and overnight with patient’s serum (1:200) or CSF (1:2) 
at 4°C. Subsequently, sections were incubated with biotinylated goat anti-human IgG, 
avidin-biotin peroxidase and the reactivity developed with diaminobenzidine. IHC was 
considered positive if a previously reported neuropil staining pattern characteristic of 
Caspr2 antibodies was identified.2 
 Sera were tested for VGKC-complex antibodies with radioimmunoassay (RIA) 
in the Erasmus Medical Center, using 125I-α-dendrotoxin labeled VGKC extracts of 
mammalian brain, according to the manufacturer’s instructions (DLD Diagnostika 
GmbH, Hamburg, Germany). Results were expressed as picomoles of 125I-α-
dendrotoxin binding sites precipitated per liter of serum, corrected for mean results of 
control samples. Samples < 50 pM were considered negative. All samples > 50 pM were 
tested twice. Results ranging from 50 to 100 pM were inconclusive, results > 100 pM 
were considered positive.
References
1. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by 
neuropil antibodies: MRI and PET correlates. Brain 2005 Aug;128:1764-1777.
2. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and 
neuromyotonia. Ann Neurol 2011 Feb;69:303-311.
The clinical spectrum of Caspr2-antibodies
75
4
Table e-1: Caspr2 core symptoms in 38 patients with confirmed Caspr2 antibodies
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1 M 69 No 6 7
2 F 53 Yes 6 7
3 M 77 No 6 7
4 M 74 No 6 7
5 F 45 No 6 7
6 F 45 No 5 5
7 M 68 No 5 6
8 M 71 Yes 5 6
9 M 62 Yes 5 7
10 M 69 No 5 7
11 M 74 No 5 7
12 M 54 Yes 5 7
13 M 68 No 4 5
14 M 68 No 4 7
15 M 66 No 4 7
16 M 62 No 4 7
17 M 61 No 4 7
18 M 53 Yes 4 7
19 M 74 Yes 4 7
20 M 61 No 3 4
21 M 57 Yes 3 4
22 M 59 No 3 7
23 M 62 Yes 3 7
24 M 76 No 3 7
25 M 66 No 3 7
26 M 40 No 3 7
27 M 74 No 2 3
28 M 25 Yes 2 3
29 M 72 Yes 2 5
30 M 60 Yes 2 7
31 M 72 N.A. 1 7
32 M 68 Yes 2 7
33 M 75 Yes 1 6
34 M 74 No 2 7
35 M 62 No 1 6
36 F 58 Yes 1 4
37 M 67 N.A. 1 4
38 M 58 No 1 3
Subacute onset = progression to maximum disease severity in three months
Green = symptom present. Orange = symptom absent. Grey = symptom not documented.
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Table e-2: Symptoms and diagnosis in 10 patients with antibodies detected only 
with CBA (without confirmation with brain IHC)
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s Final diagnosis 
or 
clinical description
1 M 83 No 4 7 Creutzfeldt Jakob disease
2 F 28 No 3 7 Cramp fasciculation 
syndrome
3 M 56 Yes 2 2 Autoimmune 
encephalopathy
4 M 63 No 2 6 Encephalopathy with 
hypokinetic rigidity
5 M 78 No 2 7 Creutzfeldt Jakob disease
6 F 62 Yes 1 2 Psychiatric symptoms
7 F 37 Yes 1 2 Neuro-SLE
8 F 83 Yes 1 2 Episodic cognitive 
disturbance
9 M 62 No 1 7 Limbic encephalitis
10 M 78 No 1 7 Limbic encephalitis
Subacute onset = progression to maximum disease severity in three months
Green = symptom present. Orange = symptom absent. Grey = symptom not documented.
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Positive	Caspr2	cell-based	assay	 
n	=	51 
Missing	clinical	information 
n	=	2 
Missing	sample 
n	=	1 
Caspr2-positive	patients	included 
n	=	38 
Additional	investigations	not	
confirming	Caspr2	antibodies	 
n	=	10	 
Patients	tested	for	antibodies 
n	≈	10.000 
Figure e-1: Flow chart showing inclusion for the study 
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Abstract
Objectives 
This study assessed the clinical relevance of a positive voltage-gated potassium channel 
(VGKC)-test in patients lacking antibodies to LGI1 and Caspr2.  
Methods 
VGKC-positive patients were tested for LGI1 and Caspr2 antibodies. Patients lacking 
both antibodies were matched (1:2) to VGKC-negative patients. Clinical and paraclinical 
criteria were used to blindly determine evidence for autoimmune inflammation in both 
groups. Patients with an inconclusive VGKC-titer were analyzed in the same way.
Results 
1455 patients were tested by VGKC radioimmunoassay. 56 patients tested positive, of 
which 50 patients were available to include. 25 patients had antibodies to LGI1 (n=19) 
or Caspr2 (n=6) and 25 patients lacked both antibodies. Evidence for autoimmune 
inflammation was present in 7 (28%) of the VGKC-positive patients lacking LGI1 
and Caspr2, compared to 9 (18%) of the VGKC-negative controls (p=0.38). Evidence 
for autoimmune inflammation was mainly found in patients with limbic encephalitis/
encephalomyelitis (57%), but not in other clinical phenotypes (5%, p<0.01). VGKC-
titers were significantly higher in patients with antibodies to LGI1 or Caspr2 (p<0.001). 
However, antibodies to Caspr2 could also be detected in patients with inconclusive 
low VGKC-titer while many VGKC-positive patients had no evidence for autoimmune 
inflammation 
Conclusions 
VGKC-positivity in the absence of antibodies to LGI1 and Caspr2 is not a clear marker 
for autoimmune inflammation and seems not to contribute in clinical practice. No cut-
off value for the VGKC-titer was appropriate to discriminate between patients with and 
without autoimmune inflammation.
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Introduction
Voltage-gated potassium-channel complex antibodies (VGKC) were initially detected 
in patients with neuromyotonia, Morvan’s syndrome and limbic encephalitis (LE).1-3 
Samples were positive in the VGKC-radioimmunoassay but did not show reactivity 
to cells transfected with VGKCs. Major progression was made in 2010 with the 
detection of antibodies to proteins associated with the VGKC-complex: leucine-rich 
glioma-inactivated protein1 (LGI1) and contactin-associated protein-like 2 (Caspr2).4,5 
LGI1-antibodies are associated with limbic encephalitis, while Caspr2-antibodies can 
cause both central and peripheral nervous system symptoms.4,6 
 A substantial part of the VGKC-positive patients lack antibodies to both LGI1 
and Caspr2. In literature these ‘double negative’ patients are often grouped together 
with LGI1/Caspr2-positive patients, although it is unknown if pathogenic mechanisms 
are similar. At least clinically, these ‘double negative’ patients form an essentially distinct 
subgroup. Increasing numbers of patients are published with a myriad of symptoms, 
including epilepsy,7 neuropathic pain,8 and even Creutzfeldt-Jakob disease (CJD).9 
While the clinical spectrum of ‘double negative’ patients is broadening, it is unclear if 
VGKC-positivity in these patients reflects clinical relevance.10 At least in some patients, 
i.e. with CJD, autoimmune etiology is proven unlikely, but this has not been studied 
on group level. It is also unclear whether VGKC-titer levels adequately assess clinical 
relevance.We assessed the probability of an autoimmune basis for disease in VGKC-
positive patients without LGI1/Caspr2 antibodies, compared to matched VGKC-
negative patients. The clinical relevance of VGKC-titer levels is explored. The aim of 
this study is to assess the clinical relevance of a positive VGKC-test in patients without 
antibodies to LGI1/Caspr2. 
Methods
Patients and clinical evaluation 
The Erasmus University Medical Center is the national referral center for neuronal 
and extracellular antibody testing in the Netherlands. Serum samples had been sent 
for radioimmunoassay (RIA) for VGKC-complex antibodies between January 2008 
and December 2013. Patients with a positive or inconclusive VGKC-RIA were tested 
for LGI1 and Caspr2 antibodies, as well as matched negative controls. VGKC-positive 
patients lacking both antibodies were the main study group. The patients with an 
inconclusive VGKC-RIA were analyzed separately. 
 VGKC-positive patients without antibodies to LGI1/Caspr2 were matched 
with VGKC-negative patients. Matching (1:2) was based on clinical syndrome (as noted 
in free text by the referring physician), age (±5 years) and gender. The first two matching 
patients from a consecutive list of VGKC-negative test results were selected. Clinical 
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information from patients and controls was obtained retrospectively from the treating 
physician and additional laboratory tests were performed as described below. Treatment 
response was only included in the analysis if explicitly noted in the patient file. Two 
investigators (MT/PSS) were blinded for VGKC-test result and (effect of) immunotherapy, 
and independently reviewed evidence for autoimmune inflammation in all cases. Evidence 
for autoimmune inflammation was based on rigorous clinical criteria and supporting results 
of ancillary testing, Table 1. These criteria were established upfront of the current study, 
since there is no consensus on international diagnostic criteria for autoimmune encephalitis 
yet. The investigators assessed each criterion (A-D) separately and finally concluded whether 
the patient met the criteria for autoimmune inflammation. If in disagreement, reviewers 
convened to achieve agreement. Additionally, the investigators rated the probability of 
autoimmune basis for disease for each patient on a 0-10 point scale. Higher scores indicate a 
higher likelihood of autoimmune etiology. The mean of the scores of the two reviewers was 
calculated as ‘autoimmune rating score’. Investigators also defined the clinical subtype. 
Table 1. Criteria for autoimmune classification. 
Evidence for autoimmune inflammation when fulfilling criteria A, B, C1 or C2, and D
A. Subacute onset of disease (substantial part of disease within 3 months) 
B. Clearly defined clinical syndrome*:
        - Limbic encephalitis
        - Morvan’s syndrome
        - Encephalomyelitis / progressive encephalomyelitis with rigidity and myoclonus (PERM)
        - Brainstem encephalitis
        - New onset focal epilepsy
        - Psychosis
        - Neuromyotonia
C1. Antibody detected:  
NMDAR, AMPAR, DPPX, GABAaR, GABAbR, GAD65, aquaporin-4
antibodies or classical onconeural antibodies**
Antibodies detected in both serum and CSF, or confirmation with immunohistochemistry or neuronal cell culture 
(not needed in aquaporin-4 antibodies)
or 
C2: ≥ 2 results of ancillary tests supporting autoimmune diagnosis:
        - CSF: pleiocytosis and/or unmatched oligoclonal bands
        - Brain MRI: abnormalities consistent with autoimmune inflammation, i.a.T2 hyperintens temporal lobe lesion
        - Tumor: systemic tumor present within two years of neurological diagnosis
        -  Positive serum immunohistochemistry and neuronal cell culture, or positive CSF immunohistochemistry or 
neuronal cell culture
        - Serological markers for autoimmune disease, i.a. anti-TPO
        - Histopathological evidence for autoimmune inflammation (brain biopsy or autopsy)
D. No other diagnosis
*according to Graus et al19 Syndromes irrelevant for the current study are omitted. Morvan’s syndrome, new onset 
focal epilepsy and psychosis were added according to recent literature 4,20,21
**antibodies to Hu, Ri, Yo, Tr, CV2, Ma1, Ma2, amphiphysin
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 Patients and controls were classified in four subgroups. The first and second 
group consisted of patients with antibodies to LGI1 or Caspr2, respectively. The third 
group consisted of patients without antibodies to LGI1/Caspr2 but fulfilling criteria for 
autoimmune inflammation (‘autoimmune’ group). The fourth group were patients not 
meeting these criteria (‘non-autoimmune’ group)
Laboratory investigation
All assays have been performed as described before. Methods are described in short 
below, and in more detail in the Supplemental material.
 Sera were tested for antibodies to the VGKC-complex by commercial RIA, using 
125I-α-dendrotoxin-labeled VGKC-extracts of mammalian brain, according to the 
manufacturer’s instructions (DLD Diagnostika GmbH, Hamburg, Germany). Results 
were expressed as picomoles (pM) of toxin bound per liter of test serum, corrected for 
mean results of control samples. Samples <50 pM were considered negative, results 
ranging from 50 to 100 pM inconclusive and titers >100 pM were considered positive. 
These cut-off values are based on extensive validation studies with an external laboratory.
Patients were tested for LGI1 and Caspr2 antibodies using commercial cell-based 
immunofluorescence assay (CBA) of fixed human embryonic kidney293 cells transfected 
with cDNA encoding the relevant protein (Euroimmun, Lübeck, Germany). Both 
positive and negative samples were additionally screened for antibodies to cell-surface 
antigens with immunohistochemistry on rat brain. This screening test can show antigen-
specific staining patterns, i.e. NMDAR and LGI1, or nonspecific diffuse neuropil 
staining, i.e. Caspr2, AMPAR and GABAbR. When results were contradictory, samples 
were tested on live hippocampal neuronal cell cultures for confirmation. Tests were 
performed on serum samples, and CSF if available.  
 Immunoblot assays were used to test for antibodies to classical onconeural 
antigens (Hu/Ri/Yo/Tr/CV2/Ma1/Ma2/amphiphysin) (Ravo Diagnostika GmbH, 
Freiburg, Germany and Euroimmun, Lübeck, Germany) and CBAs were used to test 
for other extracellular antibodies, including antibodies directed to NMDAR/GABAbR 
/AMPAR (Euroimmun, Lübeck, Germany, performed according to manufacturer’s 
instructions), or DPPX/GABaR/AQP4/GlycineR (in house assay).
Standard protocol approvals, registrations and patient consents
The Institutional Review Board of the Erasmus University Medical Centre approved the 
study. Informed consent was obtained in all patients. 
Statistical analysis
Inter-rater agreement for the criteria of autoimmune inflammation was analyzed with 
Cohen’s kappa for categorical data. Intra-class correlation coefficient was used to assess 
inter-rater agreement of the 0-10 point rating scale. Subgroups were compared with 
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Fisher-Freeman-Halton exact test for categorical data. Numerical data were analyzed 
with Mann Whitney-U test (2 groups) or Kruskal-Wallis test (>2 groups). The relation 
between mRS or delay of testing with VGKC-RIA titer was tested with Spearman’s 
rank correlation coefficient. Statistical significance was defined as p-value <0.05, with 
Bonferroni correction for multiple testing in post hoc analysis. SPSS Statistics 21 (IBM 
Corp., Armonk, NY) was used for analysis.
Results
1455 patients had been tested by VGKC-RIA, of which 51.5% were male and 8.6% 
were children under age 18. 56 patients (3.8%) had a positive result (titer>100pM) and 
41 patients (2.8%) had an inconclusive test result (titer 50-100pM). 
 50 VGKC-positive patients were included in the study, including three 
children. Six patients were excluded because data were missing. Median age at onset was 
62 years (range 1–84 years). 54% of the patients were male. 19 patients had antibodies 
to LGI1 and six patients were positive for Caspr2 antibodies. 25/50 patients (50%) were 
negative for antibodies to LGI1/Caspr2 (‘double negatives’) and were matched to 50 
VGKC-negative patients. 32 patients with an inconclusive VGKC-result were analyzed, 
of which 30 patients were negative for LGI1/Caspr2 antibodies. See Figure 1
VGKC RIA tested
n = 1,455
VGKC positive (RIA > 100 pmol)
n = 56 (3.8%)
VGKC negative (RIA < 50 pmol)
n = 1,358 (93.3%)
VGKC inconclusive (RIA 50- 100 pmol)
n = 41 (2.8%)
VGKC positive included
n = 50
Anti-LGI1
n = 19 (38%)
Anti-Caspr2
n = 6 (12%)
Double negative
n = 25 (50%)
Autoimmune
n = 7 (28%)
Non autoimmune
n = 18 (72%)
Missing data n=6 Missing data n=9
VGKC inconclusive included
n = 32
Anti-Caspr2
n = 2 (6%)
Double negative
n = 30 (94%)
Autoimmune
n = 5 (17%)
Non autoimmune
n = 25 (83%)
Non autoimmune
N = 41 (82%)
Control 
group
Main study
group VGKC negative included
n = 50
Autoimmune
n = 9 (18%)
Figure 1: Flow chart for the inclusion of patients and the comparison of subgroups. Serum samples from 1,455 patients 
had been tested by anti-VGKC radioimmunoassay. Dashed red blocks: 25 VGKC-positive patients lacking antibodies to 
LGI1 and Caspr2 (main study group) were compared to 50 matched VGKC-negative patients (control group). Dashed 
blue blocks: titer analysis included 50 VGKC-positive and 32 VGKC-inconclusive patients.
The relevance of VGKC-positivity
85
5
Interrater agreement
105 LGI1/Caspr2-antibody negative cases were reviewed for evidence for autoimmune 
inflammation by two investigators independently (25 VGKC-positive, 50 VGKC-negative 
and 30 VGKC-inconclusive patients). Cohen’s kappa for final conclusion (autoimmune or 
non-autoimmune) was κ=0.94 (Supplemental material). The probability for autoimmune 
disease, as scored on a 0-10 point rating scale, had an intra-class correlation coefficient 
of 0.88 (95%CI 0.83–0.92). The median difference between the reviewers’ scores was 0 
(range -4 to +3), and only in 4 patient rating scores differed >2 points. 
VGKC-positive cohort
50 VGKC-positive patients were analyzed.  The clinical and paraclinical features varied 
between the four subgroups (Table 2). The LGI1 and Caspr2 patients are not discussed further. 
The double negative patients with and without evidence for autoimmune inflammation are 
described below, and subsequently compared to matched VGKC-negative patients. 
  7/25 (28%) VGKC-positive patients without LGI1/Caspr2 antibodies fulfilled 
criteria for autoimmune inflammation. The clinical picture consisted of LE (n=4, one patient 
had additional ataxia) or encephalomyelitis (EM) (n=3). Another antibody was detected in 
two patients: anti-NMDAR and anti-Aquaporin4 antibodies respectively. In the other five 
patients, evidence for auto-immune inflammation was based on supporting test results. 
 18/25 (72%) VGKC-positive patients lacking LGI1/Caspr2 antibodies had 
insufficient clinical and paraclinical evidence for autoimmune inflammation. Clinical 
phenotypes were more heterogeneous, including LE, epilepsy, psychiatric symptoms, 
cramp fasciculation syndrome, myoclonus and polyradiculopathy. Patients did not fulfil 
criteria for subacute onset (n=4), had less than two results of ancillary tests supporting 
autoimmune inflammation (n=18) or another diagnosis was established (n=2, 
leptomengeal metastasis, intracerebral bleeding). All three VGKC-positive children 
lacked evidence for autoimmune inflammation.
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Table 2.  VGKC-positive patients classified in subgroups (n = 50)
Anti-LGI1
(n = 19, 38%)
Anti-Caspr2
(n = 6, 12%)
Autoimmune
(n = 7, 14%)
Non 
autoimmune
(n = 18, 36%)
p-value
Median age at onset (range) 61 (31-84) 73 (62-83) 50 (18-75) 58,5 (1-79) 0.030*
Male gender 10/19 (53%) 6/6 (100%) 4/7 (57%) 7/18 (39%) 0.069
Clinical subtype
- Limbic encephalitis
- Morvan’s syndrome
- Encephalomyelitis/PERM
- Brainstem encephalitis
- New onset focal epilepsy
- Psychosis
- Neuromyotonia
- Other
16 (84%)
2 (11%)
0
0
1 (5%)
0
0
0
4 (67%)
0
0
1 (17%)
1 (17%)
0
0
0
4 (57%)
0
3 (43%)
0
0
0
0
0 
3 (17%)
0
0
0
1 (6%)
2 (11%)
1 (6%)
11 (61%)
<0.001*
0.72
0.003*
0.12
0.57
0.58
0.62
<0.001*
Cognitive symptoms 18/19 (95%) 5/6 (83%) 6/7 (86%) 12/18 (67%) 0.13
Epilepsy
FBDS
17/19 (89%)
10/19 (53%)
5/6 (83%)
0/6 (0%)
4/7 (57%)
0/7 (0%)
7/18 (39%)
0/18 (0%)
0.006*
<0.001*
PNS symptoms 2/19 (11%) 2/6 (33%) 0/6 (0%) 3/18 (17%) 0.35
Sleep disorder 5/10 (50%) 1/3 (33%) 0/2 (0%) 4/10 (40%) 0.81
Hyponatremia 
(serum sodium < 135 mmol/L)
12/18 (67%) 1/6 (17%) 0/7 (0%) 3/16 (19%) 0.004*
CSF
- Cell count > 5 cell/µL
- Protein > 0.58 g/L
1/18 (6%)
2/18 (11%)
1/5 (20%)
1/5 (20%)
4/7 (57%)
3/6 (50%)
2/13 (15%)
0/13 (0%)
0.030*
0.029*
MRI
- Abnormalities limbic area
- Other abnormalities
- Normal
7/19 (37%)
0/19 (0%)
12/19 (63%)
2/6 (33%)
1/6 (17%)
3/6 (50%)
2/6 (33%)
2/6 (33%)
2/6 (33%)
1/13 (8%)
8/13 (62%)
4/13 (31%)
0.24
<0.001*
0.31
EEG
- Epileptic
- Slow
- Normal
8/18 (44%)
8/18 (44%)
5/18 (28%)
3/5 (60%)
0/5 (0%)
2/5 (40%)
2/6 (33%)
5/6 (83%)
0/6 (0%)
5/11 (45%)
7/11 (64%)
1/11 (9%)
0.91
0.033*
0.24
Tumor 2/19 (11%) 0/6 (0%) 1/5 (20%) 4/13 (31%) 0.27
VGKC RIA titer, median (range) 936 (245 – 1314) 412 (385 – 653) 148 (105 – 295) 117 (102-219) <0.001*
*p < 0.05 (Fisher-Freeman-Halton exact test, comparing the four groups).  
PERM = progressive encephalomyelitis with rigidity and myoclonus. FBDS = faciobrachial dystonic seizures. 
PNS = peripheral nervous system. CSF = cerebrospinal fluid. MRI = magnetic resonance imaging. EEG = 
electroencephalography. RIA = radioimmunoassay.  
VGKC-positive vs VGKC-negative patients
The VGKC-positive patients without LGI1/Caspr2 antibodies (n=25) were compared to 
matched VGKC-negative patients (n=50), Table 3. None of the criteria for autoimmune 
inflammation differed. There was no difference in the proportion of patients with 
evidence for autoimmune inflammation in the VGKC-positive ‘double negative’ group 
compared to VGKC-negative patients (28% vs 18%, p=0.38). 
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Table 3. VGKC-positive (LGI1/Caspr2 negative) vs VGKC-negative patients
VGKC-positive 
LGI1/Caspr2 negative 
n = 25
VGKC-negative
n = 50
Subacute onset 21/25 (84%) 39/50 (78%) p = 0.76
Ancillary tests supporting autoimmune diagnosis
Antibody detected
Brain MRI
CSF
Tumor detected
Immunohistochemistry and cell culture
Serological markers
Histopathology
2/25 (8%)a
7/19 (37%)
7/20 (35%)
5/18 (28%)
4/25 (16%)
1/12 (8%)
2/2 (100%)
3/50 (6%)b
12/41 (29%)
14/41(34%)
6/28 (21%)
6/50 (12%)
6/29 (21%)
1/3 (33%)
p = 1.00
p = 0.57
p = 1.00
p = 0.73
p = 0.72
p = 0.65
p = 0.40
Other diagnosis 2/25 (8%) 9/50 (18%) p = 0.32
Evidence for autoimmune inflammation 7/25 (28%) 9/50 (18%) p = 0.38
Autoimmune rating score, medianc 3,5 2 p = 0.14
aAntibodies detected: anti-NMDAR, -Aquaporin-4
bAntibodies detected: anti-NMDAR (2x), -GAD65 serum titer > 50.000 IU/mL, CSF titer > 1000 IU/mL. 
NMDAR and GAD65 antibodies confirmed with immunohistochemistry. 
cProbability expressed on a 0-10 point scale. Patients with ‘other certain diagnosis’ excluded 
(1 VGKC-positive patient and 9 VGKC-negative patients)
VGKC-inconclusive patients
41/1455 patients (2.8%) had an inconclusive VGKC-RIA (titer 50-100pM). Nine 
patients were excluded because data were missing. 32 VGKC-RIA inconclusive 
patients were included in the subgroup analysis. Median age at onset was 62 years 
(range 2–83 years). 56% of the patients were male. Two patients (6%) had Caspr2-
antibodies, presenting with either LE or Morvan’s syndrome. LGI1-antibodies were 
not detected. 30 patients (94%) were double negative, of which 5 patients (17%) 
met criteria for autoimmune inflammation. One of them had GABAbR-antibodies. 
There was insufficient evidence for autoimmune inflammation in 25/30 (83%) VGKC-
inconclusive patients without LGI1/Caspr2 antibodies. Among them were a patient with 
glioblastoma multiforme, a patient with progressive multifocal leukoencephalopathy 
and a patient with histopathologically proven CJD.   
Therapy and outcome
Clinical outcome was known in 111 of the 132 patients (84%). 17/19 (89%) of the anti-
LGI1 patients and 8/8 (100%) of the anti-Caspr2 patients showed substantial clinical 
improvement. Of patients lacking LGI1/Caspr2 antibodies, improvement was noted in 
11/24 (46%) of the VGKC-positive patients, 20/29 (69%) of the VGKC-inconclusive 
patients and 23/31 (74%) of the VGKC-negative patients (p=0.087). 
 In patients without antibodies to LGI1/Caspr2 improvement on immunotherapy 
was noted in 6/12 (50%) VGKC-positive, 7/13 (54%) VGKC-inconclusive and 9/11 
(82%) VGKC-negative patients (p=0.25). In these patients, those with evidence for 
autoimmune inflammation showed more effect of immunotherapy (12/14 [86%]) than 
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the non-autoimmune group (10/22 [45%], p=0.033). Improvement on therapy was seen 
in 15/15 (100%) of the anti-LGI1 patients and 6/7 (86%) of the anti-Caspr2 patients, 
irrespective of VGKC-results. Five patients were excluded for analysis of therapeutic 
response because they had disease known to improve on immunotherapy, but unrelated 
to antibodies (Guillain-Barre syndrome[3], chronic inflammatory demyelinating 
polyneuropathy[1], Behçet's disease[1]). 
Relevance of VGKC-titer
VGKC-titers differed between the four subgroups (p<0.001; Figure 2). However, the 
subgroups showed considerable overlap of VGKC-titers. The shortcoming of current 
cut-off values is depicted by the two patients with Caspr2 antibodies while VGKC-RIA 
results were inconclusive, and by the high amount of patients with a positive VGKC-
result without evidence for autoimmune inflammation. However, no change of cut-off 
values would obviate both problems. 
VG
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LGI1 Caspr2 AIE + AIE -
100
1000
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 *
***
Figure 2: Anti-VGKC RIA positive and inconclusive titers.  Titer levels differ significantly between subgroups (p<0.001). 
*p < 0.05; *** p < 0.0005; AIE+ = subgroup of patients with evidence for autoimmune inflammation; AIE- = subgroup 
op patients without evidence for autoimmune inflammation.
 VGKC-titer was not correlated with disease severity measured with mRS. There 
was no correlation between delay from onset of disease to VGKC testing and VGKC-
titers (data not shown).
Relevance of clinical syndrome
Probability for autoimmune inflammation was independent of VGKC-result, but 
strongly associated with clinical syndrome. Clinical syndrome was defined by the 
independent investigators for all patients without LGI1/Caspr2 antibodies (n=105). 
57% of the patients with LE or EM had evidence for autoimmune disease compared to 
5% of the patients with other clinical syndromes (p<0.01). (Suppl. Figure e-1) 
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Discussion
This study investigated the clinical relevance of VGKC-positivity in patients without 
LGI1/Caspr2 antibodies by analyzing evidence for autoimmune inflammation, 
compared to matched VGKC-negative patients. We provide some relevant findings: 1) 
Half of the VGKC-positive patients lack antibodies to LGI1 and Caspr2, 2) There is no 
evidence that VGKC-positivity in the absence of antibodies to LGI1/Caspr2 is a marker 
for autoimmune inflammation, 3) No cut-off value for the VGKC-titer is appropriate to 
discriminate between patients with and without autoimmune inflammation.
 Half of the VGKC-positive patients had antibodies to LGI1 (38%) or Caspr2 
(12%). Other studies report LGI1 or Caspr2 antibodies in 26–77% of the VGKC-positive 
patients. The higher percentages are reported in cohorts of patients with higher VGKC-
RIA titer cut-offs and in studies only including patients with LE.4,11-13 This relation with 
LE also applies to our cohort (77% of LE patient had LGI1 or Caspr2 antibodies). 
We compared VGKC-positive patients without LGI1/Caspr2 antibodies to matched 
VGKC-negative patients. This comparison did not reveal differences between these two 
groups on any of the assessed criteria. Evidence for autoimmune inflammation was 
present in 28% of VGKC-positive patients without LGI1/Caspr2 antibodies and 18% 
of VGKC-negative patients. Although we cannot exclude that some of these patients 
with LE or EM have an autoimmune disease somehow related to the VGKC-complex, 
this small non-significant difference is most likely due to imperfect matching. Matching 
was based on the clinical syndrome noted on the request form, which in some cases 
did not correspond with the final diagnosis defined by the investigators. Five VGKC-
positive patients with LE were matched to a VGKC-negative patient with less-defined 
CNS symptoms, and in one the mismatch was in the opposite way. This resulted 
in a lower incidence of LE/EM in the control group (28% vs 40%), whereas these 
syndromes were associated with higher incidence of autoimmune inflammation than 
other syndromes (57% vs 5%). This underlines that matching by clinical syndrome is 
essential to determine the relevance of diagnostic tests. 
 VGKC-RIA titers are higher in patients with antibodies to LGI1. This is in 
line with earlier reports.12,14 However, we have shown that there is no cut-off value 
appropriate to discriminate between subgroups. 2/8 (25%) of the anti-Caspr2 patients 
had an inconclusive VGKC titer (50-100pM) and would have been missed with current 
cut-off values for positivity. Several anti-LGI1 or anti-Caspr2 patients without VGKC-
positivity have been reported before.6,15 A third of the VGKC-positive patients lacked 
evidence for autoimmune inflammation, and decreasing cut-off values would further 
decrease specificity. 
 Several other studies examined the relevance of the VGKC-test and titer level. 
High VGKC-titers were associated with CNS symptoms, but these studies included 
anti-LGI1 patients in titer analysis.11,14 As we have shown, anti-LGI1 encephalitis is 
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related to both CNS symptoms and higher VGKC-titers. Previous studies report 
high tumor rates (10-15%) and response to immunotherapy in >80% of the VGKC-
positive patients.11,12,14 This is in line with our results and might at first sight suggest a 
paraneoplastic, immune mediated disease. However, both features are seen in matched 
VGKC-negative patients as well, and are probably more related to clues to request a 
VGKC-test than to the VGKC-test result itself. The improvement after immunotherapy 
might reflect true therapeutic response, but could also be natural history, regression to 
the mean or a secondary immune response, irrespective of the VGKC-result.  
 On group level, we did not detect relevance of the positive VGKC-test in 
patients without LGI1/Caspr2 antibodies. The presence of a shared, novel antibody 
is unlikely in this heterogeneous group of patients, but could be present in a small 
subgroup of LE or EM patients. Although the presence of a novel antibody should be 
considered in those patients, it will not apply to the majority of the VGKC-positive 
patients. The search for (novel) antibodies should be pursued in all patients with high 
clinical suspicion, and should not be restricted to VGKC-positive patients. 
 Unlike VGKC-positivity in a substantial part of the patients, most other 
neurological antibodies are clearly associated with disease. These pathogenic antibodies 
are directed to (subunits of ) a single receptor or protein, such as the NMDA receptor 
or GABAb receptor. The VGKC-complex is composed of an array of proteins, probably 
both intracellular and extracellular, and related to neurons and other cell types. Recently, 
VGKC-positivity was considered a nonspecific marker for neuronal inflammation,16 
but this association remains controversial. VGKC-complex antibodies possibly arise as 
an epiphenomenon occurring with any kind of cell damage without necessity to be 
pathogenic or even inflammation-related. This would explain the presence of VGKC-
complex antibodies in some patients with prion disease, which we recently detected in 
another patient and has also been reported by others.17,18 
 The study has some limitations. First, sample size was relatively small, especially 
after subgroup classification. Contactin-2 antibodies were not tested as these have only 
been reported in one study without confirmation.4 Patients were classified according 
to the evidence for autoimmune disease, after blinding the investigators for VGKC-
test result and therapeutic outcome. However, there is no consensus on international 
diagnostic criteria for autoimmune encephalitis yet and the criteria we used were 
not verified on other autoimmune disease. Criteria were strict, in order to prevent 
over diagnosing of autoimmune inflammation. The downside is that we possibly 
underestimate the number of patients with autoimmune inflammation. This may 
especially concern patients who do not meet the criteria due to incomplete work up 
in this retrospective study. However, this affected VGKC-positive patients equally to 
matched controls, and would not have changed our conclusions. Besides, criteria used 
are less suitable for auto-immune inflammation restricted to the peripheral nervous 
system, such as Guillain-Barre syndrome. As 96% of our VGKC-positive patients had 
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central nervous system symptoms, this limitation will not apply to more than a few 
patients. Response to immunotherapy was more common in patients fulfilling criteria 
for autoimmune inflammation, supporting the criteria used. However, outcome was 
favorable in the majority of the untreated patients as well. This natural course underlines 
that improvement on immunotherapy does not equal evidence for autoimmune 
inflammation. 
 In conclusion, half of the VGKC-positive patients have antibodies to LGI1/
Caspr2. These patients usually have high VGKC-titer, but Caspr2-antibodies can be 
detected in patients with inconclusive, low VGKC-titers as well. No cut-off value for the 
VGKC-titer is appropriate to discriminate between patients with and without evidence 
for autoimmune inflammation. When antibodies to LGI1/Caspr2 are lacking, there are 
no differences between VGKC-positive patients and matched VGKC-negative patients. 
Clinical reasoning including ancillary testing is leading, whereas VGKC-positivity (by 
itself ) does not contribute in clinical practice. 
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Supplemental material
Laboratory methods
Radioimmunoassay (RIA)
In the commercial VGKC autoantibody radioimmunoassay (RIA), performed 
according to the manufacturer’s instructions (DLD Diagnostika GmbH, Freiburg, 
Germany). VGKC antibody in patient sera and controls (1:10 diluted) are allowed 
to interact with detergent solubilized VGKCs extracted from rabbit brain tissue and 
complexed with 125I-labelled α-dendrotoxin (known to react with Kv1.1, 1.2 and 1.6 
subtypes of the VGKC). After incubation at 2 – 8 °C overnight, the resulting antigen-
antibody complexes are immunoprecipitated by the addition of anti-human IgG. After 
a second incubation of 1½ hours, assay buffer is added and the samples centrifuged. 
Unbound 125I-labelled alpha-dendrotoxin-VGKC complex is removed from the tubes 
by aspiration of the supernatant. The level of radioactivity remaining in the tube is 
proportional to the antibody. Results were expressed as picomoles (pM) of toxin bound 
per liter of test serum, corrected for mean results of control samples. Samples < 50 pM 
were considered negative. All samples > 50 pM were tested twice. Results ranging from 
50 to 100 pM were inconclusive, titers > 100 pM were considered positive.
Cell-based immunofluorescence assay (CBA)
LGI1 and Caspr2 antibodies were detected in serum (1:10) or CSF (1:1) using 
the commercially available Anti-VGKC associated proteins Mosaic 1 cell-based 
immunofluorescence assay, according to the manufacturer’s instructions (Euroimmun, 
Lübeck, Germany). Fixed human embryonic kidney (HEK) 293 cells transfected with 
cDNA encoding either LGI1 or Caspr2 protein were incubated with diluted serum 
(1:10) or CSF (1:2) at room temperature. Unbound antibodies are washed away and 
bound antibodies are detected by fluorescein isothiocyanate (FITC)-conjugated goat 
IgG specific for human IgG. Results were evaluated visually by two independent 
observers using fluorescence microscopy.
Immunohistochemistry
Samples were tested for antibodies to cell-surface antigens with immunohistochemistry 
on rat brain. Paraformaldehyde (PFA) fixed tissue was prepared as reported before.(1) 
7 µm thick sagittal sections were serially incubated with 0,3% H2O2 for 15 minutes, 
5% normal goat serum for 30 minutes and overnight with patient’s serum (1:200) or 
CSF (1:2) at 4°C. Subsequently, sections were incubated with biotinylated goat anti-
human IgG (Vector, Peterborough, UK) (1:2000 diluted in 5% normal goat serum) 
for two hours, avidin-biotin peroxidase (Vectastain Elite ABC complex, Vector Labs, 
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Burlingame, CA) for one hour and finally with diaminobenzidine (Vector Labs, 
Burlingame, CA). Slides were dehydrated with ethanol series (50-100%) and mounted 
with Pertex (Klinipath, Duiven, Netherlands).
Neuronal cell culture
Embryos from pregnant mouse were removed on embryonic days 19 or 20. Hippocampal 
neurons were prepared as reported before.2 and grown for 14-17 days. Patient’s serum 
(1:200) or CSF (1:2) was incubated for 1 hour at 37°C 5% CO2, washed with phosphate-
buffered saline (PBS), fixed in 4% PFA for 5 minutes, washed in PBS again and incubated 
with anti-human IgG (1:1000) for 1 hour in the dark at room temperature. 
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Interrater agreement
105 LGI1 and Caspr2 antibody negative cases (25 VGKC-positive, 50 VGKC-negative 
and 30 VGKC-inconclusive patients) were reviewed by two investigators independently, 
according to the criteria for autoimmune inflammation (Table 1). For each criterion 
separately, Cohen’s kappa ranged between 0.82 and 1. Cohen’s kappa for final conclusion 
(autoimmune or non-autoimmune) was κ = 0.94. The investigators drew a different 
conclusion in two cases (Table e-1). One was a 62-years old female who presented with 
LE with raised CSF cell count and protein, one year after breast cancer diagnosis. The 
other patient was a 66 years old male presenting with LE. He had raised CSF protein 
and anti-TPO antibodies. Differences in evaluation were discussed in a plenary meeting 
where agreement was reached on classifying both patients in the autoimmune group. 
Table e-1. Effect of immunotherapy in VGKC positive, inconclusive and negative patients
(number of patients with improvement after treatment / number of patients treated)
VGKC positive VGKC inconclusive VGKC negative Total
Anti-LGI1 15/15 (100%) - -
Anti-Caspr2  4/5     (80%)  2/2    (100%) -
Autoimmune  4/6     (67%)  3/3  (100%) 5/5 (100%) 12/14   (86%)
Non autoimmune  2/6       (33%)  4/10  (40%) 4/6 (67%) 10/22   (45%)*
*p = 0.033 (autoimmune vs nonautoimmune)
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Figure e-1. Evidence for autoimmune infl ammation classifi ed according to clinical syndrome. 
LE = limbic encephalitis. EM = encephalomyelitis. PERM = progressive encephalomyelitis with rigidity and myoclonus. 
CNS = central nervous system symptoms. NMT = neuromyotonia. PNS = peripheral nervous system symptoms. 
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Abstract
The discovery of LGI1 and Caspr2 antibodies in 2010 represented a change of views 
of the clinical significance of voltage-gated potassium channel (VGKC) antibodies. 
Currently, all these antibodies are still grouped within the term VGKC-complex 
antibodies, and frequently considered to have a similar clinical value. However, contrary 
to this concept, recent studies show that the clinical value of these antibodies is different 
from one another. We review here the clinical significance of these immune responses 
in 3 settings: patients with antibodies against LGI1, Caspr2, or VGKC-complex but 
with negative LGI1 and Caspr2 specificity. While the first two antibodies associate 
with different but well-defined syndromes, the clinical significance of VGKC-complex 
antibodies without LGI1 and Caspr2 specificity is questionable. We describe each of 
these syndromes, discuss the function of the target antigens and review the limited 
pediatric literature on the topic. The findings emphasize the importance of defining 
these disorders according to the molecular identity of the targets (LGI1, Caspr2), and 
suggest caution in using VGKC-complex antibodies without further definition of the 
antigen for the diagnosis and treatment of patients.
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Introduction
In the last decade, major progress has been made in the field of antibody mediated 
neurological diseases. The classical paraneoplastic antibodies, described in the 1980-
1990s, are directed to intracellular antigens such as Hu, Ri and Yo. These antibodies 
associate to neurological syndromes with an inadequate response to immunotherapy and 
an invariably strong tumor association.1 In contrast, recently discovered antibodies are 
directed to extracellular antigens, such as the N-methyl-d-aspartate receptor (NMDAR). 
These antibodies are thought to be directly pathogenic, and immunotherapy is usually 
very effective.2-4 These studies have led to the discovery of over ten novel antibodies 
against extracellular proteins in the last ten years, including antibodies against leucine-
rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (Caspr2).5,6 
Diseases caused by antibodies to LGI1 or Caspr2 were previously attributed to antibodies 
against voltage-gated potassium channel (VGKC).  
 VGKC are present on the membrane of neurons in both the central and 
peripheral nerve system, where they mediate the repolarization after an action potential. 
The first report on antibodies directed to the VGKC dates back to 1995, describing 
plasma exchange responsive patients with acquired neuromyotonia, also known as 
Isaacs syndrome.7,8 This peripheral nerve hyperexcitability syndrome is characterized 
by cramps and impaired muscle relaxation. In the following years, VGKC-antibodies 
were suspected in patients with Morvan syndrome, showing the combination of 
neuromyotonia with cognitive symptoms and autonomic dysfunction or insomnia, and 
in patients with limbic encephalitis.9,10 Antibodies were detected by radioimmunoassay 
(RIA), based on 125I-α-dendrotoxin labeled VGKC-complex from mammalian brain. 
While patients’ sera showed positive result on the RIA, all attempts to show reactivity to 
VGKC-transfected cells failed. This contradiction has led to the discovery that patients in 
fact did not have antibodies against the VGKC itself, but to VGKC-associated proteins 
included in the substrate used in the test. (Figure 1 and 2) Two of these proteins were 
identified in 2010: LGI1 and Caspr2.5,6 
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Figure 1. Schematic overview of the LGI1 protein in the synaps. (A) LGI1 dimers bind to presynaptic ADAM23 and 
postsynaptic ADAM22. This structure regulates AMPAR and VGKC currents. (B) Patients’ antibodies bind to LGI1, 
presumably alterating the neuronal excitability. ADAM = a disintegrin and metalloproteinase. AMPAR =α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor. LGI1 = leucine-rich glioma-inactivated 1. NMDAR = N-methyl-
d-aspartate receptor. VGKC = voltage-gated potassium channel.
LGI1 is a synaptic protein present in the central nervous system. LGI1 antibodies 
usually associate with typical limbic encephalitis, seizures and hyponatremia. Caspr2 
is present in both the central and peripheral nervous system. This is reflected in the 
variety of symptoms and presentations associated to Caspr2-antibodies. Both antibodies 
are more prevalent in older male patients and the syndromes have a common favorable 
response to immunotherapy. Sera with either LGI1 or Caspr2 antibodies usually show a 
positive VGKC-RIA result, with higher titer in LGI1-antibody positive patients.11 It is 
not uncommon for diagnostic laboratories to start analysis with a VGKC-RIA, followed 
by cell-based assay to test for LG1 and Caspr2 antibodies after a positive RIA. This 
two-step approach has two difficulties. First, in a few patients with Caspr2 (or LGI1) 
antibodies, VGKC-RIA screening is negative, resulting in a missed diagnosis. Second, 
half of the patients with a positive VGKC-RIA lack antibodies to LGI1 and Caspr2. 
These patients present with a wide variety of clinical syndromes. The positive VGKC-
RIA has prompted many physicians to start immunotherapy. However, recent research 
has questioned the clinical relevance of a positive VGKC-test in the absence of LGI1 
and Caspr2 antibodies.11
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Figure 2. Schematic overview of the Caspr2 protein in the juxtaparanodal region of myelinated axons. Caspr2 connects 
to the dimerized contactin-2 and to PSD-95. This complex organizes Kv1 potassium channels. Patients’ antibodies bind 
to the extracellular region of Caspr2 possibly abrogating Caspr2-Contactin-2 interaction. Caspr2 = contactin-associated 
protein-like 2. PSD = postsynaptic density protein. VGKC = voltage-gated potassium channel.
Figure 2. Schematic overview of the Caspr2 protein in the juxtaparanodal region of myelinated axons. Caspr2 connects 
to the dimerized contactin-2 and to PSD-95. This complex organizes Kv1 potassium channels. Patients’ antibodies bind 
to the extracellular region of Caspr2 possibly abrogating Caspr2-Contactin-2 interaction. Caspr2 = contactin-associated 
protein-like 2. PSD = postsynaptic density protein. VGKC = voltage-gated potassium channel.
This review focuses on adult patients, but also highlights the pediatric cases. The first 
and second section cover the clinical syndromes associated to antibodies to LGI1 and 
Caspr2. Most physician have limited experience with these relatively new diseases, while 
recognition is essential because the diseases are treatable. Patient recognition should be 
based on clinical features, as the value of ancillary testing is often limited. The third 
section focusses on the subgroup of VGKC-positive patients without antibodies to 
LGI1 and Caspr2. The aim of this review is to improve the recognition of diseases 
associated to LGI1 or Caspr2 antibodies, and to clarify misconceptions regarding the 
clinical relevance of VGKC-test results. 
LGI1-antibodies
Introduction
While LGI1-antibodies were discovered only six years ago, it is probably the most 
common cause of limbic encephalitis, and the second most common cause of 
autoimmune encephalitis after anti-NMDAR encephalitis. The clinical presentation of 
anti-LGI1 encephalitis is similar in most patients. (Box 1) Recognizing this clinical 
picture is essential, because routine ancillary testing can be non-specific.11 
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Pathogenesis
Unlike other epilepsy-related proteins, LGI1 is not a structural component of a receptor 
or ion channel, but a protein secreted by neurons. LGI1 forms a trans-synaptic complex 
with the presynaptic proteins ADAM11 and ADAM23 and postsynaptic ADAM22 
and is involved in synaptic transmission excitability (Figure 1).12,13 Pre-synaptically, 
ADAM23 interacts with the Kv1 subunit of the VGKC, and is essential for localizing 
Kv1.1 and kv1.2 subunit complexes to the synaptic terminals.14 Post-synaptically, 
ADAM22 interacts with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (AMPAR) via PSD95 which is responsible for fast excitatory synaptic 
transmission, and necessary for hippocampal long-term synaptic plasticity (Figure 1A). 
During postnatal development, LGI1 mediates dendrite pruning and presynaptic and 
postsynaptic maturation in the hippocampus. 
 In humans, genetic disruptions of the LGI1-protein have been linked to 
autosomal dominant partial epilepsy with auditory features (ADPEAF).15,16 In these 
patients, the LGI1 protein is not secreted or is unstable and fails to bind ADAM22.17 
The truncated mutant LGI1 prevents normal postnatal maturation of presynaptic and 
postsynaptic functions.13
 In mice, LGI1 is widely expressed in inhibitory and excitatory neurons, but most 
extensively in the hippocampus. LGI1 null mice develop a lethal epileptic phenotype and 
most die by the third postnatal week. The lack of LGI1 disrupts synaptic connections 
and reduces AMPAR-mediated synaptic transmission in the hippocampus. This epileptic 
phenotype can be rescued by transgenic re-expression of LGI1.18 Heterozygotic mutants 
show lowered seizure thresholds.18 Mutated ADAM22 has been found to cause seizures 
as well.17 
 The pathogenesis of patients’ LGI1 antibodies has been investigated recently. 
LGI1-antibodies associated with limbic encephalitis inhibit ligand-receptor interaction 
between LGI1 and ADAM22/23 by targeting the epitempin (EPTP) repeat domain 
and leucine-rich repeat (LRR) domain of LGI1. As a consequence, the number of 
synaptic AMPAR clusters is reduced in rat hippocampal neurons similarly to epileptic 
LGI1 knock-out mouse.19 The increased excitability (manifested by seizures) in patients 
with LGI1 antibodies has been attributed to a predominant reduction of AMPARs in 
inhibitory neurons.18 It is currently unclear whether patients’ antibodies disrupt also 
the Kv1 potassium channels at the presynaptic level; this would result in increased 
excitability. 
 The exact mechanisms underlying the effects of patients’ antibodies on the 
target, LGI1, are unknown. This is in contrast with the NMDAR or AMPAR antibodies 
occurring in patients with autoimmune encephalitis. These antibodies are IgG1 subclass 
and cause internalization of the corresponding receptors.20,21 An interesting feature of 
anti-LGI1-encephalitis is that the antibodies are IgG4,22,23 which are hetero-bispecific 
(continuously undergoing half-antibody exchange) and less effective than IgG1 in 
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crosslinking and internalizing the target antigen. Therefore, it is likely that the mode of 
action of LGI1 antibodies is by interfering protein-protein interactions between LGI1 
and ADAMs. 
 Pathological analysis of the uncus of one patient with anti-LGI1 encephalitis 
showed some T-cell infiltration (half of them CD8+ cytotoxic T-cells) and complement 
activation, while MRI follow-up showed progressive atrophy.24 As IgG4-antibodies 
cannot activate complement, it is currently unknown how this process occurs, but both 
direct T-cell mediated toxicity and an additional IgG1-mediated immune response are 
potential alternatives in some of the patients.
Epidemiology
Anti-LGI1-encephalitis had an annual incidence of 0.83/million in the Dutch population 
in 2015.11 The incidence rate is rising, probably due to better recognition. Two-third of 
the patients are male. The disease usually occurs at age 50-70, but it may start as early as 
the third decade of life.5,6,11,22,25-30 
Clinical syndrome
The vast majority of the patients present with limbic encephalitis (~90%), but some 
patients develop Morvan syndrome or a fragmented syndrome with only seizures 
or encephalopathy.5,6,11,22,25,26 Common initial symptoms are seizures and cognitive 
disturbances. Disease usually progresses to a maximum severity in three to six months. 
During the course of disease, almost all patients experience disturbance of memory 
and behavior, often with spatial disorientation, and 90% develop seizures.11,22,31 Three 
types of seizures occur. (Table 1) Typical of LGI1-encephalitis are faciobrachial dystonic 
seizures (FBDS), which occur in 26-71% of the patients.11,22,30 FBDS are short-lasting 
(<30 seconds) dystonic contractions of an arm, often accompanied by ipsilateral facial 
contraction, or less frequently the ipsilateral leg.26 FBDS occur 10-100 times a day and 
often start a few weeks before onset of cognitive decline. Second, subtle focal seizures 
occur in two-thirds of the patients, usually early in disease course as well. These seizures 
have mostly cognitive or autonomic features and occur multiple times a day (median 12/
day). They are easily missed, as patient’s descriptions are often vague, such as ‘thoughts 
being pulled away’, ‘a shiver’ or ‘piloerection’.32 More easily recognized are tonic clonic 
seizures, present in 60% of the patients and usually occurring only a few times during 
the severe stage of the disease.11,31 The recognition of subtle seizures is essential in the 
diagnosis of LGI1-encephalitis, and diagnosis is even more challenging in the small 
group of patients without seizures. Subacute onset of cognitive dysfunction with spatial 
disorientation, insomnia, hyponatremia and signs of limbic encephalitis on MRI brain 
should be a clue for antibody testing. Interestingly, a small minority of patients with 
LGI1-antibodies present with Morvan syndrome.11,23 These patients have both central 
and peripheral nervous system symptoms, although the LGI1 protein is thought to 
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be present in the central nervous system only. There is no clear explanation for the 
occurrence of peripheral nerve hyperexcitability, but the co-existence of other relevant 
autoantibodies against yet unknown antigens should be considered. Half of the anti-
LGI1 patients have a sleep disorder, mostly insomnia, and autonomic dysfunction.11,22 
Symptoms of rapid-eye movement (REM) sleep behavior disorder were demonstrated in 
patients with limbic encephalitis and high titer VGKC-complex antibodies, subsequently 
proven to be LGI1 antibodies (Dr.F.Graus, personal communication).33
Table 1. Seizure subtypes in anti-LGI1 encephalitis
Faciobrachial dystonic 
seizures
Focal seizures tonic clonic seizures
Description Short unilateral dystonic 
contraction of the arm (and 
face / leg)
Subtle cognitive or autonomic 
features 
Generalized tonic-clonic 
seizures with loss of 
consciousness
Incidence 40-50% 60-70% 60-70%
Onset Usually before cognitive 
symptoms
Usually before or simultaneous 
with cognitive symptoms
Usually at maximum disease 
severity
Frequency at maximum disease 40-100 per day ~ 10 per day ~ 3 during total disease course 
Abnormalities on EEG during 
seizures
Not detectable is most patientsa Epileptic discharges Epileptic discharges
a Electrodecremental events preceding the motor movement have been described34, as well as a slow frontal wave, 
contralateral and preceding the FBDS.31
Ancillary testing
Routine ancillary testing can be contributive, although results are often non-specific. 
Mild to moderate hyponatremia is present in 60-74% of the patients.5,6,11,22 Routine CSF 
is usually normal, or shows a slightly increased cell count. Brain MRI shows unilateral 
or bilateral hyperintensities in the medial temporal lobes in most patients, but the MRI 
is normal in 10-25%.11,22,35 Basal ganglia hyperintensity on T1 and/or T2 sequences was 
reported in up to 42% of the patients with FBDS, and not in patients without FBDS.36 
However, this feature was seen in 1/16 patients with FBDS  in a recent German study,35 
similar to our cohort (A.van Sonderen/M.Titulaer, unpublished data). Almost half of 
the patients develop mesial temporal sclerosis during the follow up.11 Hippocampal 
atrophy was reported in 40-95% of patients.11,35 This large difference might be partially 
explained by case selection and differences in treatment. EEG shows focal slowing or 
epileptic discharges in half of the patients. Interestingly, the majority of the FBDS 
have no ictal EEG correlates but longer FBDS can be preceded by electrodecremental 
events, usually preceding the onset of movement by approximately 500 msec,11,34,37 or a 
slow frontal wave, contralateral to the FBDS.31 In contrast, most EEGs show epileptic 
discharges during dyscognitive or autonomic focal seizures.11,34 Variable tumor types are 
seen in 0-11% of the patients (Table 2).5,6,11,22,28,30
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Antibodies can be detected in both serum and CSF, using cell-based assay (CBA) or 
brain tissue immunohistochemistry (Figure 3A). Due to absence of intrathecal antibody 
synthesis,38 serum antibody testing might be more reliable. Accordingly, one study 
showed a higher sensitivity for serum analyses compared to CSF (100% vs 88%). The 
sensitivity for the commercial CBA with CSF was even lower (53%).11 In contrast, 
another recent study using in-house CBA combined with immunohistochemistry 
showed a higher sensitivity with CSF (100% vs 92%).22 Serum with LGI1-antibodies is 
positive on the VGKC-RIA and the titers are usually high.11  
Box 1: Clinical characteristics of anti-LGI1 encephalitis
Patient
Male (67%)
50-70 years (can be younger)
Clinical syndrome: limbic encephalitis (90%) 
Seizures (90%) 
- Faciobrachial dystonic seizures (FBDS, 50%) 
- Subtle focal seizures (65%)
- Tonic clonic seizures (65%)
Cognitive decline
- Memory disturbance (97%)
- Behavioral disturbance (90%)
- Spatial disorientation (50%)
Insomnia (65%)
Ancillary testing
Hyponatremia: 65%
MRI brain: mesial temporal lobe hyperintensity: 75%
CSF normal: 75%
Tumor: <10%
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Figure 3. Immunohistochemistry on rat brain. Whole brain (left) and magnification of the hippocampus (right). 
(A) LGI1-antibodies cause staining of the hippocampus, excluding the inner one-third of the dentate gyrus, resulting in 
a typical pale strip. (B) Caspr2-antibodies show diffuse staining of the hippocampus. (C) Negative control, no staining.
Treatment and outcome
Anti-epileptic drugs usually have little effect on seizures, while immunotherapy shows 
impressive results.11,25,30,36,39 To our experience, frequent FBDS or focal seizures almost 
disappear within hours to days after starting methylprednisolone. In patients presenting 
with FBDS, early immunotherapy is associated with preventing progression to limbic 
encephalitis.39 The proposed therapeutic scheme (Figure 4) is based on cohort studies and 
expert opinion, as no therapy trials have been performed. First-line treatment consists 
of corticosteroids, intravenous immunoglobulin, plasma exchange or a combination of 
these. This treatment is reported to be effective in 50-80% of the patients.11,22 While 
early response on seizure frequency is common, cognitive improvement usually takes 
months to a year. In a study, early treatment was associated with less severe cognitive 
outcomes.35 For sustained improvement, pulse therapy is often followed by oral 
treatment with corticosteroids, azathioprine or mycophenolate mofetil. Little is known 
about the response to second-line treatment after first-line treatment failure. Rituximab 
has been considered particularly effective in IgG4-mediated disorders.40 In a small 
series of 5 patients with anti-LGI1 encephalitis, rituximab was effective in 2 patients. 
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Anti-LGI1 encephalitis
1st line pulse therapy:
MP or IVIg (or PE)
Eﬀective in
2-3 weeks?**
Eﬀective in
2-3 weeks?**
Eﬀective in
6 weeks?**
B-cell
depletion?
Alternative 1st line
pulse therapy
2nd line therapy:
RTX
Alternative 2nd line
therapy: CTX
RTX for two
additional weeks
Consider adding
oral prednisone*
and AZA/MMF
Tapper down
predisolone
after 4 weeks
No
No
No
No
Yes
Yes
Yes
Figure 4. Proposed therapy scheme for anti-LGI1 encephalitis 
*add oral prednisone in patients with moderate or severe disease. **expect early recovery of seizures, cognitive response 
may take longer. MP = intravenous methylprednisolone (3 days 1000 mg/day or 5 days 500 mg/day). IVIg = intravenous 
immunoglobulins (5 days 0.4 g/kg/day). PE = plasma exchange (3-6 sessions, alternate days). RTX = rituximab (4 weeks 
375mg/m2 weekly). CTX = cyclofosfamide (6 months 750 mg/m2 monthly). AZA = azathioprine (usual dosage 2 dd 75 
mg), MMF = mycophenolate mofetil (2 dd 720 mg).
However the series was too small to draw conclusions and the treatment delays were very 
long.41 In a recent study, 70% of the patients had a favorable outcome (independent for 
activities of daily living) at follow up ≥2 years.11,22 In most patients but not all, antibody 
tests became negative after recovery. Failure to respond to first-line therapy and clinical 
relapses were associated with poor outcome. The initial antibody level and the persistence 
of antibodies were not related to outcome.22 The most frequent residual symptoms 
included memory deficits, apathy, and difficulties with spatial orientation. The latter
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Table 2: Overview of studies with anti-LGI1 patients
Study Additional 
inclusion 
criteria
No. of 
patients
VGKC titer 
median 
(range) pM
Male Age median 
(range)
Syndrome Tumor Treatment 
effective
Good 
outcome 
(mRS 0-2)
Relapses
Irani, 
20105
VKGC > 400 
pM
55Ϯ NP 67% NP LE            89%
MoS         4%
Epilepsy   2%
0% Mostly 
successful
34/39 (87%) NP
Lai, 
20106
VGKC  > 100 
pM & LE
57 1054 
(105-7600)
65% 60 (30-80) LE         100% 11%a NP 39/50 
(78%) good 
outcome
6/33 (18%) 
median FU 
1.5 years
Irani,  
201126
FBDS
(26/29 LGI1)
29Ϯ 1962 
(639-5409) 
66% 64 (36-83) LE          90% 0% Mostly 
successful 
NP NP
Paterson,  
201329
NA 8 NP 63% 65 (18-86) LE          63%
PNH      25%
PD         13% 
NP 5/5 (100%) NP NP
Olberg,  
201328
NA 10 1196
(140-5143) 
80% 64 (53-74) LE         80%
NMT     10%
AIDP     10% 
10%b NP NP NP
Irani,  
201339
FBDS
(9/10 LGI1) 
10 1483 
(346-4515) 
50% 68 (29-92) (Cognitive 
disorder 80%) 
NP 100% 10/10 
(100%) 
(mRS 0-1) 
4/10 (40%) 
median FU 
1.5 years 
Shin,  
201330
NA 14 NP 57% 61 (41-78) (Seizures 100% 
Cognitive 
disorder 86%) 
7%c 11/12 (92%) 
minor 
or major 
improvement 
11/12 (92%) 2/4 (50%) 
FU 1 mo – 
2 yr 
Rocamora, 
201432 
Pilo-erectile 
seizures  
3 NP 67% 39 (35-52) Pilo-erectile 
seizures 
NP 2/3 (67%)  
clear effect  
2/3 (67%) NP
Irani,  
201441
Rituximab 5 NP 20% 65 (48-73) NP NP Rituximab: 
2/5 (40%) 
minor or 
major effect 
NP NP
Malter,  
201438
LE 9 (440-7655) 67% 55 (32-67) LE          100% 0% 8/9 (89%) NP (8/9 
seizure 
free; 6/8 
remaining 
cognitive 
deficits) 
0/9 (0%)
(median 
FU 2 
years) 
Flanagan,  
201536 
FBDS 26  400 
(70-3460) 
65% 62.5 
(37-78) 
LE           81% 8%d 18/18 
(100%) 
NP NP
Steriade,  
201637
Epilepsy 
monitoring
9 NP 56% 54 (15-80) NP 0% NP NP NP
Gao,  
201625
NA 10 NP 70% 51.5 
(27-75) 
LE           90% 0% 9/9 (100%) At 10 
months: 
9/10 (90%) 
3/10 (30%) 
FU 2-30 
mo 
Li, 
201627
NA 10 NP 60% Mean 58 
(34-78) 
(Seizures 100% 
Cognitive 
disorder   40%) 
10%e 9/10 (90%) 9/10 (90%)  0/9 (0%) 
mean 
FU 10.2 
months 
Van Sonderen, 
201611
NA 38 720 
(245-1314) 
66% 64 (31-84) LE            90%
MoS          8%
Epilepsy   3% 
11%f 24/30 (80%) >2 years: 
67%  
6/17 (35%) 
Median FU 
42 mo 
Arino, 
201622
NA 76 NP 66% Mean 61 
(32-80) 
LE           83% 7%g 24/48 (50%) At 2 years: 
34/ 48 
(71%)  
13/48 
(27%) 
Median FU 
39 mo 
Finke,  
201735
NA 30 NP 63% Mean 66 LE 97%
FBDS 3% 
10%h NP 24/30 (80%) NP
NP = not provided. NA = not applicable. FBDS = faciobrachial dystonic seizures. LE = limbic encephalitis. MoS 
= Morvan syndrome. PNH = peripheral nerve hyperexcitability syndrome. NMT = neuromyotonia. AIDP = acute 
inflammatory demyelinating polyradiculoneuropathy. PD = Parkinson’s disease. FU = follow up. Ϯ8 patients overlap. 
aTumor types: a thyroid (n = 2), lung, renal, ovarian, thymoma, b lip, thyroid, c renal, dprostate (n =2), elung, 
fneuroendocrine pancreas tumor, thymoma, mesothelioma, rectum carcinoma in situ, gprostate, gastric neuroendocrine 
tumor, colon carcinoma, hneuroendocrine tumor jejunum, breast cancer, esophageal adenocarcinoma. 
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was shown with neuropsychological assessment,11 and recently confirmed in another 
study that also demonstrated impaired verbal memory.35 Overall, 86% of the patients 
suffer from persistent amnesia of the disease period and several months preceding the 
disease. This symptom is often misinterpreted as persistent disease activity, and can be 
very stressful to patients and relatives. Case fatality rate is 6-19%, including patients 
in whom the disease was not recognized and treated. Initial studies, with short-term 
follow-up, indicated relapses in 0-18% of the patients.6,30,38 However, recent studies with 
longer follow-up (>2 years) showed that 27-35% of the patients had relapses.11,22 This 
brings into consideration the use of long-term or aggressive immunotherapy, although 
it is unknown whether this actually diminishes the risk for relapses.
Pediatric cases
LGI1- and Caspr2 antibodies were identified in one child in a series of 39 children 
with VGKC-complex antibodies.42 However, cohorts of more than fifty children with 
acute encephalitis and over 400 children with epilepsy who were screened for LG1- 
antibodies did not identify any positive patients.43-47 Therefore, LGI1-antibodies are very 
uncommon in children and, in general, screening in pediatric patients with epilepsy or 
encephalitis seems not indicated.
Caspr2-antibodies
Introduction
Compared with LGI1-antibodies that associate with a discrete number of well-defined 
syndromes, Caspr2-antibodies occur in association with a wider variety of clinical 
syndromes. Most of these syndromes show a substantial overlap of symptoms, reflecting 
the frequent involvement of central and peripheral nervous system (Box 2). Clinical 
data are limited, as this disorder is rare.  
Box 2: Clinical characteristics of Caspr2 disease
Patient
- Male (90%)
- 60-70 years 
Caspr2 core symptoms
- Cerebral symptoms (cognition 80%, epilepsy 50%)
- Cerebellar symptoms (35%)
- Peripheral nerve hyperexcitability (55%)
- Autonomic dysfunction (45%)
- Insomnia (55%)
- Neuropathic pain (60%)
- Weight loss (60%)
Ancillary testing
- MRI brain: normal (70%)
- CSF: normal (75%)
- Tumor: 20% (mostly thymoma)
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Pathogenesis 
Caspr2 is a cell adhesion molecule that belongs to the neurexin IV superfamily. The 
Caspr2 protein is encoded by the CNTNAP2 gene, located on chromosome 7q35. 
Together with TAG1, Caspr2 forms a transmembrane axonal complex present in the 
central and peripheral nervous system. These complexes  cluster Kv1.1 and Kv1.2 of 
the VGKC at the juxtaparanodes of myelinated axons via PSD95 (Figure 2).48,49 Axonal 
excitability is regulated by stabilizing conduction at the nodes of Ranvier, avoiding 
repetitive firing and helping to maintain the internodal resting potential.50,51 In addition, 
Caspr2 is widely expressed by inhibitory neurons in the CNS, linked presynaptically to 
TAG1/Contactin and post-synaptically to Gephyrin.  There it may function as a cell 
recognition molecule essential for synaptic network formation.52 
 Caspr2-deficient mice show mis-localization of Kv1.1/1.2, 48,49 alterations 
in the migration of cortical neurons, and a reduction in the number of GABAergic 
interneurons.52 This is associated with epileptic phenotypes and autism-related behaviors. 
RNAi-mediated knockdown of Caspr2 affects synaptic organization and function in 
culture.53 In humans, genetic disruption as well as point mutations or deletions in the 
target domains are associated with intellectual disability, seizures and autistic features.54
 Patients’ antibodies are directed to the Caspr2-extracelullar domain. The 
N-terminal Discoïdin and Laminin G1 modules of Caspr2 have been identified as 
target epitopes of autoantibodies.55,56 Neither the 3-dimensional structure nor a single 
subdomain is absolutely necessary for antibody binding.55 Antibodies target inhibitory 
interneurons in the hippocampus, potentially disrupting the interaction of Caspr2 
with TAG1, indirectly altering the Gephyrin clustering post-synaptically.56 Caspr2-
antibodies are of the rare IgG4 subtype, just as LGI1-antibodies.22,57 IgG4 subtype 
does not mediate complement activation, and do not bind Fc receptors on effector 
cells. Therefore, Caspr2-antibodies may be pathogenic by blocking the function of the 
targets or protein-protein interaction, not by internalization or complement-mediated 
toxicity. One case report mentioned some complement deposition, although the clinical 
relevance in a disease in which IgG4 antibodies predominate remains questionable.58
Epidemiology 
Caspr2-antibody mediated disease has a strong male predominance (90%), for which 
there is no explanation yet. Age at onset is around 60-70 years, but female patients 
tend to be younger.5,57,59,60 The disease is rare, with approximately 150-200 patients 
encompassing all reported series. 
Clinical syndrome
The majority of the patients develops limbic encephalitis or Morvan syndrome,5,57 but 
there is substantial overlap in the main symptoms. Seven core symptoms have been 
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identified. (Box 2) These symptoms can be subtle and not mentioned by patients or 
family members spontaneously. Half of the patients develop seizures and 80% show 
cognitive deficits.  Over half of the patients have peripheral nerve hyperexcitability. In 
this disease, spontaneous muscle activity results in myokymia, fasciculations and muscle 
cramps. Hyperhydrosis is a common expression of autonomic dysfunction. Other 
common features are burning pain in the extremities, cerebellar symptoms, insomnia 
and weight loss. The disease often progresses for a few months, but progression over 
one year is not uncommon (~30%). Therefore, Caspr2-antibody-associated disease 
potentially mimics a neurodegenerative disease, mainly in patients with prominent 
cognitive decline.57 Although one study suggested the presence of Caspr2-antibodies 
in 10% of patients with idiopathic cerebellar ataxia61, the index case developed Morvan 
syndrome and only 3 of the other 7 patients sera showed reactivity with brain tissue; 
in our experience patients with idiopathic cerebellar ataxia (without the core symptoms 
indicated above) do not develop Caspr2-antibodies (J.Dalmau/M.Titulaer, unpublished 
data).
Ancillary testing
Standard laboratory examination is usually normal. Mildly raised CSF cell count or 
protein can be detected, but CSF is unremarkable in many patients (~75%). Brain 
MRI is usually normal, but (bilateral) hyperintensity of the medial temporal lobe can 
be present.57,60,62 EEG results are non-specific. 20% of the patients have a tumor, mostly 
thymoma and more frequently in patients with Morvan syndrome or neuromyotonia.57 
A recent study showed that the co-existence of antibodies against Caspr2 and Netrin 
receptors (DCC and UNC5a) associated with thymoma.63
 Antibodies can be detected with brain tissue immunohistochemistry and 
specifically confirmed with a CBA. The antibodies show a diffuse hippocampal staining 
on rat brain tissue. (Figure 3B) Confirmation can be achieved with combining serum 
and CSF analysis, or with the combination of CBA with immunohistochemistry or 
immunocytochemistry with cultured live neurons. Ninety percent of Caspr2-antibody 
positive samples test positive in the VGKC-RIA (median titer 414 pM; positive > 100 
pM).57,60 Since anti-Caspr2 encephalitis is rare and the specificity of serum CBA testing 
is high, but not perfect, additional testing of CSF or the use of confirmatory tests should 
be encouraged.57,64 A study suggested that the clinical manifestations varied according 
to the presence or absence of antibodies in CSF (e.g., absent antibodies in patients 
with neuromyotonia and Morvan syndrome, and present in patients with limbic 
encephalitis).59 Our experience is different; we found antibodies in CSF of patients 
with any type of anti-Caspr2 associated encephalitis, including limbic encephalitis, 
neuromyotonia and Morvan syndrome,57,65 and therefore it seems reasonable to examine 
serum and CSF in all patients.
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Treatment and outcome
Therapy trials have not been performed in patients with anti-Caspr2 associated syndromes, 
but the majority of the reported patients were treated with immunotherapy. the most 
frequent treatments included steroids, intravenous immunoglobulin or a combination 
of both, and some patients additionally received second-line treatment (rituximab and/
or cyclophosphamide). In several cohorts, response to treatment was from 79% to over 
90%.57,60,62,64 Successful tumor treatment seems essential in patients with a malignancy.57 
The largest reported series indicated a favorable outcome (modified Rankin Scale ≤2) in 
73% of the patients, and the two-year fatality rate was 10%. Relapses occurred in 25% 
of the patients, sometimes up to six years after the initial disease episode. Interestingly, 
relapses can present with symptoms similar to those of the first episode of other Caspr2 
core symptoms (Box 2).57
Table 3: Overview of studies with anti-Caspr2 patients
Study No. of 
patients
VGKC positive 
(%); median 
titer (range)
Male Age
Median 
(range)
Syndrome Tumor Treatment 
effective
Good 
outcome
(mRS 
0-2)
Relapses
Irani, 
Brain 
20105
19 100% 
(inclusion > 
400 pM)
84% NP 37%  LE
37% NMT
16% MoS
11% Epilepsy
32%a Non-tumor 
patients 
improved
11/17 
(65%) 
NP
Lancaster, 
201160
8 86% 88% 60.5 
(46-77)
NP 0% 7/7 
(100%)
7/8 (88%) NP
Malter, 
201438
3 100%
1419 pM
(509-2061)
100% 47 
(38-69)
NP 0% 2/3 
(67%)
NP (2/3 
seizure 
free; 1/2 
cognitive 
deficits)
0/3 (0%)
FU 11-58 mo
Sunwoo 
201562
5 NP 60% 43.5 
(8-65)
60% Epilepsy
20% MoS
NP 4/4 
(100%)
4/5 (80%) NP
Joubert, 
201659
18b NP 94% 64.5 
(53-75)
78% LE 17%c Mostly 
effective
12/16 
(75%) 
6/16 (38%)
FU 6-114 mo
Van 
Sonderen, 
201657
38 89%
414 pM 
(50-815)
89% 66 
(25-77)
42% LE
29% MoS
13% PNH
  8% 
Cerebellar  
19%d 25/27 
(93%) 
24/33 
(73%) 
7/28 (25% )
FU 1-14 yr
Bien, 
201764
20e 75%
(101-705 pM)
100% 63 
(33-75)
75% LE
15% MoS
5% LE + 
ataxia
5% MD
10% 11/14 
(79%)
13/17 
(76%)
NP
NP = not provided. LE = limbic encephalitis. NMT = neuromyotonia. MoS = Morvan syndrome. PNH = peripheral 
nerve hyperexcitability syndrome, MD movement disorder. mRS = modified ranking scale. FU = follow-up. Tumor 
types: a thymoma (n = 5), endometrial adenocarcinoma, b 33 patients were included, but only in only 18 detailed 
clinical details could be extracted,c prostate adenocarcinoma plus chronic lymphoid leukemia, thyroid cancer (n = 2), 
d thymoma (n = 4), lung adenocarcinoma (n = 2, one without biopsy) , carcinoma in situ of sigmoid, e 62 patients 
were included; only 27/62 were described in detail; two had no IgG antibodies; 5 no CSF tested or confirmatory 
testing. Additional patients identified in cohort screening without extensive clinical description are provided in 
Supplemental material Table S1.
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Pediatric patients
Several cohorts of pediatric patients were screened for Caspr2-antibodies. In most cases 
results were negative,43-45 and the essential laboratory confirmation was lacking in the 
majority of the Caspr2-CBA positive cases. Screening in patients with epilepsy resulted 
in 4/178 Caspr2 positive patients, of which two were positive on hippocampal neuronal 
culture.47 Three of 114 children with new-onset epilepsy were Caspr2 positive. Remarkably, 
these samples were VGKC-RIA negative and no additional laboratory confirmation was 
reported.46 One of 23 patients suspected to have autoimmune encephalitis were Caspr2 
positive on the CBA.66 One of 39 patients with VGKC-complex antibodies had antibody-
specificity for both LGI1 and Caspr2, and also showed reactivity with cultured neurons; 
this 3-year old boy had Guillain-Barré syndrome.42 We identified Caspr2 antibodies 
in a 9-years old girl with epilepsy and autonomic dysfunction, confirmed with brain 
immunohistochemistry and immunostaining of hippocampal cultures of neurons (M. 
Titulaer, unpublished data). In conclusion, Caspr2-antibodies do occur in children, but 
this is very rare and should always be confirmed with additional laboratory tests. 
VGKC-positivity in the absence of LGI1 and Caspr2 antibodies
Introduction
Since 1995, VGKC-complex antibodies have been determined with RIA. In 2010, it 
was found that the antibodies were not directed to the potassium channel itself, since 
no reactivity was seen with VGKC-transfected cells. Currently, the clinical relevance of 
VGKC-positivity in the absence of LGI1 and Caspr2 antibodies is unclear. 
 Patients with VGKC-complex antibodies lacking LGI1 and Caspr2 antibodies 
can present with limbic encephalitis or neuromyotonia,7,67 but also with many other 
manifestations. Indeed, a wide clinical spectrum of VGKC-complex antibody positivity 
(in the absence of antibodies to LGI1 and Caspr2) has emerged in recent years. For example 
pain, in combination with other neurological symptoms or as sole manifestation, was 
reported to be associated with VGKC-complex antibodies.68 Similarly, these antibodies 
were reported in patients with pathology-proven Creutzfeldt-Jakob disease,69 and many 
other diseases such as psychogenic non-epileptic seizures, REM sleep behavior disorder, 
multiple system atrophy, peripheral neuropathy, vasculitis, seizures, mitochondrial 
disease, periodic paralysis, hepatic encephalopathy, frontotemporal lobar degeneration, 
Lewy body disease, Asperger syndrome, or schizophrenia.28,29,70-73 This prominent lack 
of syndrome specificity and detection of high titer VGKC-complex antibodies even in 
cases without autoimmune disease have raised concern for misdiagnosis, unnecessary 
immunotherapies, and in general whether these antibodies have any clinical utility.74 
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Clinical relevance
Hundreds of patients have been reported in studies analyzing the clinical relevance of 
VGKC-complex antibodies. However, data regarding patients with VGKC-complex 
antibodies lacking antibodies to LGI1 and Caspr2 is very limited, for several reasons. 
First, subgroups with and without antibodies to LGI1 and Caspr2 are usually lumped 
together, even in recent studies (Suppl. Table S3). In 2016, a study reported a higher 
incidence of epilepsy in 62 patients with VGKC-complex antibodies compared to 
controls. Determination of LGI1 and Caspr2 antibodies was not performed despite 
that patients with these antibodies frequently have seizures.75 In another study, Klein 
and colleagues68  reported a high incidence of pain in 316 VKGC-complex antibody 
positive patients, mainly those with Caspr2-antibodies. Although the authors mentioned 
studies for LGI and Caspr2 antibodies, these results were not included. Analysis of pain 
characteristics and outcome was provided for the entire group irrespective of antibody 
results. Another study reported the MRI findings in 42 patients with VGKC-complex 
antibodies; 33 of them were tested for antibodies to LGI1 (22 positive) or Caspr2 (3 
positive), but this sub-classification was not considered in the analysis of the results.76 
Several other studies analyzed the relevance of VGKC-complex antibody positivity 
according to the titers of antibodies.  Huda et al. reported the difference in clinical 
syndrome between patients with a titer <400pM and >400pM. Unfortunately, antibodies 
to LGI1 and Caspr2 were only analyzed in a small number of patients, and these 
results were not taken into account in the main analysis.70 Some studies compared the 
likelihood of an autoimmune etiology in patients with lower and higher titers. Olberg 
et al. compared 12 patients with a VGKC-complex antibody titer >500pM with 20 
patients with a lower titer. They conclude that titers >500pM are most likely associated 
with autoimmune disease and response to immunotherapy. However, this conclusion 
was based on an analysis of data that included patients with LG1 and Caspr2 antibodies 
that are known to more often correlate with high titer VGKC-complex antibodies, and 
also are known to respond better to treatment.28 Paterson and colleagues reported a 
definite autoimmune disorder in 3/32 patients with a low VGKC-complex antibody 
titer (<400pM) and in 10/23 patients with a high titer (>400pM). Again, patients with 
antibodies to LGI1 and Caspr2 were included in the analyses, thereby clouding the value 
of titers of VGKC-complex antibodies lacking LGI1 and Caspr2-antibody specificity. 
Interestingly, VGKC-complex antibody titers of almost 1000pM were seen in patients 
with frontotemporal lobe degeneration and Lewy body dementia, both very unlikely to 
be autoimmune.29 Apart from lumping together cases with VGKC-complex antibodies 
with or without LGI1 and Caspr2 specificities, the reported series are heterogeneous as 
cut-off values differ between laboratories. 
 Several series conclude that the clinical relevance of VGKC-positivity is 
supported by the favorable response to immunotherapy. For example, symptoms 
improved after immunotherapy in 8/10 patients with pain syndromes and in 3/4 
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patients with seizures.68,77 However, these patients are not compared to untreated cases 
or to patients without VGKC-complex antibodies with similar syndromes. Therefore, 
the natural course of the disease, regression to the mean, and the non-immunological 
effects of corticosteroids were not taken into account. In summary, data from all these 
studies contain many confounding factors and prevent from drawing conclusions on the 
clinical value of  VGKC-complex antibodies (without LGI1 or Caspr2 antibodies). 
 In 2016, the clinical relevance of antibodies to VGKC-complex was analyzed in 
a case-control study. 25 patients without LGI1 and Caspr2 antibodies were compared 
to 50 negative patients, matched by age, gender and clinical syndrome. Results showed 
that both groups were comparable with regard to MRI abnormalities and CSF findings. 
Assessed blindly, based on predefined criteria, there was no difference in the proportion 
of patients with evidence of autoimmune inflammation in both groups (28% vs 18%, 
p=0.18). There was no cut-off value for the VGKC-titer that was found useful to 
discriminate patients with and without autoimmune inflammation. Comparing the 
matched VGKC-complex antibody positive and negative patients, tumor incidence 
(28% vs 21%, p=0.73) and response to immunotherapy (50% vs 82%, p=0.19) were 
not different.71
 In this study patients with a neurologic disorder suspected to be autoimmune 
who were found positive for VGKC-complex antibodies (but were LGI1 and Caspr2 
antibody negative) had the same likelihood to have an autoimmune disorder than 
dose who had the same clinical syndrome and were negative for VGKC-complex 
antibodies. It has been argued that patients without LGI1 and Caspr2 antibodies 
may have antibodies against a yet unknown target, but so far this target has not been 
found and patients serum or CSF samples do not show reactivity with neuronal cell 
surface antigens (J.Dalmau, unpublished data).  A group of investigators suggested that 
contactin-2 could be one alternative target. Antibodies directed to contactin-2 were 
found in 5 patients, of whom three had co-existing LGI1 or Caspr2 antibodies; clinical 
descriptions were not provided.5 The same investigators reported 3 additional patients 
with antibodies to contactin-2 among 178 children with epilepsy; two of them had 
an autistic spectrum disorder.47 Similar antibodies have been found in patients with 
multiple sclerosis78 and the clinical significance in cases with VGKC-complex antibodies 
has not been reproduced by other investigators.  
 Future research might identify other more plausible targets in patients with 
VGKC-complex antibodies who are negative for LGI1 and Caspr2 antibodies.  Of 
course the study by Van Sonderen and colleagues will need confirmation by others, but 
in the meantime, we recommend caution with the interpretation of positive VGKC-
complex antibody results. This test by itself is unreliable to establish a clinical diagnosis 
and formulate a treatment plan. In patients with VGKC-complex antibodies that are 
double negative for LGI and Caspr2 antibodies the clinical syndrome and ancillary 
studies should prevail over the positive VGKC-complex antibody findings.74,79 
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Pediatric cases
While controlled studies in adults are limited, useful data regarding pediatric cases are 
even scarcer. VGKC-complex antibodies without antibodies to LGI1 and Caspr2 were 
detected in 1/46 children with acute encephalitis,44 4/10 patients with encephalitis with 
prominent seizures,45 and 3/124 children with focal epilepsy.43 Four of 10 children with 
criteria for limbic encephalitis had VGKC-complex antibodies (not tested for LGI1 or 
Caspr2 antibodies).80 Interestingly, the response to immunotherapy was disappointing 
in most of the patients. In contrast, a series of 12 patients with VGKC-complex 
antibodies, without determination of specificity for LGI1 or Caspr2 antibodies, 
described partial or full recovery in all treated patients; as a result of this study, the 
authors recommended prompt and aggressive immunotherapy to all patients with 
VGKC-complex antibodies.81 These patients had a wide variety of symptoms, including 
motor tics, painful feet, dysarthria and global developmental regression, making it 
unlikely that all could be attributed to one disease. In addition, treatment results were 
not compared to a control group, and should therefore be interpreted with caution. 
In a recent series of 39 children with VGKC-complex antibodies and many different 
syndromes, the authors concluded that these antibodies cannot be used as a positive 
predictive value for clinical management, although an association between high titer 
of the antibodies and inflammatory disease was suggested by the ICD10-coding of 
the syndromes. The authors suggested that VGKC-complex antibodies are nonspecific 
biomarkers for (primary or secondary) inflammation.42 
 In conclusion, current data are insufficient to draw firm conclusions about 
VGKC-positivity in children. In line with studies in adult patients, VGKC-complex 
antibodies by themselves are unreliable to establish a clinical diagnosis and formulate a 
treatment plan. 
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Table 4. Overview of studies with VGKC-positive patients lacking antibodies to LGI1 and Caspr2
Study No. of 
patients
Male 
gender
Age
mean (range)
Syndrome Treatment effective Comparison to 
VGKC-negative matches 
Conclusion
Suleiman, 
201145
4 25% 11 (1-14) Encephalitis 
with seizures
NP No
Olberg, 201328 19 53% 60 (19-88) 11% LE
89% other
NP No
Paterson, 
201329
43 53 56 (18-80) 7% LE
5% MoS
5% Epilepsy
2% NMT
81% other
6/7 (86%) improvedƚ No
Malter, 201438 6 50% 52 (19-72) 100% LE NP (3/6 seizure free; 2 with 
cognitive deficits improved, 
but remained with deficits)
No
Hacohen, 
201542
39 NP Pediatric 47% 
encephalopathy
11% epilepsy
16% ADS
26% other
14/20 (70%) improvedƚ No
Lahoria, 
201672 
3 NP 61 (60-71) Peripheral 
neuropathy
1/1 (100%) improvedƚ No
Van Sonderen, 
201671
25 44% 55 (1-79) 28% LE
12% PERM 
  4% epilepsy
  4% NMT
  8% psychosis
44% other
6/12 (50%) improvedƚ Yes. 
VGKC-positivity did not 
seem to be a marker for 
autoimmunity.
NP = not provided. LE = limbic encephalitis. MoS = Morvan syndrome. NMT = neuromyotonia. ADS = acquired 
demyelinating syndrome. PERM = progressive encephalomyelitis with rigidity and myoclonus. ƚMany patients 
remained untreated; selection bias. 
Additional patients identified in cohort screening without extensive clinical description are provided in Supplemental 
material Table S2.
Conclusion
In recent years, major advances have been made in the field of VGKC-complex related 
antibodies. Antibodies to LGI1 and Caspr2 were discovered in 2010 and are very likely 
to be pathogenic. They are related to well-described clinical syndromes. Recognizing 
these syndromes is essential, as these patients are treatable with immunotherapy with 
a favorable prognosis. Tumor screening is indicated in these patients. There is no 
convincing evidence that VGKC-complex antibodies in the absence of antibodies to 
LGI1 and Caspr2 are specific markers for autoimmune neurological diseases. As all these 
autoantibodies are very infrequent in children, even more caution should be taken to 
formulate diagnostic and treatment decisions in the pediatric population. 
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Key points 
•	 Three groups of VGKC-positive patients should be distinguished: patients with 
antibodies to LGI1, patients with antibodies to Caspr2 and patients lacking these 
antibodies.
•	 Patients with LGI1 antibodies usually present with typical limbic encephalitis, 
including alteration of memory, behavior, spatial disorientation and several types 
of seizures.
•	 Patients with Caspr2 antibodies present with various syndromes involving the 
central and/or peripheral nerve system, mainly including cognitive decline, epilepsy 
and peripheral nerve hyperexcitability. 
•	 Patients with antibodies to LGI1 or Caspr2 usually respond well to immunotherapy.
•	 The clinical relevance of antibodies against VGKC-complex, but without reactivity 
with LGI1 and Caspr2, is uncertain; in these patients, clinical assessment and 
ancillary tests prevail for the establishment of a diagnosis and formulation of 
treatment.  
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Supplemental material
Table S1: Patients with Caspr2 antibodies identified in cohort screening (no extensive clinical description 
provided) 
Study Cohort Caspr2 positive 
patients
Antibodies 
confirmeda
Male Age
Median (range)
Suleiman, 20131 Pediatric new-onset epilepsy 
(n= 114)
n =3 No 67% 7 (0.5-10)
Ekizoglu, 20142 Patients with focal epilepsy
(n = 81)
n = 4 No 25% 37 (35-40)
Baysal-Kirac, 20163 Patients with autonomic seizures 
(n = 58)
n = 5 Yes, 4/5 
confirmedb 
20% 30 (15-36)
Vanli-Yavuz, 20164 Patients with epilepsy and hippocampal 
sclerosis (n = 111)
n = 11 No 18% 17 (0-49)
Wright, 20165 Pediatric epilepsy 
(n = 178)
n = 4 Yes, 2/4 
confirmedc
100% 9.7 (0.6 – 12.5)
aAntibody confirmation with addition laboratory techniques or CSF analysis
bCommercial CBA followed by in-house CBA and immunohistochemistry
bIn house CBA followed by staining with live hippocampal neurons
Table S2: VGKC-positive patients without LGI1 and Caspr2 antibodies; identified in cohort screening  
(no extensive clinical description provided) 
Study Cohort VGKC positive patients 
(LGI1 and Caspr2 neg)
Antibodies 
confirmeda
Male
Suleiman, 20131 Pediatric new-onset epilepsy 
(n= 114)
n = 4 75% 3 (1.5-4.9)
Brenner, 20136 Epilepsy 
(n = 416)
n = 19 63% NP
Hacohen, 20137 ƚ Pediatric autoimmune encephalopathy
(n = 48)
n = 7 NP 8.9 (6-15)
Hacohen, 20148 Pediatric acute demyelinating disorder
(n = 65)
n = 3 67% 9 (6-14)
Baysal-Kirac, 20163 Patients with autonomic seizures 
(n = 58)
n = 3 67% 26 (24-57)
Vanli-Yavuz, 20164 Patients with epilepsy and hippocampal sclerosis
(n = 111)
n = 4 50% 6 (0-13)
Borusiak, 20169 Pediatric focal epilepsy
(n = 124)
n = 3 33% 5 (2-6)
Wright, 20165 Pediatric epilepsy 
(n = 178)
n = 3 33% 4 (1.7-7.4)
Hacohen, 201610 Pediatric brainstem encephalitis
(n = 57)
n = 3 NP NP
ƚ Overlap with Hacohen et al, Neurology 2015. NP = not provided
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Table S3: VGKC-positive patients, analyzed (predominantly) irrespective of 
LGI1 and Caspr2 antibody result
Study Additional 
inclusion 
criteria
No. of 
patients
Antibody 
classification 
Male Age
Median 
(range)
Syndrome VGKC titer 
median 
(range)
Treatment effect FU and 
outcome
Haberlandt, 
201111
Pediatric  LE 4 NP 25% 14 
(3-16)
LE 180
(134 – 310)
NP 1/4 (25%) 
recovered, 1/4 
(25%) died
Dhamija 201112 Pediatric 12 NP 33% 7.5 
(8 mo-14 y)
Diverse NP 7/7 (100%)  
minor/major 
improvement*
NP
Cornelius, 
201113
NA 15 NP 60% 56 (17-80) 33% LE 
27% MoS
1,510 
(90-4,860)
9/11 (82%) 
improved
NP
Somers, 201114 NA 152 NP 45% 59 (2-87) 44% 
neuropsychiatric 
symptoms 
150 
(30-14,500)
11/21 (52%) 
improved *
NP
Jaben, 
201215
PE 5 NP 40% 59 (46-76) 80% LE 
20% NMT 
(80-2062) 3/5 (60%) 
improved 
NP
Irani, 
201216 ƚ
MoS 29 
(23 
VGKC 
positive) 
6/27 Caspr2
3/27 LGI1
15/27 
LGI1+Caspr2
93% 57 (19-80) MoS 
(38% thymoma)
NP 17/27 improved 
(63%)
31% died
Klein, 
201217 ƚƚ
NA 316 53/316 LGI1
36/316 Caspr2
NP NP Diverse
Pain in 50% 
NP 13/16 (81%) 
pain reduction *
NP
Lilleker, 201318 Seizures & 
Titer>400pM
6 1/6 LGI1
1/6 Caspr2
83% Mean 52.5 
(27-77)
Seizures (180-3450) 6/6 (100%) 
improved
NP
Baumgartner, 
201319
LE 7 1/7 LGI1
2/7 Caspr2
71% 61 (26-71) LE NP NP NP
Frisch,
201320
LE 15 NP 53% 57 (38-73) LE NP NP Majority 
improved
Sarkis, 
201421
LE 4 NP 75% 59 (29-80) LE NP NP NP
Liewluck, 
201422
CFS 9 2/7 LGI1
1/7 Caspr2
89% 45 (12-62) CFS NP 3/4 (75%) 
improved *
NP
Kotsenas, 
201423
Seizures 42 22/32 LGI1
3/32 Caspr2
52% 56 (8-79) Seizures NP NP NP
Huda, 
201424
NA 57 3/19 LGI1
2/19 Caspr2
56% 59 (25-77) 21% LE 
37% PNH
  2% MoS
40% Other
251 
(101-4064)
20/23 (87%) 
improved *
NP
Urbach, 201525 LE 36 16/36 LGI1
6/36 Caspr2 
61% Mean 58 
(19-86)
LE NP NP NP
Wagner, 201626 LE 16 5/16 LGI1
5/16 Caspr2
63% 55 (19-72) LE 1,318 
(427-7,655)
NP NP
O’Sullivan, 
201627
NA 62 NP NP NP Diverse NP NP NP
NP = not provided. NA = not applicable. LE = limbic encephalitis. PE = plasma exchange. MoS = Morvan’s syndrome.  
CFS = cramp fasciculation syndrome. NMT = neuromyotonia. PNH = peripheral nerve hyperexcitability syndrome. 
ƚ Three patients also described in Irani et al, Brain 2010
ƚ ƚ Klein JAMA Neurol 2013 excluded due to substantial overlap in patients with Klein Neurology 2012. 
*Many patients remained untreated; selection bias.
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Abstract
Objective
We report the clinical features, co-morbidities, and outcome of 22 newly identified 
patients with antibodies to the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (AMPAR). 
Methods
This was a retrospective review of patients diagnosed between May 2009 and March 
2014. Immunological techniques have been previously reported. 
Results
Patients’ median age was 62 years (range 23-81; 14 female). Four syndromes were 
identified: 12 (55%) patients presented with distinctive limbic encephalitis (LE), eight 
(36%) with limbic dysfunction along with multifocal/diffuse encephalopathy, one with 
LE preceded by motor deficits, and one with psychosis with bipolar features. Fourteen 
patients (64%) had a tumor demonstrated pathologically (5 lung, 4 thymoma, 2 breast, 
2 ovarian teratoma) or radiologically (1 lung). Additional antibodies occurred in seven 
patients (3 onconeuronal, 2 tumor-related, and/or 3 cell-surface), all with neurological 
symptoms or tumor reflecting the concurrent autoimmunity. Treatment and outcome 
were available from 21 patients (median follow-up 72 weeks, range 5-266): five had 
good response to immunotherapy and tumor therapy, 10 partial response, and six did 
not improve. Eventually five patients died, all had a tumor or additional paraneoplastic 
symptoms related to onconeuronal antibodies. Coexistence of onconeuronal antibodies 
predicted a poor outcome (p=0.009). 
Conclusion
Anti-AMPAR encephalitis usually manifests as LE, can present with other symptoms 
or psychosis, and is paraneoplastic in 64% of the cases. Complete and impressive 
neurological improvement can occur, but most patients have partial recovery. Screening 
for a tumor and onconeuronal antibodies is important because their detection influences 
outcome.
Encephalitis and AMPA receptor antibodies
135
7
Introduction
The recent characterization of autoimmune synaptic disorders has led to the 
identification of subtypes of limbic, multifocal or generalized encephalitis that often 
respond to immunotherapy. One of the antibodies targets the GluA1 or GluA2 
(previously called GluR1 or GluR2) subunits of the alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR), an ionotropic receptor that belongs 
to the family of glutamate receptors. AMPAR mediates most of the fast excitatory 
synaptic transmission in the brain, and is important for synaptic plasticity, memory, and 
learning.1 The initial description of the encephalitis associated with these antibodies was 
published in 2009 and included 10 patients, all with limbic encephalitis (LE) who had 
CSF and serum antibodies that reacted with the neuropil of rat brain and the cell surface 
of cultures of rat hippocampal neurons, leading to precipitate and characterize the target 
antigens as the GluA1 or GluA2 subunits of the AMPAR.2 Recent studies have shown 
that these antibodies cause a selective decrease in the total surface amount and synaptic 
localization of GluA1 and GluA2-containing AMPAR through increased internalization 
and degradation3, resulting also in a decrease of AMPAR-mediated currents3, 4. Since the 
initial description of this disorder, only a few cases with similar antibodies have been 
reported and therefore the clinical manifestations are largely unknown.5-8 We report 22 
additional patients and describe the clinical presentation, cancer-association, response 
to treatment, co-morbidities, prognostic factors, and outcome.
  
Materials and Methods
Patients
Sera or CSF of 10,573 patients with suspected autoimmune encephalitis or paraneoplastic 
neurological syndromes (including LE, non-focal encephalitis, encephalomyelitis, 
psychiatric disorders, dementia, Morvan syndrome, and cerebellar dysfunction) were 
included in the studies of antibody screening. The samples were received between May 
2009 and March 2014 in the Department of Neurology, University of Pennsylvania, 
Department of Neurology, Erasmus Medical Center, Rotterdam, and the Center of 
Neuroimmunology at Institut d´Investigació Biomèdica August Pi i Sunyer (IDIBAPS), 
Hospital Clinic, University of Barcelona. Clinical information was obtained by the 
investigators or from questionnaires completed by the referring physicians and telephone 
interviews. One patient was previously published as isolated case report.9 
Standard protocol approvals, registrations, and patient consents
Informed consent for antibody studies was obtained in all patients. The study was 
approved by the Institutional Review Boards of the Hospitals of the University of 
Pennsylvania, Erasmus Medical Center Rotterdam, and University of Barcelona.
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Screening for antineuronal antibodies
Serum and CSF samples were tested for antibodies to intracellular and cell surface 
antigens using brain immunohistochemistry on rat brain as previously reported.2, 
10 Samples showing specific tissue staining were further examined with in-house 
or immunoblot assays for antibodies to onconeuronal antigens (Hu, Yo, Ri, CV2, 
amphiphysin, Ma1/2, Tr), tumor-associated antigens (SOX1, ZIC4), and non-
tumor-associated antigens (GAD65, AK5, Homer3).11,12 The identity of the target 
cell- surface or synaptic autoantigens was determined with HEK293 cells expressing 
LGI1, CASPR2, NMDAR, AMPAR, and GABA(B)R, as reported.2,13-16 The type of 
AMPAR subunit identified by patients´ antibodies was investigated using HEK293 cells 
expressing only the GluA1 or GluA2 subunits of the receptor.2 We did not include in 
these investigations the determination of antibodies using immunoblot of recombinant, 
denaturated AMPAR subunits,4 given that these antibodies do not produce the typical 
neuropil immunostaining of the antibodies studied here and their syndrome association 
remains to be established.
Review of previously reported cases of tumor-associated anti-AMPAR encephalitis
In order to assess the significance of the presence of an underlying tumor or additional 
paraneoplastic antibodies in the clinical outcome (survival and relapse frequency), we 
reviewed the current data along with all previously reported oncological or paraneoplastic 
cases of anti-AMPAR encephalitis.2,5,6,8
Statistical Analysis
Age between groups was compared by Mann-Whitney U test, time until diagnosis 
by Student t test, and comparison of serum and CSF by McNemar test. For survival, 
Kaplan-Meier curves were created, using log-rank tests. The association of relapses 
with type of therapy (aggressive, nonaggressive) was compared with Fisher exact test. 
Statistical significance was defined as p-value less than 0.05.
Results
Patients
We identified 22 patients with AMPAR antibodies. A summary of the clinical 
information is shown in Tables 1 and 2. The median age was 62 years (interquartal range 
[IQR] 37.3-70.3 years; range 23 to 81 years) with no differences between patients with 
or without tumor (60.5 years, IQR 38.8-70.3, and 64 years, IQR 35-72, respectively; 
p=0.80). The female: male ratio was 14:8. Fourteen patients (64%) had an underlying 
tumor; in 13 the tumor was demonstrated pathologically, including five small-cell lung 
cancer (SCLC), four thymoma, two breast cancer, and two ovarian teratoma, and in 
another patient the tumor was demonstrated radiologically (lung cancer). One patient 
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had onconeuronal antibodies (CRMP5), but no tumor has been identified until now 
(30 weeks follow-up).
 The median time from symptom onset until diagnosis of autoimmune 
encephalitis was 6.5 weeks (IQR 4-18.3 weeks), and was not different between patients 
with or without tumor (5.5 weeks [IQR 3.8-8.8] vs 13 weeks [5-52], respectively; 
p=0.11). In 12 patients the neurological symptoms occurred before tumor diagnosis or 
led to tumor screening (median 5 weeks [IQR 2.3-37.5], range 1.5 to 56 weeks) and 
in two patients the tumor was identified before developing encephalitis (1 year and 
6 months, respectively). The CSF analysis showed lymphocytic pleocytosis in 11/22 
patients (median leukocyte count 23 cells/ml, range 5 – 820), and elevated protein 
concentration in 10/20 (median 71 mg/dl, range 49 – 425); only 5/22 patients had an 
elevated protein concentration as isolated finding (Table 1).
Table 1. Clinical presentation in patients with AMPAR autoimmune encephalitis.
N° age/
sex
Symptom 
onset until 
diagnosis 
(weeks)
Clinical 
presentation
(initial 
symptoms)
Other symptoms 
during course of 
the disease
Initial MRI EEG CSF Additional 
antibodies
1 42/F 6 LE mild hemiparesis 
left
bilateral increased signal in 
temporal lobe
epileptiform activity 
(clinically no seizures)
normal WBC 
and protein
 -
2 51/F 2 LE  - increased signal in left 
medial temporal lobe
NA normal WBC 
and protein
 -
3 59/M 17 LE  - bilateral increased signal in 
temporal lobes
normal 6 WBC, 50 
mg/dl protein
 -
4 62/M 7 LE hemiparesis, 
mutism
bilateral increased signal in 
temporal lobe and insula
NA normal WBC 
and protein
 -
5 63/F 4 LE with 
seizures
 hyponatremia increased signal in medial 
temporal lobes
NA normal WBC, 
425 mg/dl 
protein
GABA(B)R
SOX1
6 70/F 8 LE   - normal epileptiform activity 
(clinically no seizures)
normal WBC, 
64 mg/dl 
protein
-
7 81/F 4 LE  hyponatremia bilateral increased signal in 
temporal lobe
focal spike waves; 
polymorphic delta 
left fronto-temporal
normal WBC 
and protein
SOX1
8 33/F 9 LE with 
seizures
 - bilateral increased signal in 
hippocampi and amygdalae
epileptiform activity 14 WBC, 
normal protein
 -
9 35/M 2 LE  - increased signal in medial 
temporal lobes
focal activity 
temporal
23 WBC, 
proteins NA
 -
10 64/F 52 LE  - increased signal in left 
medial temporal lobe
diffuse slowing and 
focal abnormalities
5 WBC, 
normal protein
 -
11 72/F 22 LE spasticity increased signal in medial 
temporal lobes
general slowing 50 WBC, 
49mg/dl 
protein
 -
12 72/F 13 LE  - bilateral increased signal in 
temporal lobe
slow (theta) activity 52 WBC, 100 
mg/dl protein
 -
13 23/M 3 short-term 
memory 
loss, seizures, 
psychosis
catatonia, 
decerebrate 
posturing right 
arm
patchy increased signal in 
cortex of both hemispheres 
and basal ganglia 
general slowing  and 
epileptiform activity 
left temporal lobe.
23 WBC, 
normal protein
-
14 25/F 2 psychosis, 
confusion, 
agitation, non-
verbal, seizures, 
dyskinesias
fever, 
hypertension, 
required 
intubation
normal NA normal WBC 
and protein
NMDAR
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15 53/F 5 confusion, 
bradypsychia, 
status 
epilepticus, 
autonomic 
dysfunction
 - increased signal in medial 
temporal lobes, frontobasal, 
and caudate
NA 164 WBC, 92 
mg/dl protein
CRMP5
16 65/F 52 short-term 
memory loss, 
confusion, 
abnormal 
behavior, 
itching, and 
involuntary 
arm movement
seizures hyperintensities in the 
corpus callosum
normal Normal WBC, 
71 mg/dl 
protein
 -
17 71/M 5 somnolent, 
seizures, 
disoriented, 
tremor
 - abnormality in the 
hypothalamic region with 
mass effect on pituitary 
gland; T2/FLAIR increased 
signal in right temporal
generalized slowing normal WBC, 
elevated 
protein
NMDAR
18 72/M 6 short-term 
memory 
loss, ataxia, 
insomnia, 
psychotic 
features
sensory 
polyneuropathy
normal normal Normal WBC, 
65 mg/dl 
protein
Amphi
19 62/M 26 short-term 
memory loss, 
confusion, 
and abnormal 
behavior, 
psychosis, optic 
neuropathy
insomnia, ataxia hyperintensities in basal 
ganglia
focal activity 33 WBC, 173 
mg/dl protein
CRMP5
20 69/M 52 seizures, short-
term memory 
loss, confusion, 
psychosis, 
aphasia
hyponatremia, 
fatigue, weakness, 
ataxia; later 
Parkinsons disease
increased signal in medial 
temporal lobes, cortical 
parietal, cingulum, frontal
lateralized periodic 
slowing temporal and 
hippocampi
normal WBC 
and protein
 -
21 29/F 11 left sided 
weakness, 
spasticity
LE, psychosis, 
dysarthria, 
tachycardia, 
hypertension
increased signal in insula, 
putamen, and thalamus
generalized slowing 
of background, focal 
slowing in right 
hemisphere
13 WBC, 
normal protein
 -
22 38/F 5 psychosis with 
bipolar features
nystagmus, 
anti-psychotic 
induced-
neuroleptic 
malignant 
syndrome, 
fencing posturing, 
autonomic 
dysfunction
normal normal 90 WBC, 
protein NA
 -
Amphi = amphiphysin antibodies; FLAIR = fluid-attenuated inversion recovery; LE = limbic 
encephalitis; NA = not available; WBC = white blood cells.  
Clinical presentation of LE defined by the presence of short-term memory loss, confusion, 
and abnormal behavior
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Clinical presentation and MRI features
Four clinical presentations were identified: 12 patients (55%) developed symptoms 
of LE, defined by the presence of short-term memory loss, confusion, and abnormal 
behavior (Table 1, patients 1-12). Two of these patients developed seizures (nos. 5 
and 8) and one of them (no. 5) had additional GABA(B)R and SOX1 antibodies. 
Hyponatremia occurred in two patients, both with SCLC. In 11 of the 12 patients, the 
clinical diagnosis of LE was confirmed by the MRI findings of unilateral (2 patients) 
or bilateral (9 patients) mesiotemporal increased fluid-attenuated inversion recovery 
(FLAIR)/T2 signal abnormalities (Figure 1 A and B). In patient 6 (Table 1), the brain 
MRI was normal.  
 Eight patients (Table 1, cases 13-20) had diffuse encephalitis with clinical and/
or MRI evidence of involvement of multiple areas of the CNS (Figure 1 C and D). All 
developed limbic dysfunction along with one or more of the following symptoms: 6 
had seizures, 5 prominent psychiatric manifestations, 3 ataxia, 2 abnormal movements, 
and 1 each, optic neuropathy and aphasia. Hyponatremia occurred in one patient 
without cancer. Two patients in this group had NMDAR-antibodies (further described 
in Immunological studies). 
 Another patient (Table 1, patient 21) was a 29-year-old woman, who first 
presented with left sided weakness and spasticity involving face, arm, and leg, and 
two months later developed memory loss, confusion, abnormal behavior, psychiatric 
symptoms, visual hallucinations, autonomic dysfunction, and dysarthria. The MRI 
showed increased FLAIR/T2 signal in the right thalamus, bilateral putamen, and 
cerebellum. Tumor screening revealed an ovarian teratoma but NMDAR-antibodies 
were negative.
 The remaining case (patient 22, table 1) was a 38-year-old woman who presented 
with new onset psychosis with bipolar features. She was started on anti-psychotic 
medication and one week later developed nystagmus and neuroleptic malignant syndrome 
(rigidity, tonic fencing-like posture, and autonomic instability), requiring intubation for 
airway protection. The brain MRI was normal, EEG demonstrated moderate generalized 
slowing, CSF showed 90 leukocytes/mm3, and the tumor screening was negative. Her 
mental status did not improve and she was lost to follow-up after 5 weeks.
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Figure 1. Brain MRI findings of anti-AMPAR encephalitis.
Brain MRI obtained 6 weeks after symptom onset (patient 4, table 1) shows increased T2/fluid-attenuated inversion 
recovery (FLAIR) signal abnormalities involving medial temporal lobes (A) and insular cortex (B). In addition, the 
frontal and parieto-occipitial cortex and claustrum show mild focal hyperintensity (B). Diffusion-weighted images of 
patient 13 (table 1) show widespread involvement of the temporal cortex (C). Similar abnormalities are shown on FLAIR 
sequences involving the left frontal and right temporal cortex as well as the right putamen (D).
Immunological studies
All patients´ serum and/or CSF samples showed intense neuropil staining on brain 
tissue immunohistochemistry and reacted with HEK cells co-expressing GluA1/2 
subunits of the AMPAR2. From 5 patients only CSF was available and from another 
3 only serum was available; paired samples were available from 14 patients, all CSF 
were antibody positive but only 10/14 sera were positive (p=0.13). Four patients had 
antibodies only against the GluA1 subunit, 7 only against the GluA2 subunit, and 
9 against both subunits (Figure 2); in 2 cases the limited amount of sample did not 
allow for independent subunit assessment. There were no significant differences among 
clinical presentation, association with a tumor, or prognosis in patients with antibodies 
recognizing different subunits.
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Figure 2. Reactivity of patients´antibodies with GluA1 or GluA2 subunits of the AMPAR.
Patients´antibodies were identified on HEK293 cells transfected with GluA1 or GluA2 subunits of the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR). Examples of patients with antibodies targeting only 
GluA1 (patient  9), or GluA2 (patient 15), or both subunits (patient  3) are shown. Patients´antibodies are shown with 
green fluorescence; commercial monoclonal antibodies against GluA1 or GluA2 are shown with red fluorescence; the 
blue nuclear staining is shown with 4’,6-diamidino-2-phenylindole (DAPI). All panels: x 400.  
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Additional neuronal antibodies were found in 7 patients (3 onconeuronal-intracellular, 
1 SOX1 [tumor-associated], 2 cell surface-synaptic, and 1 SOX1 and cell surface/
synaptic), 6 of them with an associated tumor or cancer (table 2). The three patients with 
onconeuronal antibodies (2 CRMP5, 1 amphiphysin) developed a clinical phenotype, 
outcome, or tumor association that were more characteristic of the additional immune 
response than that of the AMPAR-antibody syndrome (tables 1 and 2). Two of the 
3 patients with additional antibodies to cell-surface/synaptic proteins [1 GABA(B)R, 
2 NMDAR] developed syndromes influenced by the additional antibody: the patient 
with GABA(B)R-antibodies had seizures and SCLC, both typical of this autoimmune 
syndrome, and one patient with NMDAR-antibodies developed psychosis, confusion, 
agitation, decrease of verbal output, seizures, and dyskinesias, all typical of anti-NMDAR 
encephalitis. In contrast, the second patient with NMDAR-antibodies was atypical in 
many respects, including demographics (71-year-old man), symptoms (somnolence, 
seizures) and tumor (thymic carcinoid). The presentation with somnolence is atypical 
of NMDAR autoimmunity, and it was likely related to an inflammatory lesion in the 
hypothalamus (table 1); this case probably represents an overlap syndrome of 2 or more 
autoimmune disorders.
Treatment and follow up
Clinical follow-up was available from 21 patients (median 72 weeks, range 5 to 266). 
The remaining patient (patient 22) was lost to follow-up shortly after diagnosis. Twenty 
patients received first-line immunotherapy (steroids, IV immunoglobulins, or plasma 
exchange) and 5 of them also second-line immunotherapy (rituximab, cyclophosphamide) 
(table 2). Thirteen patients had one or more of the following oncological treatments: 
7 tumor resection, 8 chemotherapy, and 6 radiation therapy (table 2). Five patients 
showed good neurological response to immunotherapy or oncologic therapy with a 
modified Rankin Scale (mRS) score between 0 and 1 at the last follow-up; 10 patients 
had partial response with an mRS score between 2 and 3, and 6 patients had poor or no 
response to treatment (table 2). One of the patients with partial response (patient 11, 
table 2) relapsed 2 months later; this patient was lost to follow-up after relapse. Of the 6 
patients with poor or no response to treatment, 4 had a malignant tumor or additional 
antibodies (1 SOX1, 1 amphiphysin, and 2 CRMP5) with superimposed paraneoplastic 
symptoms (see details in supplemental information). 
 There was no significant change in survival for patients with or without a tumor 
(median 123 weeks vs not met, all 6 without a tumor still alive; p=0.086; figure 3A; the 
patient with onconeuronal CRMP5-antibodies but without tumor was excluded from 
this as well as from the following analysis). On the other hand, the median survival of 
the 4 patients with tumor and onconeuronal or SOX1-antibodies (cases 5, 7, 15, and 
18) was 52 weeks (range 5 – 123  weeks; all died), while that of the 10 patients with 
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tumor but without additional onconeuronal antibodies was not met (median follow-up 
61 weeks, range 10 – 266 weeks; 9 of 10 alive at last follow-up; p=0.009; figure 3B). 
 In order to further assess the significance of the presence of an underlying 
tumor and onconeuronal antibodies in patient outcome, we reviewed the data of all 
oncological cases of the current study together with those previously reported.2,5,6,8 Of 
24 patients identified, 7 had onconeuronal, GAD65, or SOX1 antibodies and 17 had no 
additional antibodies. Six out of 7 patients with paraneoplastic syndromes and additional 
antibodies have died (median survival 65 weeks); in contrast, 15 of 17 patients with 
tumor, but without additional onconeuronal antibodies were alive (median survival not 
met; median follow-up 60 weeks, range 10 – 516 weeks; p=0.003). Eleven out of 13 
patients without tumor are alive (median follow-up 104 weeks; range 25 to 390), which 
was not significant compared to patients with tumor (p=0.079; figure 3C). 
 To determine whether clinical relapses were associated with less aggressive 
therapy, we reviewed the data of 21 patients of the current study and those of 16 
previously reported cases for which information was available.2,5,6,8 Overall, relapses 
occurred in 6/37 patients (16%, 1 case in the current study). While 0/19 patients who 
received aggressive therapy (chemotherapy or rituximab) had relapses, 6/18 who did not 
receive aggressive therapy had relapses (p=0.008). 
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Figure 3. Survival of patients with paraneoplastic or idiopathic anti-AMPAR encephalitis.
(A) Kaplan-Meier survival curves for patients with paraneoplastic anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor  (AMPAR) encephalitis (with or without onconeuronal antibodies, red) and patients with idiopathic anti-
AMPAR encephalitis (blue). (B) Kaplan-Meier survival curves for 4 patients with paraneoplastic anti-AMPAR encephalitis 
plus additional onconeural antibodies (dark red) and 10 patients with paraneoplastic anti-AMPAR encephalitis without 
onconeuronal antibodies (orange). (C) Kaplan-Meier survival curves for all assessable reported patients with paraneoplastic 
anti-AMPAR encephalitis and onconeuronal antibodies (dark red), paraneoplastic anti-AMPAR encephalitis without 
onconeuronal antibodies (orange) and idiopathic anti-AMPAR encephalitis (blue).2,5,6,8
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Table 2.  Treatment and outcome of patients with AMPAR autoimmune encephalitis.
N° Tumor Additional 
antibodies
Symptom 
onset until 
start of 
treatment 
(weeks)
Neurological 
outcome 
measuring mRS 
(compared with 
mRS at diagnosis)
immunotherapy or 
chemotherapy
Treatment 
response
Follow-up 
(weeks)
1 breast 
cancer
 - 4 2 (5) tumor resection, 
chemotherapy, IVIg
partial 195
2 SCLC  - 2 1 (3) chemotherapy + 
radiotherapy, steroids
full 266
3 SCLC  - 11 1 (3) chemotherapy + 
radiotherapy, IVIg
full 72
4 Malignant 
thymoma
 - 8 1 (5) tumor resection, steroids, 
IVIg
full 19
5 SCLC GABA(B)R
SOX1
13 2 (4) chemotherapy + 
radiotherapy
partial 65, died of 
cancer
6 SCLC  - 8 2 (3) chemotherapy + 
radiotherapy, steroids
partial 39, patient died 
of cancer
7 SCLC SOX1 4 3 (3) chemotherapy, steroids no 123, patient died 
of cancer
8  -  - 13 3 (3) steroids, plasmaexchange, 
rituximab, 
cyclophosphamide
no 160
9  -  - 2 2 (3) steroids, IVIg, rituximab partial 104
10  -  - 52 2 (3) steroids, IVIg, 
plasmaexchange
partial 78
11  -  - 4 3 (5) steroids, IVIg partial / relpase 25
12  -  - 13 2 (3) steroids partial 142
13 thymoma - 5 3 (5) tumor resection, IVIg, 
steroids, rituximab
partial 10
14 ovarian 
teratoma
NMDAR 2 0 (5) tumor resection, steroids, 
IVIg
full 50
15 malignant 
thymoma
CRMP5 1 5 (4) tumor resection, 
chemotherapy, 
radiotherapy, steroids, 
IVIg
no 5, patient died of 
cancer
16 breast 
cancer
 - 13 2 (3) tumor resection, 
chemotherapy, 
radiotherapy, steroids, 
IVIg, plasmaexchange
partial 260
17 thymic 
carcinoid
NMDAR 3 1 (4) tumor resection, steroids, 
plasma exchange
full 78
18 lung tumor Amphi 4 5 (4) steroids* no 39, patient died 
of cancer
19  - CRMP5 21 4 (3) steroids, rituximab no 30
20  -  - 52 3 (4) IVIg, plasmaexchange partial 247
21 ovarian 
teratoma
 - 8 5 (5) tumor resection; steroids, 
IVIg, plasmaexchange, 
rituximab
no 19
22  -  - NA NA (5) NA NA 5
Amphi = amphiphysin antibodies; IVIg = IV immunoglobulin; mRS = modified Rankin Scale; NA = not available; 
SCLC = small cell lung cancer Treatment response was defined by decrease of at least 1 score in the mRS with an 
mRS at the last follow-up < 3. At the last follow-up, all patients with good response had mRS of 0-1, and all cases 
with partial response had mRS of 2-3. 
* patient died befor tumor diagnosis was confirmed.
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Discussion
We report 22 newly identified patients with anti-AMPAR encephalitis and provide 
several clinically relevant findings including (1) the frequent presentation of the disorder 
as LE, sometimes with prominent psychiatric features, psychosis, or hyponatremia that 
can mislead the initial diagnosis, (2) the presence of an underlying tumor in 64% of the 
patients, (3) the coexistence of onconeuronal and cell surface autoantibodies in 32% of 
the patients, all with symptoms or tumors that reflect the concurrent autoimmunity, and 
(4) the frequent but limited response to treatment, with long-term outcome influenced 
by the presence of onconeuronal antibodies and related paraneoplastic symptoms or 
tumors. 
 The term LE refers to an inflammatory process of the brain restricted clinically 
or radiologically to the limbic system, which includes the medial temporal lobes and 
frontobasal and cingular regions.  Despite a well-defined syndrome, it is frequently poorly 
recognized, misnaming as LE any type of autoimmune or paraneoplastic process above 
the foramen magnum. Among the many antigens of paraneoplastic and autoimmune 
encephalitis, there are three that typically associate with LE, including LGI1, GABA(B)
R, and  AMPAR.2,13,16-18 At least 60% of the patients with any of these disorders develop 
a typical clinical or radiological picture of LE, with additional symptoms or associations 
that can suggest the antigen. For example, while the LE with LGI1-antibodies frequently 
associate with hyponatremia but almost never to SCLC13, the LE with GABA(B)
R-antibodies frequently occurs with early and prominent seizures and 50-60% of the 
patients have SCLC.16,18 Recognition of each autoantigen is important because all 3 
disorders are potentially treatable but for the appropriate treatment one should consider 
the associated comorbidities or tumors (further discussed later). Our findings show 
that LE with hyponatremia not only occurs in patients with LGI1-antibodies, but 
also in some patients with antibodies to the AMPAR or GABA(B)R, either as part of 
SCLC-related syndrome of inappriopriate antidiuretic hormone (which was not further 
investigated in 2 of our patients) or as a primary effect of the immune-response (one 
patient did not have cancer).
 In the initial report of 10 patients with anti-AMPAR encephalitis the main 
findings were that all developed LE, 7 had a tumor (lung, breast, or thymoma), and the 
disorder frequently responded to treatment but had tendency to relapse. The current 
data confirm some of these findings and expand on others. Ten of the current patients 
did not initially present with classical LE, although most of them had limbic dysfunction 
concurrent or heralded by other symptoms. Importantly, 6 of these patients had 
prominent psychiatric symptoms, one of them manifesting as pure psychosis for 1 week 
before developing a neuroleptic malignant syndrome induced by treatment along with 
mild additional neurological symptoms. The presentation of anti-AMPAR encephalitis 
as pure psychosis (without additional neurological symptoms) has been previously 
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reported in 2 cases6, indicating that this type of encephalitis should be included in the 
differential diagnosis of autoimmune psychosis.
 The histological types of tumors were similar to those previously reported in 
anti-AMPAR encephalitis2, but 2 patients had ovarian teratoma (one without evidence 
of  NMDAR-antibodies), an association not previously reported. We do not know why 
patients in the current study had fewer neurological relapses than those in previous 
studies (1/21 versus 5/16);2,5,6,8 however, the approach to therapy may be a reason. 
Indeed, when considering all current and previous cases for which treatment information 
is available (n = 37), all clinical relapses were in the group who did not receive aggressive 
therapy (6 of 18 patients, p=0.008). Aggressive treatment has been associated with lower 
relapse risk in anti-NMDAR encephalitis.19 Another possible explanation could be a 
diagnosis bias: at the time of the initial study, patients with monophasic disease were 
often not sent for antibody testing and missed, resulting in an overrepresentation of 
relapsing patients.
 Overall, 71% of the patients responded to immunotherapy or treatment of 
the tumor, most of them showing a partial neurological response (48%). These data 
suggest that patients with AMPAR antibodies have less substantial recoveries than those 
with other types of autoimmune encephalitis [NMDAR, LGI1 or GABA(B)R]. Despite 
this, substantial and sometimes unexpected recoveries do occur, but require aggressive 
therapy. An example is patient 13 who presented with severe encephalitis, refractory 
seizures, and a large thymoma, but his Karnofsky performance status was considered 
too low (30/100) for treatment. The patient was transferred to our Institution (Hospital 
Clinic, Barcelona) under pharmacologically induced coma and mechanical ventilation. 
The brain MRI showed changes suggestive of widespread cortical damage (figure 2). 
He underwent intensive immunotherapy and tumor removal, and currently is at home, 
free of seizures, and rapidly improving. This case suggests caution in clinically assessing 
autoimmune encephalitis using Karnofsky or similar neurological scales for treatment 
decisions.
 The presence of concurrent antibodies, mainly onconeuronal (CRMP5, 
amphiphysin) or tumor biomarkers linked to paraneoplastic autoimmunity (e.g. SOX1), 
is associated with additional paraneoplastic symptoms and a poorer prognosis. The 5 
patients who died had one or more of these features along with an underlying tumor. 
These findings along with the review of previously reported cases with tumor (either 
with or without an additional paraneoplastic neurological autoimmunity),2,5,6,8 suggest 
that the presence of an additional paraneoplastic autoimmunity is the main prognostic 
factor for a poor outcome. Indeed, the survival of patients with tumor but without 
additional paraneoplastic autoimmunity was similar to that of patients without tumor, 
but the survival of patients with tumor and additional paraneoplastic autoimmunity 
was significantly worse than that of the other subgroups. Similar comorbidities linked 
to a poor prognosis have been reported in patients with anti-GABA(B)R encephalitis, 
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a disorder that frequently occurs with SCLC and may associate with concurrent 
paraneoplastic immune responses (e.g., amphiphysin, Ri, SOX1).18
 This and previous studies suggest an interesting molecular link between the 
symptoms of LE and the effects of LGI1 and AMPAR antibodies. Indeed, LGI1 is 
a secreted neuronal protein that forms a trans-synaptic complex interacting at the 
postsynapse with ADAM22 and the AMPAR and at the presynapse with ADAM23 and 
the shaker potassium channel Kv1.20 There is evidence that LGI1-antibodies prevent 
the binding of LGI1 to ADAM22 and by unclear mechanisms result in a decrease of 
AMPAR (the effects on the presynapse have not been determined).21 On the other 
hand, the antibodies of patients with anti-AMPAR encephalitis bind directly to the 
GluA1/2 subunits causing a decrease of the levels of receptors by antibody-mediated 
internalization.2 Therefore, 2 seemingly different immune responses against different 
synaptic proteins result in a common downstream effect (decrease of post-synaptic 
AMPAR clusters), providing a potential explanation for the frequent association of both 
disorders to classical LE. 
 The current findings taken together with those of previous studies have several 
practical implications. First, in patients with classic LE with or without tumor association, 
determination of AMPAR-antibodies should be considered. These antibodies may also 
occur in patients with multifocal encephalitis usually involving the limbic system, and 
less frequently can present as pure psychosis. Second, detection of GluA1/2 AMPAR- 
antibodies should lead to an extensive screening, including underlying tumors, classical 
paraneoplastic antibodies, and other cell surface antibodies. Third, prompt treatment 
of the tumor and immunotherapy are important, because the disorder is potentially 
reversible, but the outcome seems related to the presence of concurrent paraneoplastic 
autoimmunity linked to an underlying tumor.     
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Abstract
Objectives
Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) is a severe, but 
treatable disease. This study aims to give a detailed description of electroencephalogram 
(EEG) results in pediatric and adult patients to improve disease recognition, and analyzes 
the predictive value of first EEG for final clinical outcome. 
Methods 
This nationwide cohort study includes patients with NMDA receptor antibodies 
confirmed with cell-based assay and immunohistochemistry, in serum and cerebrospinal 
fluid. EEG recordings were re-evaluated by two experienced neurophysiologists, mixed 
with control EEGs for blinding. Initial EEG as well as follow up registrations were 
analyzed. 
Results 
35 adults and 18 children were included.  Only two patients (4%) had a normal EEG. 
During first recording, the majority of the patients had normal posterior rhythm (71%), 
which was associated with better modified Rankin Scale at final outcome (OR 4.74; 
95%CI 1.56–14.47; p=0.006). In addition, EEGs showed focal (73%) or diffuse (67%) 
slowing. First EEG was severely abnormal in 26%. However, 8/14 patients with a 
severely abnormal first EEG still had a favorable outcome. During the course of disease, 
extreme delta brushes (EDB) were present in 6/53 (11%) patients. 
Conclusions 
First EEG commonly shows normal posterior rhythm with focal or diffuse slowing. 
Although sensitivity of an abnormal EEG is high (96%), normal EEG does not exclude 
anti-NMDAR encephalitis. EDBs are only present in severely affected patients. First 
EEG recording is predictive for final clinical outcome.
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Introduction
Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) is the most 
common antibody-mediated encephalitis. Patients develop subacute psychiatric 
symptoms, memory loss, movement disorders and seizures, often followed by intensive 
care unit (ICU) admission due to consciousness decline, autonomic dysfunction or 
hypoventilation.1 Disease mostly affects women of childbearing age, or children. 38% of 
the patients have a tumor, mainly ovarian teratoma. Antibodies are directed to the NR1 
subunit of the NMDAR, which is found across the brain. This explains why disease is 
not restricted to the limbic area. MRI brain is often normal, but electroencephalogram 
(EEG) is useful to analyze the functional deficits caused by the NMDAR-antibodies. 
EEG studies have reported diffuse slowing in a substantial part of the patients.2,3 In a study 
of 9 children, diffuse abnormalities with lack of normal posterior rhythm was associated 
with poor outcome,4 but this has not been studied further. Most larger studies aim to 
give a description of all disease characteristics and therefore do not analyze or report 
detailed EEG data.1,2,5-9 Also, questions remain regarding the occurrence of extreme 
delta brushes (EDB). The pattern of EDB is pathognomonic for anti-NMDARE,10,11 
but incidence ranges from 0-100%, depending on patient selection, clinical situation 
and timing of EEG.3,8,10,12 Our study aims to give a full description of EEG results in 
an unselected group of pediatric and adult patients with anti-NMDARE. First EEG as 
well as follow up registrations are analyzed, and the predictive value of EEG is discussed. 
Methods
Patients accrual and laboratory testing
Samples had been sent for antibody testing to the laboratory of Medical Immunology of 
the Erasmus University Medical Center, Rotterdam. Samples were sent from July 2006 
until July 2017. NMDAR-antibodies were detected with cell-based assay (Euroimmun, 
Lübeck, Germany) and immunohistochemistry on rat brain,13,14 in both serum and 
CSF, if available. Patients were considered positive if at least two tests confirmed the 
presence of NMDAR-antibodies. Both adult and pediatric (< 18 years at disease onset) 
patients were included in this study if at least one EEG recording was available for 
analysis. Patients were included in the longitudinal part of the study if EEG recordings 
from predefined stages of disease were available: within 2 weeks after disease onset, after 
one month and after three months (at least 2 out of 3). 
 Clinical information was obtained from medical records, and included 
demographic data, clinical symptoms, tumor presence, intensive care admissions 
and treatment. First line immunotherapy included corticosteroids, intravenous 
immunoglobulin and/or plasma exchange. Second line treatment included 
cyclophosphamide and/or rituximab. Disease severity and clinical outcome were 
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measured with the Modified Rankin Scale (mRS). Outcome was analyzed if follow up 
was at least 6 months after disease onset. Outcome mRS ≤ 2 was considered favorable, 
as this reflect independency in daily life. 
EEG analysis
EEG recordings were collected retrospectively. All recordings were based on the 
International 10-20 system and the majority of the recordings were spot EEG. In the 
few cases with continuous registration, only the first thirty minutes were included in 
the analyses. EEG recordings were independently re-evaluated by two experienced 
neurophysiologists (DT, SA), mixed with control EEGs for blinding. If in disagreement, 
both neurophysiologists convened to achieve agreement.  In all patients, the first available 
EEG was evaluated. If serial EEGs were recorded, the EEG at disease nadir was analyzed 
as well. The following EEG characteristics were evaluated: posterior dominant rhythm, 
diffuse slowing (mild, moderate, severe), focal slowing, rhythmic delta activity, ictal 
and interictal epileptiform discharges, periodic discharges and EDB. Status epilepticus 
was defined as the occurrence of virtually continuous or repetitive epileptiform seizure 
pattern in an EEG, whereas seizure pattern was defined as a phenomenon consisting 
of repetitive epileptiform EEG discharges at >2 c/s and/or characteristic pattern with 
quasi-rhythmic spatio-temporal evolution (i.e. gradual change in frequency, amplitude, 
morphology and location).15 EEG findings were subdivided into 4 categories: 1) Normal 
EEG. 2) Normal posterior rhythm (reactive, posterior dominant rhythm with an age-
appropriate frequency) with diffuse or focal abnormalities. 3) Lack of normal posterior 
rhythm, with focal or diffuse abnormalities. 4) Severely abnormal EEG, defined as lack 
of normal posterior rhythm with A) severe slowing or B) periodic discharges or C) status 
epilepticus. (Adjusted from Amodio 1999)16 EEGs showing status epilepticus (SE) were 
excluded for analysis of specific EEG characteristics. 
Standard protocol approvals, registrations and patient consents
The study was approved by the Institutional Review Board of the Erasmus University 
Medical Center, Rotterdam. Informed consent was obtained in all patients. 
Statistical analysis
Categorical data were analyzed with Fisher-Freeman-exact test. In the comparison 
between pediatric and adult patients, 8 EEG characteristics are evaluated. According to 
Bonferroni, p-values < 0.00625 are considered significant. Kaplan-Meier analyses are 
used to calculate follow up time, censoring deceased patients. Ordinal logistic regression 
was performed to analyze the association between characteristics of first EEG and final 
mRS. Mann-Whitney U test was performed to analyze the relation between posterior 
rhythm and duration of hospital stay. These analyses are exploratory. Therefore, p-values 
< 0.05 are considered significant, but should be interpreted with caution. SPSS Statistics 
21 (IBM Corp., Armonk, NY) was used for analysis.
EEG in anti-NMDAR encephalitis
163
9
Figure 1. EEG fragments. A. Rhythmic delta activity mixed with polyspikes over the left frontal region, consistent with a 
focal seizure (asymptomatic). (Pre-school child, EEG in source derivation, 150 Hz/cm, high pass filter 0.27 Hz; low pass 
filter 35 Hz; notch filter on) B. Rhythmic delta activity at 2 Hz over the left (fronto)temporal region. (Adolescent, EEG 
in average reference montage, 100 Hz/cm, high pass filter 0.27 Hz; low pass filter 70 Hz; notch filter off) C. Generalized 
periodic discharges (Adolescent, EEG in bipolar double banana, 70 Hz/cm, high pass filter 0.27 Hz; low pass filter 70 Hz; 
notch filter on) D. Left frontal rhythmic delta activity at 2 Hz with superimposed burst of rhythmic 22 Hz beta frequency, 
consistent with the pattern of extreme delta brush (Adolescent, EEG in bipolar double banana montage, 70 Hz/cm, high 
pass filter 0.27 Hz; low pass filter 70 Hz; notch filter on)
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Results
Patient and disease characteristics
70 adults and 35 children tested positive for NMDAR-antibodies. EEG recordings were 
available in 53 patients (35 adults and 18 children), all included in the study (See Fig 1 for 
EEG fragments). Of the adult patients, 30/35 were female and median age was 26 years 
(range 18-74, Table 1). Tumors were present in 10/28 female patients, including ovarian 
teratoma (n=8), SCLC (n=1) and merkel-cell carcinoma (n=1). All five male patients 
had no tumor. All but three adult patients received immunotherapy. Two untreated 
patients died, in both cases diagnosis was established post-mortem. Eighteen pediatric 
patients were included in the analyses, of which 14 were female.17 Five children were 
younger than 12 years of age. Three children had an ovarian teratoma. These patients 
were 13 to 17 years old at disease onset. All children were treated with immunotherapy, 
and all pediatric patients survived. 
Table 1: patient characteristics 
Adults (n = 35) Children (n = 18)
Female sex 30/35 (86%) 14/18   (78%)
Age at onset, median (IQR, range) 26 (21 – 48, 18 – 74) 14.5 (7 – 17, 3 – 17) 
Clinical seizures 26/34 (76%) 15/18   (83%)
mRS at maximum disease severity
- 1
- 2
- 3
- 4
- 5
-   
  1/35 (3%)
15/35 (43%)
  2/35 (6%)
17/35 (49%)
- 
2/18   (11%)
8/18   (44%)
2/18   (11%)
6/18   (33%)
Admission to the ICU 18/35 (51%) 6/18   (33%)
First line immunotherapy 32/35 (91%) 18/18 (100%)
Second line immunotherapy 14/35 (40%)   6/18   (33%)
Follow up in months, median (IQR) 13 (9 – 18) 25 (14 – 46)  
mRS at follow up (> 6 months)
- 0
- 1
- 2
- 3
- 4
- 5
- 6
 5/35 (14%)
13/35 (37%)
9/35 (26%)
2/35 (6%)
1/35 (3%)
- 
5/35 (14%)
5/17   (29%)
4/17   (24%)
6/17   (35%)
- 
2/17   (12%)
-
-
Adult patients: cross-sectional EEG analysis
Median time from disease onset to first EEG recording was 19 days (Table 2). At the 
timing of first EEG, only 3/34 patients were admitted to the ICU. Two-third of the 
patients had normal posterior rhythm, often with focal (65%) or diffuse (65%) slowing. 
Diffuse slowing was either mild (n = 9), moderate (n = 6) or severe (n = 7). Epileptic 
discharges were present in 24% of the recordings. Two patients had EDB on their first 
recording. Their functional scores were mRS 4 and 5 during EEG, and one of them was 
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admitted to the ICU. Two patients had a normal EEG; no follow-up EEG was done, 
and both patients had a favorable outcome (mRS 0 and 1). 
 17 patients had follow up EEG at maximum disease severity. Ten patients 
were admitted to the ICU. 2 patients (12%) had status epilepticus. 14/15 (93%) had 
diffuse slowing. EDB were present in 3/15 patients. They had a mRS of 4 (n = 2) or 5 
(n = 1), and one of them was in the ICU at that time. 6/15 (40%) patients still had 
normal posterior rhythm. 
Table 2: cross-sectional EEG results  
Adults (n = 35) Children (n = 18) p-value
First EEG 
Time to first EEG in days, median 
(range)
19 (0 – 125) 8 (1 – 105) 0.61
Status epilepticus 1/35 (3%) 0/17 (0%) 1.00
EEG patterns 
- Normal posterior rhythm
- Diffuse slowing
- Focal slowing
- Rhythmic delta activity
- Interictal epileptic discharges
21/33 (64%) 
22/34 (65%)
22/34 (65%)
14/34 (41%, 7 FIRDA, 
 7 TIRDA)
  6/34 (18%)
14/18 (78%) 
13/18 (72%)
16/18 (89%)
14/18 (78%, 4 FIRDA, 8 TIRDA, 
 2 OIRDA)
3/18 (17%)
0.53
0.76
0.10
0.02
1.00
Normal EEG   2/35 (6%) 0/18 (0%) 0.54
Follow up EEG (disease nadir)*
Status epilepticus   2/17 (12%) 0/9 (0%) 0.53
EEG patterns
-  Normal posterior rhythm 
reactivity
- Diffuse slowing
- Focal slowing
- Rhythmic delta activity
- Interictal epileptic discharges
- Ictal epileptic discharges
- Periodic discharges 
- EDB
  7/15 (47%) / 6/7 (86%)
14/15 (93%)
  7/15 (47%)
  7/15 (47%, 4x FIRDA, 
 2x  TIRDA, 1x OIRDA)
  2/15 (13%)
  2/15 (13%)
  2/15 (13%)
  3/15 (20%)
4/9 (44%) / 3/4 (75%)
8/9 (89%)
8/9 (89%)
7/9 (78%, 3x FIRDA, 1x TIRDA, 
 1x OIRDA, 2x GRDA)
1/9 (11%)
4/9 (44%)
4/9 (44%)
0/9 (0%)
1.00
1.00
0.08
0.21
1.00
0.15
0.15
0.27
Normal EEG   0/17 0/9 1.00
P-values < 0.00625 are considered significant (Bonferroni). *Median time between first EEG and follow up EEG 
was 21 days (IQR 11.5-36). TIRDA = temporal intermittent rhythmic delta activity, FIRDA = frontal intermittent 
rhythmic delta activity, OIRDA = occipital intermittent rhythmic delta activity, GRDA = generalized rhythmic delta 
activity.
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Figure 2. Predictive value of a normal posterior rhythm on first EEG recordings.  Figure shows functional status 
measured with mRS during first EEG, and at final follow up, comparing patients with and without normal posterior 
rhythm. A) The unselected population (n = 52), B) The subgroup of patients with severe disease (mRS≥ 3) and early EEG 
(within 30 days) (n = 29). mRS = modified Rankin Scale. FU = follow up. 
Pediatric patients: cross-sectional EEG analysis
Median time from disease onset to first EEG recording was 8 days. (Table 2) There were no 
normal EEGs. However, 14/18 patients had normal posterior rhythm. Focal slowing (89%) 
and diffuse slowing (72%) were common. One child had EDB on his first EEG (mRS = 5), 
he was the only pediatric patient admitted to the ICU during first recording. 
Nine pediatric patients had follow up EEG at maximum disease severity, of which three were 
admitted to the ICU. 3/9 (33%) children still had normal posterior rhythm. Focal slowing 
(89%), diffuse slowing (89%) and intermittent rhythmic delta activity (78%) were common. 
 There was a trend towards more rhythmic delta activity in pediatric EEGs 
compared to adult patients, but differences between the populations were not significant 
(Table 2). 
Predictive value of first EEG recording
The predictive value of normal posterior rhythm on first EEG recording could be 
analyzed in 52 patients (Figure 2 and 3A). 35 patients had normal posterior rhythm, of 
which 32 patients had a favorable outcome (91%). 17 patients had no normal posterior 
rhythm, of which only 10 patients had a favorable outcome (59%). Ordinal logistic 
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regression shows that the presence of a normal posterior rhythm was associated with 
lower mRS at final follow up (OR 4.74; 95% CI 1.56 – 14.47; p = 0.006). To explore 
whether limited disease was a confounding variable for both good EEG result and good 
clinical outcome, we restricted the analyses to the 40 patients with mRS ≥ 3 during first 
recording. The association between normal posterior rhythm and better clinical outcome 
remained (OR 4.28; 95% CI 1.29 – 14.25; p = 0.018). To mimic the clinical setting, 
we further narrowed the analyses to those with mRS ≥ 3 during first EEG within 30 
days after onset. With these test limitations, 29 patients could be included. 15 patients 
had normal posterior rhythm, of which 13 patients had a favorable outcome (87%). 14 
patients had no normal posterior rhythm, of which 8 patients had a favorable outcome 
(57%). Time since disease onset was not significantly different between patients with 
and without normal posterior rhythm. Although the frequencies of good outcome 
were similar, the association was no longer significant (OR 3.95, 95% CI 1.00-15.64; 
p = 0.051), due to smaller sample size.  
 The presence of normal posterior rhythm on first EEG was also associated with 
shorter hospital stay, which probably reflects early recovery. Patients who had died during 
hospital stay were excluded. Data were available in 45 patients. Thirty-two patients had 
a normal posterior rhythm with a median hospital stay of 35.5 days (range 0-338). 
Thirteen patients did not have a normal posterior rhythm, and their median hospital 
stay was 67 days (range 31-551, p = 0.003).  Looking from the other perspective, a 
severely abnormal first EEG was associated with higher final mRS (OR 0.23; 95% CI 
0.07 – 0.74; p = 0.014). However, more interestingly, 8/14 patients with a severely 
abnormal first EEG still had a favorable outcome in the end. 
Longitudinal EEG analysis
EEG recordings from 13 patients (6 children and 7 adults) were available for inclusion 
in the longitudinal analysis (Figure 3B). Initially, eight patients had a normal posterior 
rhythm with focal or diffuse abnormalities (category 2). EEG worsened (to category 
4) in three patients. EEG remained only slightly abnormal in the other five patients, 
also including patients with severe disease (mRS 4 or 5). Three patients had a severely 
abnormal EEG at week 1-2. Their EEG recordings had not improved at one and three 
months into disease. However, one of these patients finally improved well (mRS = 1). 
All patients with a severely affected EEG during the course of disease had a mRS of 5 
at nadir.
Discussion
We report an extensive analysis including systemic re-evaluation of EEG data in over 
fifty patients with anti-NMDARE. Most relevant findings are 1) first EEG recordings 
have a predictive value for clinical outcome, 2) diffuse and focal slowing are the most 
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common EEG findings, 3) normal EEG does not exclude anti-NMDARE, 4) EDBs are 
only present in severely affected patients but not necessarily admitted to the ICU, 5) 
long-term severe electrographic abnormalities can be followed by good clinical outcome. 
Electrographic abnormalities in the pediatric and adult population were comparable. 
 The first EEG recording has a predictive value for final clinical outcome. 
The relation between mild disease, normal posterior rhythm and better outcome has 
been reported earlier in a study of 9 pediatric cases.4 In our large unselected cohort, 
we have shown that a normal posterior rhythm on first recording predicts a favorable 
clinical outcome, while a severely abnormal EEG is associated with poor outcome. 
To analyze whether the EEG adds information to the clinical findings, we restricted 
our subsequent analyses to patients with mRS ≥ 3. The association between normal 
posterior rhythm and better clinical outcome remained, showing that normal 
posterior rhythm also in patients with clinically severe disease predicts a better 
outcome. Only a trend towards significance (p=0.051) is found if analysis is restricted 
to patients with mRS ≥ 3 during first EEG recorded within 30 days after onset. 
This is probably due to the limited number of patients in the latter analysis, as the 
differences between groups (frequencies of good outcome and OR) remained similar. 
Figure 3: A) Relation between timing of first EEG, EEG category and final clinical outcome in 52 patients. B) 
Longitudinal EEG analyses in 13 patients. Patients with favorable clinical outcome are marked in blue (dots), patients 
with unfavorable outcome are marked red (stars). EEG categories:  1: normal EEG.  2: normal posterior rhythm with 
diffuse or focal abnormalities.  3: lack of normal posterior rhythm, with focal or diffuse abnormalities. 4: severely abnormal 
EEG (lack of normal posterior rhythm with severe slowing or periodic discharges or status epilepticus) 


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 EEG is abnormal in the vast majority of the anti-NMDARE patients, but we 
have shown that a normal EEG registration does not exclude the diagnosis. Unremarkable 
EEG was seen in 4% of our patients, compared to 0-10% in earlier reports.1-3,7,18,19 
In our study, EEG has a sensitivity for anti-NMDARE of 96%; which is higher 
than the sensitivity of MRI brain (33%) or serum antibody analysis (87%).1,13 
 Schmitt et al. were the first to report the pattern of EDB in anti-NMDARE 
in 2012.10 Their study analyzed patients in a tertiary neuro ICU with continuous EEG 
registrations and found EDB in 7/23 (30%) patients. Since then, several studies described 
EDB in subgroups: EDB were present in 9/17 (53%) pediatric patients and in 16% 
of children and adult patients at peak stage of disease.3,20 A meta-analyses in pediatric 
anti-NMDARE calculated incidence of EDB as 16%.21 In our unselected group, EDB 
were present in only 6/53 (11%) patients, either at first EEG registration (n=3) or 
only at follow up EEG (n=3). All six patients had mRS ≥ 4 when EDB were present, 
three patients were admitted to the ICU. The estimated overall incidence of EDB in 
anti-NMDARE is 10-15%, and this unique pattern only occurs during severe illness. 
 Longitudinal analyses of EEG recordings showed that EEG in the course of the 
first month remained stable or worsened. Lack of improvement of EEG is consistent 
with the earlier clinical observation that anti-NMDARE progresses over the first weeks 
of disease.1 We did not identify EEG patterns related to specific stages of disease, as 
reported earlier in five pediatric cases.22 Severely abnormal EEG was only seen in patients 
with severe clinical disease, while slightly abnormal EEGs were present in patients with 
either mild or severe disease. Long-term severe electrographic abnormalities can be 
followed by good clinical outcome, which is important in clinical decision making. 
 Due to the retrospective nature of our study, we were not able to collect EEG 
registrations on pre-defined stages of disease. Therefore, the availability of follow up 
EEGs was likely subject to selection bias. We analyzed the EEGs from begin stage 
and during maximum disease severity (if available) to obtain clinically most relevant 
data. In addition, the retrospective design made it impossible to perform structured 
cognitive assessment during disease. The advantage of the retrospective study design 
is the opportunity to include over fifty patients. Most reliable data were obtained by 
independent re-evaluation of all registrations by two experienced neurophysiologists. 
 We have shown that the sensitivity of an abnormal EEG is high, but normal 
EEG does not exclude the diagnosis anti-NMDAR encephalitis. EDBs are only present 
in severely affected patients. Most importantly, the first EEG recording has a predictive 
value for clinical outcome. A normal posterior rhythm on first recording predicts a 
favorable clinical outcome, while a severely abnormal EEG is associated with poor 
outcome.
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Summary 
Several antibodies to extracellular antigens have been discovered in the last ten years. 
The diseases are very interesting, not in the least because prompt recognition may lead 
to successful treatment. This thesis aimed to gain more insight in the most prevalent 
diseases associated with antibodies to extracellular antigen.
Part I: The presynaptic VGKC-complex
The voltage-gated potassium channels (VGKC) are present on the membrane of 
neurons in both the central and peripheral nervous system, where these contribute to 
depolarization following action potentials. Initially, disease was thought to result from 
antibodies to the VGKC itself, but attempts to show reactivity to VGKC-transfected 
cells failed. This had led to the discovery that antibodies were not directed to the VGKC 
itself, but to associated proteins: leucine-rich glioma-inactivated 1 (LGI1) and contactin-
associated protein-like 2 (Caspr2). 
 LGI1 is a synaptic protein, mainly expressed in the hippocampus and temporal 
cortex. Antibodies to LGI1 result in a typical limbic encephalitis, evolving in weeks 
to months (Figure 1). Two-third of the patients are male and median age at onset is 
64 years. Our study reports the first incidence rates and shows a dramatic increase 
over recent years: the annual incidence in the Netherlands was 0.83/million in 2015, 
compared to 0.22/million in the three years before. Increase of incidence is probably 
due to better recognition. More insight in the clinical syndrome will further improve 
recognition in the future. Patients usually have disorders of memory, behavior and spatial 
orientation. The vast majority of the patients have one or more seizures types. Early in 
disease, patients have frequent faciobrachial dystonic seizures or subtle focal seizures. 
Especially subtle focal seizures are easily missed, while they are a clue for early diagnosis, 
and this seizure type had not been clearly described in anti-LGI1 encephalitis before. 
Recognizing these seizures is essential for early diagnosis and treatment, preventing 
further cognitive impairment. Tonic clonic seizures usually occur at maximum disease 
severity. 65% of the patients have hyponatremia. The majority of the patients have signs 
of limbic encephalitis on MRI brain. Interestingly, mesotemporal sclerosis is seen in 
some patients at follow up imaging. Diagnosis is based on the detection of antibodies in 
serum or cerebrospinal fluid (CSF). However, the sensitivity of commercial CSF analysis 
is disappointing. Our retrospective study reports effect of first line immunotherapy in 
80% of the patients, with early decrease of seizures. Cognitive improvement tends to 
take months to a year. After follow-up over two years, two-third of the patients had a 
favorable outcome (mRS 0-2). 86% suffered from persistent amnesia for the disease 
period, which was often very stressful to them and their relatives. It is often experienced 
as sign of ongoing disease, while it should be considered a sequela. Better patient 
counseling will be valuable. Neuropsychological assessment showed residual impairment 
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of spatial recognition. 35% of the patients had a relapse, although this could be an 
overestimation as some patients were only diagnosed at relapse. (Chapter 2)
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Figure 1: Disease course in anti-LGI1 encephalitis. The continuous blue line is based on our study results. In the future, 
we expect that earlier recognition of disease with prompt start of treatment will limit disease severity and improve final 
outcome. This hypothesized disease course is marked with the dashed pink line. 
Antibodies to LGI1 are thought to be pathogenic, although this has not been proven 
by passive transfer yet, as required according to the Witebsky postulates. Some indirect 
evidence is available. First, anti-LGI1 encephalitis shows resemblance to the genetic 
disruption of the LGI1 protein. The latter is known to cause epileptic syndromes in 
animals and in human. Second, response to immunotherapy is mostly favorable. A third 
support for the autoimmune hypothesis is the discovery of an HLA-association. We 
detected a remarkably strong association with HLA-DR7 and HLA-DRB4 in our non-
tumor LGI1 patients. This is the first report of a genetic predisposition for antibody-
mediated limbic encephalitis, and our findings were confirmed by a simultaneous 
publication from South-Korea (back-to-back publications). These results enable 
further studies, including the possibility to culture disease-specific T-cells from patient’s 
peripheral blood and to analyze the target epitope of the LGI1-protein. The strong HLA 
association seems not to apply to the small group of four tumor patients, suggesting two 
different immunopathogenic pathways. Considering the small size, absence of HLA-
DR7 or HLA-DRB4 in anti-LGI1 patients could raise tumor suspicion. (Chapter 3)  
 Caspr2 is a transmembrane protein in the central and peripheral nervous system. 
Caspr2 binds the Kv1 subtype VGKC, which is essential for clustering of VGKCs at the 
juxtaparanodes of myelinated axons. Antibodies are almost exclusively seen in older male 
patients (89%). Data regarding the clinical syndrome were very limited, as only a few 
dozen of patients were reported before we started our analysis of 38 anti-Caspr2 patients. 
Our results show that the disease can progress relatively slow, in contrast to the subacute 
onset of most antibody-associated encephalitis. This can lead to diagnostic delays or 
to misdiagnosing the disorder as a primarily neurodegenerative disease, preventing 
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the early use of immunotherapy. While LGI1-antibodies cause a homogenous clinical 
syndrome, Caspr2-antibodies are related to a variety of clinical syndromes, including 
limbic encephalitis, neuromyotonia and Morvan’s syndrome. However, a repertoire of 
seven symptoms comprises the spectrum of clinical manifestations: cerebral symptoms 
(cognition, epilepsy), cerebellar symptoms, peripheral nerve hyperexcitability, autonomic 
dysfunction, insomnia, neuropathic pain and weight loss. 77% of the patients had three 
or more of these core symptoms, which reflect the involvement of multiple areas of the 
nervous system. A tumor was present in 19% of the patients, mostly thymoma. Morvan’s 
syndrome and neuromyotonia were more common in tumor patients compared to the 
non-tumor group. 90% of the patients was reported to respond to immunotherapy in 
our retrospective analysis. After median follow up of three years, 73% of the patients 
had a favorable follow up (mRS 0-2). 25% of the patients had a relapse. Interestingly, 
relapses can involve different parts of the nervous system than the initial disease episode. 
(Chapter 4)
 About half of the VGKC-positive patients have antibodies to LGI1 or Caspr2, 
with a well-defined clinical syndrome. The clinical presentation of VGKC-positive 
patients lacking antibodies to LGI1 and Caspr2 is diverse, including REM sleep behavior 
disorder, multiple system atrophy, peripheral neuropathy, vasculitis, non-epileptic 
seizures seizures  and psychogenic non-epileptic seizures. This raised the question whether 
VGKC-positivity in the absence of antibodies to LGI1 and Caspr2 is clinically relevant. 
To clarify this issue, we compared VGKC-positive patients without antibodies to LGI1 
or Caspr2 to VGKC-negative patients, matched by age, gender and clinical syndrome. 
All cases were blindly analyzed for evidence for autoimmune inflammation, according to 
predefined criteria. None of the criteria for autoimmune inflammation differed between 
the two groups. Probability of autoimmune inflammation was independent of VGKC 
result. However, it was strongly associated with clinical syndrome: 57% of the patients 
with limbic encephalitis had evidence for autoimmune disease compared to 5% of 
the patients with other clinical syndromes (p < 0.01). No cut-off value for the VGKC 
titer was appropriate to discriminate between patients with and without autoimmune 
inflammation. In conclusion, VGKC positivity (by itself ) does not contribute in clinical 
practice. (Chapter 5)
 Chapter six reviews the clinical syndromes of antibodies to LGI1 and Caspr2, 
and aims to improve recognition of the diseases. Pediatric cases are described as well. 
Cohort of hundreds of children have been screened, identifying only a few positive 
cases. Positive test results in children need to be confirmed with additional laboratory 
tests, because false positive (Caspr2) results are not uncommon. Chapter six also clarifies 
the issues regarding VGKC-positive patients without antibodies to LGI1 and Caspr2 by 
providing a review of the literature and the results of our analysis. (Chapter 6)
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Part II: The postsynaptic glutamate receptors
The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) is a 
postsynaptic ionotropic receptor that mediates fast excitatory synaptic transmission. The 
receptor belongs to the family of glutamate receptors and consists of a GluA1 and GluA2 
subunit. Antibody binding to one or both of these subunits results in internalization 
of the receptor. The initial description of anti-AMPAR-encephalitis was published in 
2009 and included ten patients. We reported the clinical syndrome and outcome in an 
additional 22 patients. Two-third of the patients was female and median age at onset 
was 62 years. Most patients presented with a classical limbic encephalitis or diffuse 
encephalitis. Seizures and psychiatric manifestations were relatively common.  Fourteen 
patients had a tumor, mostly small cell lung cancer or thymoma. Seven patients had 
additional neuronal antibodies, such as antibodies to CRMP5 or SOX1, of which six 
had a tumor. Their clinical syndrome and outcome were more characteristic for the 
additional antibody than for anti-AMPAR encephalitis. Response to immunotherapy 
was limited, with good response in 25% and partial response in 50%. The presence of 
an additional paraneoplastic antibody was the main prognostic factor for poor outcome. 
These findings underline the need for tumor screening and additional antibody analysis 
in patients with AMPAR-antibodies. (Chapter 7)
 Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) is the most 
common antibody-mediated encephalitis. Disease mostly affects women of childbearing 
age, or children. 38% of the patients have a tumor, mainly ovarian teratoma. Patients 
subacutely develop psychiatric symptoms, memory loss, movement disorders and 
seizures, often followed by intensive care unit (ICU) admission due to consciousness 
decline, autonomic dysfunction or hypoventilation. Routine ancillary testing, including 
MRI brain and CSF analysis, is needed to exclude other diagnosis. However, results have 
limited contribution in the detection of anti-NMDAR encephalitis. In contrast, EEG is 
abnormal in almost all patients, and a specific pattern called ‘extreme delta brushes’ has 
been reported. Most studies into anti-NMDAR encephalitis only briefly report EEG 
results, therefore data are limited. We re-evaluated EEG registrations in 53 pediatric 
and adult patients, and analyzed the predictive value of first EEG. We have shown that 
the presence of physiological reactive background activity on first EEG registration is 
associated with better clinical outcome. Severely abnormal first EEG was associated 
with worse outcome, but this should be interpreted with caution as 8/14 patients with 
a severely abnormal EEG finally had a good outcome. (Chapter 9)
 Most patients show good response to immunotherapy. Over fifty percent of the 
patients respond to first line therapy within four weeks. If needed, second line therapy 
with rituximab and cyclophosphamide is started. Overall, 81% of the patients have a 
favorable outcome after two years. Unfortunately, these good results on group level do 
not apply to every individual patient. We have reported a severe case of anti-NMDAR 
encephalitis in a 25-year old woman. She was admitted to the ICU for almost a year. 
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NMDAR-antibody titer remained high, despite removal of bilateral ovarian teratoma 
and extensive first and second line immunotherapy. This is the first report of intrathecal 
administration of rituximab in anti-NMDAR encephalitis. It was safely used but 
extensive laboratory results did not support a direct effect on the central nervous system. 
After 1.5 years of hospital stay, patient finally improved. This severe case underlines the 
need for perseverance in treating anti-NMDAR encephalitis. (Chapter 8)
Future perspectives
In the last decade, there have been major breakthroughs in the field of antibody 
mediated encephalitis and great developments will follow in coming years. Patient 
numbers will increase due to better recognition, and the detection of new antibodies is 
expected. However, research should be planned thoughtfully. We should be vigilant for 
misinterpretation (or overinterpretation) of laboratory results in this rapidly developing 
scientific field. With careful patient selection, a HLA link might be detected in patients 
with antibodies to NMDAR or Caspr2, just as in anti-LGI1 encephalitis. Other 
interesting steps forward will be the development of predictive models for (long-term) 
outcome, and the development of evidence-based treatment strategies. 
Research strategies
Research is complicated by the rare occurrence of specific antibodies and therefore 
it seems attractive to lump patients with different antibodies. However, this should 
be avoided as antibodies and their syndromes differ significantly. Extrapolating data 
from well-studied antibodies (i.e. NMDAR) to rare antibodies is probably not very 
reliable. Antibodies differ in their pathophysiological characteristics, including different 
IgG subtypes (IgG1 NMDAR antibodies vs IgG4 LGI1 and Caspr2 antibodies) and 
different sites of antibody production (intrathecal vs systemic). Also, epidemiology 
differs per antigen, including age at onset (anti-NMDARE in children and adolescents 
vs anti-Caspr2 encephalitis in the elderly), and gender (female anti-NMDARE patients 
compared to male anti-Caspr2 patients) and there are relevant differences in clinical 
syndromes. 
 Clinicians and laboratory experts need to collaborate to avoid misinterpretation 
of laboratory results. A clear example is the positive VGKC-radioimmunoassay, which 
has resulted in diagnosis of ‘anti-VGKC-encephalitis’ for years. The unlimited clinical 
presentations of VGKC-positivity should have alarmed more physicians and researchers. 
This was ultimately proven in 2010 with the discovery of the clearly distinct subgroups 
of anti-LGI1 and anti-Caspr2 encephalitis patients, and later with our description of the 
lack of clinical significance of VGKC-positivity in the absence of these two antibodies. 
This misinterpretation of VGKC-results should be a warning. But in contrast, some 
laboratories still report VGKC-patients without providing results of LGI1 and Caspr2 
tests, and reviewers still allow this. In addition, Caspr2 and NMDAR serum cell-based 
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assays (CBA) have been shown to be positive but clinically irrelevant in some patients, 
and need confirmation with CSF, or with immunohistochemistry or cell cultures in 
all patients. However, some study groups have included these patients in their studies 
without laboratory confirmation. These studies blur research, create the false impression 
that the clinical phenotype expands, and reinforce the confusion about relevant or 
irrelevant antibodies. 
HLA-associations
The discovery of an HLA-association in non-tumor anti-LGI1 patients creates curiosity 
about a possible HLA-link in patients with other antibodies. As a pilot, we have 
performed HLA analysis in ten anti-NMDARE patients without a teratoma, but we 
were not able to detect an association yet, neither did a Korean study group in 17 
patients. Confirmation of both the HLA link in anti-LGI1 encephalitis and the lack of 
an HLA association in a large group of anti-NMDARE patients was also found and will 
soon be published by a German study group. An HLA-link in anti-NMDARE patients 
might be truly absent. But possibly, a HLA-link is present but currently not observed in 
unselected patient groups. Anti-NMDARE is a more heterogeneous disease (compared 
to anti-LGI1 encephalitis), with a heterogeneous epidemiology: pediatric patients vs 
elderly, with or without teratoma, postviral or idiopathic. This might be disturbing the 
evaluation of HLA results. In contrast, HLA analyses have been more straightforward 
in the homogeneous group of anti-LGI1 patients, all presenting with similar disease 
courses. Careful clinical observation including ancillary testing of anti-NMDARE 
patients (truly translational research) will possibly enable the selection of a homogenous 
subgroup in which a HLA-association might be detected. As far as we know, HLA 
analyses have not been performed in patients with anti-Caspr2 disease yet. Results in 
this interesting subgroup are difficult to predict, as this patient group is remarkably 
homogenous, but with very diverse clinical phenotypes.   
Outcome prediction
The development of predictive models for clinical outcome is useful for several reasons: 
to provide information for patients and relatives, to assess the need for extensive first- 
or second line pulse therapy in the acute phase and for maintenance therapy in the 
long-term, and to offer appropriate (cognitive) rehabilitation programs. In addition, a 
predictive model allows for the selection of patients for therapy trials. Predictive models 
will differ per disease and antibody, and the development is complicated by the large 
number of patients needed to analyze. Several outcome predictors are available for the 
most common autoimmune encephalitis (anti-NMDARE), and should be included in 
a predictive model. Early start of immunotherapy, no need for ICU admission and 
lower CSF antibody titers are associated with better outcome, as is normal posterior 
rhythm on first EEG. The course of antibody titers and CXCL13 levels in CSF seem 
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to be predictive as well, but these data are not available early into disease. Brain FDG/
PET hypometabolism in the occipital lobes correlates with disease severity, and might be 
predictive of outcome, but it is not widely available and therefore not a useful marker. 
Gender, age and tumor presence were not distinctive in earlier studies. 
Evidence-based treatment
Therapy studies will soon be feasible, as patient numbers increase due to better 
recognition and international collaboration continues. Patients with the most common 
antibodies, directed to NMDAR and LGI1, form the best groups for initial studies. 
The three most relevant and feasible research questions are: 1) what is the best first-
line treatment option, comparing methylprednisolone, intravenous immunoglobulins, 
plasma exchange or a combination, 2) what is the best second-line treatment option, 
and when should it be initiated, and 3) is maintenance therapy effective in preventing 
relapses, and which steroid-sparing option is safe and most effective? The second question 
mainly refers to anti-LGI1 encephalitis. Preferentially, a double-blind randomized 
controlled trial is initiated, but such a trial across borders in these rare diseases will 
probably be very complex. A good alternative will be a study design in which different 
sites follow their own predefined protocol. Inclusion and exclusion criteria should be 
similar, and the same clinical and laboratory measurements should be obtained on 
predefined stages of disease. Outcome measures need to be disease-specific and sensitive. 
For example, long term cognitive deficit is common in anti-LGI1 encephalitis, but will 
be insufficiently clarified with the rough modified Rankin Scale. A good option to assess 
cognitive outcome, independent of language and culture, would be a computerized 
neuropsychological assessment battery, for example CANTAB (see chapter 2). Follow 
up should be at least one year. However, a study arm with extended follow up of three 
years would be very interesting to analyze the effects of maintenance therapy.  
 In conclusion, exciting years are to come in the rapidly developing field of 
autoimmune encephalitis. Interesting questions will hopefully be answered with 
transparent research. The strong link between clinicians and laboratory experts is 
essential. New laboratory findings should lead to extensive clinical analyses of the study 
group and controls. In addition, selection of subgroups of patients with similar clinical 
characteristics is probably the most promising starting point for the discovery of new 
antibodies. Further expansion of international collaboration is useful to increase patient 
numbers in research projects, which also allows for therapy trials. With these efforts, 
early reliable diagnoses and evidence based treatment strategies will come within reach. 
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Samenvatting
Sinds 2007 zijn er verschillende antistoffen ontdekt die zich richten tegen extracellulaire 
antigenen en een neurologische ziekte veroorzaken. Vlotte herkenning van de ziekte is 
essentieel, omdat de aandoeningen veelal behandelbaar zijn. Het doel van dit proefschrift 
is om meer inzicht te geven in de meest voorkomende ziekten die geassocieerd zijn met 
antistoffen tegen extracellulaire antigenen. 
Deel 1: Het pre-synaptische VGKC-complex (kaliumkanaal)
Het spanningsafhankelijke kalium kanaal (VGKC) is aanwezig op neuronen in het 
centrale en perifere zenuwstelsel. Het kanaal zorgt ervoor dat de cel na een actiepotentiaal 
terugkeert naar de rusttoestand. Aanvankelijk werd gedacht dat antistoffen zich direct 
tegen het kaliumkanaal richtten, maar in het laboratorium werd dit niet aangetoond. In 
2010 werd ontdekt dat antistoffen zich richten tegen twee eiwitten die een nauwe relatie 
hebben tot het kaliumkanaal: LGI1 en Caspr2. 
 LGI1 is een eiwit dat wordt uitgescheiden in de synaps tussen twee 
zenuwcellen. De hersengebieden waar veel LGI1 aanwezig is, zijn de hippocampus 
en de temporaalschors. Antistoffen tegen LGI1 veroorzaken een hersenontsteking 
genaamd limbische encefalitis. Patiënten ontwikkelen in enkele weken tot maanden 
geheugenklachten, gedragsveranderingen en epilepsie. Twee derde van de patiënten is 
man en de mediane leeftijd is 64 jaar. Uit ons onderzoek komen de eerste incidentiecijfers 
naar voren. De jaarlijkse incidentie in Nederland was 0.83/miljoen in 2015, vergeleken 
met 0.22/miljoen in de drie jaren daarvoor. Deze opvallende stijging is waarschijnlijk 
veroorzaakt door betere herkenning van de ziekte en meer inzicht in de ziekte zal de 
incidentiecijfers verder doen toenemen. Patiënten hebben verschillende vormen van 
epilepsie. Vroeg in de ziekte komen specifieke faciobrachiale dystone aanvallen voor, 
evenals subtiele focale insulten. Met name de focale insulten worden veel gemist, terwijl 
deze een clou zijn tot het stellen van de diagnose. Dit is essentieel, omdat snelle behandeling 
(verdere) achteruitgang van de cognitie kan voorkomen. Tonisch clonische epileptische 
insulten komen vooral voor als de ziekte op zijn maximum is. Een verlaagd natrium in 
serum (bloed) komt voor bij 65% van de patiënten. De meerderheid van de patiënten 
heeft tekenen van een limbische encefalitis op de MRI van de hersenen. Op follow up 
scans wordt soms mesotemporaal sclerose gezien. De diagnose anti-LGI1 encefalitis is 
gebaseerd op het aantonen van de antistoffen in serum of liquor (hersenvocht), waarbij 
in onze studie serum sensitiever bleek. In onze retrospectieve studie verbeterde 80% van 
de patiënten op eerstelijns immuuntherapie. Epilepsie vermindert snel, terwijl cognitief 
herstel maanden tot een jaar duurt. Na minimaal 2 jaar follow up had twee derde van de 
patiënten een gunstige uitkomst (mRS 0-2). 86% van de patiënten had nog amnesie voor 
de ziekteperiode. Dit gaf veel zorgen bij patiënten en hun naasten die dit beschouwden 
als teken van voortdurende ziekte, terwijl het in werkelijkheid een restverschijnsel is. 
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Goede voorlichting is hierom van belang. Neuropsychologisch onderzoek toonde veelal 
nog een beperking van de ruimtelijke oriëntatie. Anamnestisch was ook het executief 
functioneren gestoord, maar dit is niet formeel getest. 35% van de patiënten had een 
recidief van de ziekte, echter dit kan een overschatting zijn doordat een aantal patiënten 
pas tijdens het recidief werd gediagnosticeerd. (Hoofdstuk 2)
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Figuur 1: Ziektebeloop van anti-LGI1 encefalitis. The blauwe lijn is gebaseerd op resultaten van onze studie. We 
verwachten dat snellere herkenning en vlotte start van behandeling in de toekomst leidt tot minder ernstige ziekte en 
betere klinische uitkomsten. Dit veronderstelde ziektebeloop is aangegeven met de roze stippellijn.
Antistoffen tegen LGI1 worden als pathogeen beschouwd, hoewel dit nog niet door 
passieve overdracht is bewezen. Er is wel indirect bewijs. Allereerst lijkt de ziekte op de 
genetische verstoring van het LGI1 eiwit, hetgeen een epilepsie syndroom veroorzaakt. 
Ten tweede is immuuntherapie meestal werkzaam. Een derde ondersteunend bewijs 
voor de auto-immuun hypothese is de HLA-associatie die wij beschrijven in hoofdstuk 
3. We hebben een opvallend sterke associatie ontdekt met HLA-DR7 en HLA-DRB4 
in onze anti-LGI1 patiënten zonder tumor (88%). Dit is de eerste ontdekking van een 
genetische predispositie voor een antistof gemedieerde limbische encefalitis, en onze 
resultaten zijn bevestigd in een onderzoek uit Zuid-Korea dat gelijktijdig is gepubliceerd 
(back-to-back publicatie). De sterke HLA-associatie vonden we niet terug in de vier 
patiënten met een tumor, hetgeen mogelijk een andere pathofysiologie suggereert in 
deze groep. Dit moet uiteraard bevestigd worden in een grotere groep patiënten, maar 
afwezigheid van HLA-DR7 en HLA-DRB4 bij anti-LGI1 patiënten kan de verdenking 
op een tumor doen stijgen. (Hoofdstuk 3) 
 Caspr2 is een transmembraan eiwit in het centrale en perifere zenuwstelsel. 
Caspr2 is essentieel voor het clusteren van kaliumkanalen op de juxtaparanodale regio 
van gemyeliniseerde axonen. Antistoffen komen voornamelijk voor bij oudere mannen 
(89%). Voorheen waren er weinig gegevens over de ziekte bekend, omdat er weinig 
patiënten waren beschreven. Wij analyseerden 38 patiënten en bemerkten dat de ziekte 
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zich langzaam ontwikkelt, in tegenstelling tot het subacute beloop van de meeste 
antistof gemedieerde encefalitiden. Het langzame beloop kan leiden tot de misdiagnose 
van een neurodegeneratieve aandoening, zoals een dementie, waardoor patiënten niet 
de juiste behandeling krijgen. Het klinisch beeld van Caspr2-antistoffen is gevarieerd: 
limbische encefalitis, neuromyotonie en het syndroom van Morvan komen voor. Er is 
wel degelijk overlap, doordat er zeven symptomen zijn die in verschillende combinaties 
veel voorkomen: cerebrale symptomen (cognitie en epilepsie), cerebellaire symptomen, 
perifere zenuw hyperexcitabiliteit, autonome dysfunctie, insomnie, neuropathische pijn 
en gewichtsverlies. 77% van de patiënten had drie of meer van deze symptomen. 19% 
van de patiënten had een tumor, met name thymomen. Het syndroom van Morvan en 
neuromyotonie kwamen vaker voor bij patiënten met een tumor. In ons retrospectieve 
onderzoek reageerde 90% van de patiënten op immuuntherapie. Na een mediane follow 
up van drie jaar had 73% van de patiënten een gunstige uitkomst (mRS 0-2). 25% van 
de patiënten had een recidief van de ziekte, waarbij soms juist een ander deel van het 
zenuwstelsel betrokken was dan bij de eerste ziekte episode. (Hoofdstuk 4) 
 Ongeveer de helft van de VGKC-positieve patiënten heeft antistoffen tegen 
LGI1 of Caspr2, met een duidelijk omschreven klinisch beeld. Het klinisch beeld van 
de VGKC-positieve patiënten zonder antistoffen tegen LGI1 en Caspr2 is daarentegen 
heel divers, waaronder REM-slaap stoornissen, multipele systeem atrofie, perifere 
neuropathie, vasculitis en psychogene, non-epileptische aanvallen. Dat roept de vraag 
op of een positieve VGKC-test in afwezigheid van antistoffen tegen LGI1 en Caspr2 
wel klinisch relevant is. Om deze vraag te beantwoorden hebben wij deze patiënten 
vergeleken met VGKC-negatieve patiënten, gematcht voor leeftijd, geslacht en klinisch 
beeld. Alle casus werden blind beoordeeld op bewijs voor een auto-immuun ontsteking, 
aan de hand van vooraf opgestelde criteria. De twee groepen verschilden niet van elkaar 
en de kans op een auto-immuun ziekte was onafhankelijk van de VGKC-uitslag. Er was 
geen grenswaarde voor de VGKC-test die differentieerde tussen patiënten met en zonder 
auto-immuun ontsteking. We concludeerden dat VGKC-positiviteit zonder antistoffen 
tegen LGI1 en Caspr2 niet klinisch relevant is. (Hoofdstuk 5)    
 Hoofdstuk 6 geeft een overzicht van de klinische syndromen veroorzaakt door 
antistoffen tegen LGI1 en Caspr2, met als doel de herkenning van de ziektes te verbeteren. 
Ook de casus van patiënten op de kinderleeftijd worden besproken. In verschillende 
onderzoeken zijn honderden kinderen gescreend, waarbij slechts enkele patiënten 
positief bleken. Een positieve testuitslag bij een kind moet altijd bevestigd worden met 
aanvullende laboratoriumtesten, omdat de ziekte bij kinderen zeer zeldzaam is en vals-
positieve uitslagen van met name Caspr2-antistoffen niet zeldzaam zijn. (Hoofdstuk 6)
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Deel II: De postsynaptische glutamaatreceptoren 
De AMPA receptor is een postsynaptische ionotrope receptor die een snelle synaptische 
signaaloverdracht reguleert. Wanneer antistoffen aan de receptor binden worden deze 
inactief door internalisatie. De eerste beschrijving van anti-AMPAR encefalitis dateert uit 
2009. Er werden tien patiënten beschreven. In hoofdstuk 7 rapporteren wij het klinisch 
beeld en de uitkomst van 22 nieuwe patiënten. Twee derde van de patiënten is vrouw, 
en de mediane leeftijd is 62 jaar. De meeste patiënten hebben een limbische encefalitis 
of een diffuse encefalitis. Epileptische insulten en psychiatrische symptomen komen veel 
voor. Veertien patiënten hadden een tumor, meestal een kleincellige longtumor of een 
thymoom. Zeven patiënten hadden een tweede neuronale antistof, tegen bijv CRMP5 
of SOX1, zes van hen had een tumor. Het klinisch beeld in deze patiënten paste meer bij 
de tweede antistof dan bij anti-AMPAR encefalitis. Slechts 25% van alle patiënten had 
een goede reactie op immuuntherapie, 50% reageerde deels. De aanwezigheid van een 
tweede antistof was de belangrijkste voorspeller voor een slechte uitkomst. Daarom is 
tumorscreening en onderzoek naar additionele antistoffen van belang in patiënten met 
AMPAR-antistoffen. (Hoofdstuk 7)
 Anti-NMDAR encefalitis is de meest voorkomende antistof-gemedieerde 
encefalitis. De ziekte komt vooral voor bij vrouwen in de vruchtbare leeftijd, en bij 
kinderen. 38% van de patiënten heeft een tumor, veelal een ovariumteratoom. Patiënten 
ontwikkelen in enkele dagen tot weken psychiatrische symptomen, geheugenverlies, 
bewegingsstoornissen en insulten. De meeste patiënten moeten worden opgenomen op de 
intensive care vanwege een verlaagd bewustzijn, autonome dysfunctie en hypoventilatie. 
Aanvullend onderzoek zoals MRI en liquor analyse zijn nodig om andere oorzaken uit 
te sluiten, maar dragen nauwelijks bij aan de diagnose anti-NMDAR encefalitis. Het 
EEG daarentegen kan van meerwaarde zijn, omdat het specifieke patroon van ‘extreme 
delta brushes’ alleen bij deze patiënten voorkomt. In de literatuur is verder weinig 
informatie beschikbaar over het EEG bij anti-NMDAR encefalitis. We hebben daarom 
EEGs van 53 kinderen en volwassenen herbeoordeeld en de voorspellende waarde van 
het EEG geanalyseerd. Onze resultaten laten zien dat een normaal achtergrondpatroon 
op het eerste EEG voorspellend is voor een goede uitkomst (91% vs 59%). Een ernstig 
afwijkend EEG was geassocieerd met een slechte uitkomst, maar dit moet voorzichtig 
worden geïnterpreteerd omdat 8 van de 14 patiënten met een ernstige afwijkend EEG 
wel een goede uitkomst had. (Hoofdstuk 9)
 De meeste anti-NMDAR patiënten reageren goed op eerstelijns immuun-
therapie, maar in een deel van de patiënten is tweedelijns behandeling met rituximab 
en/of cyclofosfamide nodig. 81% van de patiënten heeft een gunstige uitkomst na twee 
jaar. Helaas zijn deze gunstige gegevens niet van toepassing op iedere individuele patiënt. 
In hoofdstuk 8 beschrijven wij een casus van een 25-jarige vrouw die bijna een jaar op de 
intensive care was opgenomen. De antistoftiters bleven hoog, ondanks het verwijderen 
van ovariumteratomen beiderzijds en uitgebreide eerste en tweedelijns immuuntherapie. 
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Dit is de eerste publicatie van intrathecale toediening van rituximab in anti-NMDAR 
encefalitis. Uitgebreid laboratoriumonderzoek inclusief antistoftiters en B-cel tellingen 
toonde geen direct effect op het centrale zenuwstelsel. Na ruim 1.5 jaar opname in het 
ziekenhuis herstelde patiente redelijk. Deze ernstige casus benadrukt het belang van 
volhardendheid bij de behandeling van anti-NMDAR encefalitis. (Hoofdstuk 8)
Visie op de toekomst
De afgelopen jaren zijn er grote doorbraken geweest op het gebied van antistof-
gemedieerde encefalitis en nieuwe ontwikkelingen zullen volgen. Het aantal patiënten 
zal stijgen door betere herkenning van de ziekte en waarschijnlijk worden er nog nieuwe 
antistoffen ontdekt. In dit snel ontwikkelende vakgebied moeten we waken voor 
misinterpretatie van laboratoriumuitslagen, waarbij nauwe samenwerkingen tussen 
clinici en laboratorium experts essentieel is. Het is interessant om te onderzoeken 
of er ook bij patiënten met antistoffen tegen NMDA of Caspr2 een HLA-associatie 
bestaat. Andere interessante onderzoeksrichtingen zijn het ontwikkelen van een 
voorspellend model voor lange termijn uitkomsten, en studies naar de meest effectieve 
behandelstrategieën. Internationale samenwerking is daarbij van belang. Met deze 
inspanningen is vlotte diagnostiek en effectieve behandeling van antistofgemedieerde 
encefalitis hopelijk binnen handbereik. (Future Perspectives)
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 Met stip op één: mijn co-promotor dr. M.J. Titulaer. Beste Maarten, in 2012 bracht 
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mijn verdediging van gedachten te wisselen over mijn proefschrift. In het bijzonder prof. 
dr. Bart Jacobs, prof. dr. Jan Verschuuren en prof. dr. Steven Kushner, veel dank voor de 
beoordeling van het manuscript van mijn thesis. 
 Aan de basis van dit proefschrift staan laboratoriumresultaten van vele onderzochte 
samples. Deze data zijn grotendeels tot stand gekomen door het goede werk van onze 
laboranten Esther en Mariska op het JNI. Mijn dank is groot! Ook de samenwerking met 
Marco Schreurs en met de laboranten op het Laboratorium Medische Immunologie was 
van grote waarde. 
 De kans om tijdens mijn opleiding tot neuroloog onderzoek te doen heb ik te 
danken aan de neurologen in het Haga Ziekenhuis, in het bijzonder aan mijn opleider 
Bas de Bruijn. Jullie hebben mij de mogelijkheid geboden een dag in de week naar 
Rotterdam te gaan, en de keuzetijd van mijn opleiding aan wetenschap te besteden. Ik 
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ben jullie daar erg dankbaar voor, en zeker voor het vertrouwen dat jullie mij gaven. Paul 
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met mij wilden delen; zowel op werk als privé. Ook Roos wil ik daar graag bij noemen. 
Als MS-onderzoeker zat je bij ons in het hoekje op de kamer. Vroeg beginnen, hard 
werken, maar tussendoor genoeg tijd voor koffie en bijkletsen, en je was altijd bereid 
mee te denken over figuren of statistiek. Ook de andere dames van onze kamer op 
de 22e wil ik bedanken voor het uitwisselen van ervaringen en de gezelligheid. Het is 
een heel fijn kippenhok. Een promotie-onderzoek kan een eenzaam traject zijn, maar 
dankzij jullie was het dat in mijn geval zeker niet. 
 Ik wil mijn ouders en broer bedanken voor de fijne thuisbasis. Ondanks dat ik 
al enige tijd arts was, hield prof. dr. J.C.M. van Sonderen vol dat hij de enige ‘doctor’ 
in de familie was. Binnenkort niet meer, pap! Jij hebt me altijd aangemoedigd hard te 
werken, en zeker ook om te promoveren, en daar ben ik je dankbaar voor. Zoals mijn 
vader de druk opvoerde (“hoe lang heb je nog nodig?”) zorgde mijn moeder juist voor 
de balans. Zij adviseerde me tijd voor mezelf te maken en niet alleen maar te werken. 
Mam, veel dank voor je interesse en je bruikbare adviezen om de balans te bewaren. Als 
oppas-oma en lieve (schoon)moeder beteken je ongelooflijk veel voor ons gezinnetje. 
Neef Koen, bedankt voor de uren praten, en voor je interesse in mijn onderzoek. Je bent 
de enige niet-arts die snapt wat ik heb onderzocht. Dirk, Margreet, Pieter, Julia en Kris, 
bedankt voor de warme ontvangst in jullie familie. Fijn dat jullie bijspringen met oppas 
wanneer nodig, zodat Dirk en ik ons werk kunnen combineren. Ook wil ik graag mijn 
vrienden en vriendinnen bedanken voor de interesse in mijn onderzoek, maar vooral 
ook voor de warmte en energie die jullie mij geven. Koffie dates, uren tafelen, dagjes weg 
en samen sporten. Zonder deze afleiding had ik het nooit gered. 
 Tot slot wil ik mijn knappe geliefde Dirk bedanken. We delen de liefde, onze 
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